1,3-dihydro-2h-pyrrolo[3,4-c]quinoline derivatives as cgas inhibitors for the treatment of inflammatory and / or autoimmune diseases

Abstract

The present invention relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of cGAS, yet more in particular for the prevention or treatment of inflammation conditions or cancer. The present invention also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of cGAS, yet more in particular for the prevention or treatment of inflammation conditions or cancer. The present invention also relates to processes for the preparation of said compounds.

Description

[0001] 1 ,3-DIHYDRO-2H-PYRROLO[3,4-C]QUINOLINE DERIVATIVES AS CGAS INHIBITORS FOR THE TREATMENT OF INFLAMMATORY AND / OR AUTOIMMUNE DISEASES

[0002] FIELD OF THE INVENTION

[0003] The present invention relates to novel compounds. The present invention also relates to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of cyclic GMP-AMP synthase (cGAS), yet more in particular for the prevention or treatment of inflammatory and / or autoimmune diseases. The present invention also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.

[0004] The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of cGAS, yet more in particular for the prevention or treatment of inflammatory and / or autoimmune diseases. The present invention also relates to processes for the preparation of said compounds. The invention also relates to combinations of the novel compounds with other therapeutic agents.

[0005] BACKGROUND OF THE INVENTION

[0006] Innate immunity is considered a first line cellular stress response defending the host cell against invading pathogens and initiating signaling to the adaptive immune system. These processes are triggered by conserved pathogen-associated molecular patterns (PA Ps) through sensing by diverse pattern recognition receptors (PRRs) and subsequent activation of cytokine and type I interferon gene expression. The major antigen-presenting cells, such as monocytes, macrophages, and dendritic cells, produce type I interferons and are critical for eliciting adaptive T- and B-cell immune system responses. The major PRRs detect aberrant, i.e. mislocalized, immature or unmodified nucleic acids on either the cell surface, the inside of lysosomal membranes or within other cellular compartments (Barbalat et al., Annu. Rev. Immunol. 29, 185-214 (2011)).

[0007] Cyclic GMP-AMP (cGAMP) synthase (cGAS) is a key sensor of cytosolic double-strand DNA, serving as ubiquitous danger-associated molecules when originating from microbial source or host sources that can be mitochondrial, extracellular (engulfment tissue damage DNA by myeloid cells) or nuclear (retroelements reverse transcription, nuclear damage). Upon dsDNA binding, cGAS catalyzes synthesis of cyclic nucleotide (and 2nd messenger) cGAMP from one ATP and one GTP. cGAMP binds the ER-resident dimeric transmembrane receptor stimulator of interferon genes (STING) causing its activation and exit from ER. STING translocates to the Golgi apparatus where it recruits and activates TANK-binding kinase 1 (TBK1) causing phosphorylation and activation of interferon regulatory transcription factor 3 (IRF3). Next, IRF3 dimerizes and translocates to the nucleus where it promotes expression of type I interferons (IFN-I). In addition, STING also activates the canonical NFk pathway through the kinase IKK leading to the production of pro-inflammatory cytokines.

[0008] The cGAS-STING signaling pathway has emerged as a key mediator of inflammation in the settings of infection, cellular stress and tissue damage which are important in different disease indications. Rare genetic diseases like Type I interferonopathies, driven by loss-of-function mutations in cytosolic nucleases (TREX1 , SAMHD1 , DNASE2), cause accumulation of cytosolic dsDNA which amplifies cGAS-STING signaling and Type I IFN responses. These are the most obvious auto-immune diseases that would benefit from cGAS inhibition (e.g. Aicardi Goutieres Syndrome (AGS), TREX1 subsets of lupus, heterozygous TR EX1 mutation in Familial Chilblain Lupus). Mitochondrial leakage or defects causing accumulation of mtDNA in the cytosol is increasingly recognized as an underlying pathologic inflammatory response in neurodegenerative diseases like Parkinson’s disease subsets (TDP43, PINK1-Perkin), Amyotrophic lateral sclerosis subsets (alpha-synuclein, SOD1) and Frontotemporal dementia (FTD). Several other inflammatory diseases are linked to mtDNA accumulation in the cytosol (nonalcoholic steatohepatitis (NASH), chronic obstructive pulmonary disease (COPD), Inflammatory bowel disease (I BD)), anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) and autoimmune diseases (several subsets of SLE). Also reverse transcription of Alu repeat elements into cytosolic Alu cDNA is shown to activate cGAS and is causally linked to an advanced stage of dry age-related macular degeneration (AMD) - Geographic atrophy (GA). Additionally, chromosomal instability also causes increased cytosolic DNA. Recently, it is suggested that some subsets of diverse cancer types show TREX deficiency linked with increased type I interferon responses and worse disease progression suggesting pro-tumorigenic traits of cGAS-STING pathways. Therefore, small molecule inhibitors of cGAS are useful for the treatment or prevention of different disease with an inappropriate cGAS-STING activity.

[0009] In 2017, Pfizer published compound PF-06928215 as an inhibitor of cGAS (Hall et al, PLoS ONE 12(9): e0184843). Nitropyrazole and pyridoindole compounds have been published as cGAS inhibitors in Lama et al, Nat Com 10, 2261 (2019). The patent applications WO / 2022066851 , WO / 2023081441 , WO / 2022238327, WO / 2022238335, WO / 2022051634, and WO / 2022137082 also describe cGAS inhibitors.

[0010] However, there is still a great need for novel, alternative or better therapeutics for the prevention or treatment of inflammatory and / or auto-immune diseases and disease indications mediated by cGAS activation. Therapeutics with better target engagement, (cellular) potency, less side- effects, a higher activity, a lower toxicity, better pharmacokinetic or -dynamic properties, a better (oral) bioavailability, higher (hepatocyte) metabolic stability, varied volume of distribution, effective dosage or combinations thereof would be very welcome.

[0011] The present invention provides a class of novel compounds which can be used as inhibitors of cGAS or as modulators of cGAS activity in disease indications mediated by cGAS. SUMMARY OF THE INVENTION

[0012] The present invention is based on the unexpected finding that at least one of the above- mentioned problems can be solved by the below described compounds.

[0013] The present invention provides new compounds, especially compound of formula (I) as defined by the claims and / or embodiments described herein, a stereo-isomeric form, a tautomer, a salt (in particular a pharmaceutically acceptable salt), solvate, polymorph and / or prodrug thereof

[0014] The present invention provides new compounds which have been shown to possess modulatory, more in particular inhibitory activity on cGAS. The present invention furthermore demonstrates that these compounds efficiently inhibit the activity of cGAS. Therefore, these compounds constitute a useful class of new potent compounds that can be used in the treatment and / or prevention of cGAS mediated disorders in animals, mammals and humans, more specifically for the treatment and / or prevention of inflammation conditions, more in particular diseases with cGAS activity or activation, yet more in particular inflammatory diseases, auto-immune diseases, allergic diseases, fibrotic diseases and cancer.

[0015] The present invention furthermore relates to the compounds of the invention for use as a medicine, to the use of such compounds as medicines and to their use for the manufacture of medicaments, more in particular for treating and / or preventing cGAS mediated diseases, in particular inflammation conditions such as in (i) inflammatory diseases, (ii) auto-immune diseases, (iii) allergic diseases, (iv) fibrotic diseases and also for cancer in animals or mammals, more in particular in humans.

[0016] The invention also relates to pharmaceutical compositions comprising the compounds of the invention in an effective amount, to said pharmaceutical compositions for use as a medicine, more in particular for use as a medicine for the prevention or treatment of cGAS mediated disorders and to the method of preparation of manufacturing of said pharmaceutical compositions.

[0017] The present invention also relates to a method of treatment or prevention of cGAS mediated disorders in humans by the administration of one or more such compounds, optionally in combination with one or more other medicines, to a patient in need thereof. Also disclosed herein is a method of treating inflammation conditions (inflammatory diseases, auto-immune diseases, allergic diseases, fibrotic diseases) and cancer in a patient in need thereof, comprising administering to the patient an effective amount of a compound disclosed herein in combination with an additional therapeutic agent. In some embodiments, the additional medicine or therapeutic agent is an anti- inflammatory agent, anti-fibrotic agent or anti-allergic agent.

[0018] When reference is made to the treatment or prevention of a cGAS mediated diseases in animals or mammals, more in particular in humans, this in a particular embodiment refers to (i) inflammation conditions, more in particular to inflammatory diseases, auto-immune diseases, allergic diseases, inflammatory conditions of any tissue or organ, diseases with an inflammatory component or any other inflammatory conditions, more in particular which are responsive to cGAS inhibitor or modulator treatment, yet more in particular for which cGAS activity or activation drives, contributes, sustains, enables or the like such disease and (ii) cancer. In a particular embodiment, the cGAS mediated diseases are selected from inflammatory, allergic or autoimmune diseases such as systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (OLE), Lupus Nephritis (LN), interferonopathies, psoriasis, insulin-dependent diabetes mellitus (IDDM), vasculitis, scleroderma, Aicardi Goutieres syndrome, dermatomyositis, sepsis, inflammatory bowel diseases, multiple sclerosis, rheumatoid arthritis, Sjogren's syndrome (SS), age related macular degeneration (AMD), Amyotrophic Lateral sclerosis (ALS), Fronto-temporal dementia (FTD), Alzheimer’s disease, Huntington’s disease and Parkinson’s disease.

[0019] More in particular in relation to the treatment or prevention of inflammation conditions, the invention comprises administering to the patient an effective amount of a compound disclosed herein, also in combination with an additional therapeutic agent. In some embodiments, the additional therapeutic agent is an anti- inflammatory agent, anti-fibrotic agent or anti-allergic agent. In particular related to the treatment or prevention of inflammation conditions comprises the treatment or prevention of SLE, interferonopathies or Aicardi Goutieres syndrome in a patient in need thereof, comprising administering to the patient an effective amount of a compound disclosed herein, or comprises treating and / or controlling neuroinflammation in a patient in need thereof, comprising administering to the patient an effective amount of a compound disclosed herein. The present invention also relates to a method of preparation of the compounds of the invention comprising the steps for synthesis of the compounds as described herein.

[0020] DESCRIPTION OF THE FIGURES

[0021] Figure 1 : In vivo activity of CPD 058. Anti-inflammatory activity of CPD 058 in a UVB-induced damage and inflammation mouse model performed in accordance with example 65.

[0022] DETAILED DESCRIPTION OF THE INVENTION

[0023] The present invention will be further described and in some instances with respect to particular embodiments, but the invention is not limited thereto. The term “cGAS mediated diseases” or “cGAS mediated disorders” refers to diseases, disorders or conditions in which cGAS signaling is active or activated and whereby cGAS activity or activation is contributing, driving, sustaining, enabling or the like such disease. cGAS mediated diseases includes inflammatory diseases, autoimmune diseases, allergic disorders, but also cancer, fibrotic disorders and neurodegenerative diseases and any other disease with an inflammatory component or any other disease, disorder or ailment favourably responsive to cGAS inhibitor or modulator treatment. In a particular embodiment, the term “cGAS mediated diseases” or “cGAS mediated disorders” refers to diseases, disorders or conditions whereby cGAS is active or activated, more in particular as a consequence of, or cGAS activity is believed to be linked to (i) a genetic abnormality or in a genetic disease like Type I interferonopathies, driven by loss-of-function mutations in cytosolic nucleases (TREX1 , SAMHD1 , DNASE2), such as in e.g. Aicardi Goutieres Syndrome (AGS), TREX1 subsets of lupus, heterozygous TREX1 mutation in Familial Chilblain Lupus, and / or (ii) (accumulation of) mtDNA in the cytosol such as via mitochondrial leakage or defects thereby underlying pathologic inflammatory response such as in in neurodegenerative diseases like Parkinson’s disease subsets (TDP43, PINK1-Perkin), Amyotrophic lateral sclerosis subsets (alpha- synuclein, SOD1) and Frontotemporal dementia (FTD) or in several other diseases with an inflammatory component such as nonalcoholic steatohepatitis (NASH), chronic obstructive pulmonary disease (COPD), Inflammatory bowel disease (I BD)), anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) and subsets of Systemic Lupus Erythematosus (SLE), and / or (iii) cytosolic Alu cDNA, such as through reverse transcription of Alu repeat elements, can form the basis for inflammation via activation of cGAS such as in (advanced stage of) dry age-related macular degeneration (AMD) or Geographic atrophy (GA).

[0024] The term “auto-immune disease(s)” or “auto-immune disorder(s)” refers to diseases that result from an aberrant immune response against its own cells and / or tissues due to a failure of an organism to recognize its own constituent parts (down to the sub-molecular level) as “self’. Auto-immune disorders are divided into “systemic auto-immune diseases” (such as lupus erythematosus, psoriasis, vasculitis, polymyositis, scleroderma, multiple sclerosis, ankylosing spondylitis, rheumatoid arthritis and Sjogren’s syndrome), “auto-immune endocrine disorders” (such as thyroiditis) and “organ-specific auto-immune diseases” (such as Addison disease, haemolytic or pernicious anaemia, Goodpasture syndrome, Graves disease, idiopathic thrombocytopenic purpura, insulin-dependent diabetes mellitus, juvenile diabetes, uveitis, Crohn's disease, ulcerative colitis, pemphigus, atopic dermatitis, autoimmune hepatitis, primary biliary cirrhosis, autoimmune pneumonitis, auto-immune carditis, myasthenia gravis, glomerulonephritis and spontaneous infertility). The autoimmune disorders are thus directed to own cells or tissues and include a reaction to “auto-antigens”, meaning antigens (e.g. of proteins) that are own constituent parts of the specific mammalian organism. In this mechanism, auto-antigens are recognized by B -and / or T-cells which will install an immune reaction against said auto-antigen.

[0025] A non-limitative list of diseases encompassed by the term “auto-immune diseases” or “autoimmune disorders” comprises therefore Acute disseminated encephalomyelitis (ADEM), Addison's disease, Alopecia areata, Antiphospholipid antibody syndrome (APS), Autoimmune haemolytic anaemia, Autoimmune hepatitis, Bullous pemphigoid, Behcet's disease, Coeliac disease, inflammatory bowel disease (IBD) (such as Crohn’s Disease and Ulcerative Colitis), Dermatomyositis, Diabetes mellitus type 1 , Goodpasture's syndrome, Graves' disease, Guillain-Barre syndrome (GBS), Hashimoto's disease, Idiopathic thrombocytopenic purpura, Lupus erythematosus, Mixed Connective Tissue Disease, Multiple sclerosis (MS), Myasthenia gravis, Narcolepsy, Pemphigus vulgaris, Pernicious anaemia, Psoriasis, Psoriatic Arthritis, Polymyositis, Primary biliary cirrhosis, Rheumatoid arthritis (RA), Sjogren's syndrome, Temporal arteritis, Vasculitis, Wegener's granulomatosis and atopic dermatitis. Also the following disorders are suspected to be auto-immune diseases: Ankylosing spondylitis, Autoimmune inner ear disease, Chagas disease, Chronic obstructive pulmonary disease (COPD), Endometriosis, Hidradenitis suppurativa, Kawasaki disease, IgA nephropathy, Interstitial cystitis, Morphea, Neuromyotonia, Schizophrenia, Scleroderma, Stiff person syndrome and Vitiligo. Auto-immune disorders are divided into “systemic auto-immune diseases” (such as lupus erythematosus, psoriasis, vasculitis, polymyositis, scleroderma, multiple sclerosis, ankylosing spondylitis, rheumatoid arthritis and Sjogren’s syndrome), “autoimmune endocrine disorders” (such as thyroiditis) and “organ-specific auto-immune diseases” (such as Addison disease, haemolytic or pernicious anaemia, Goodpasture syndrome, Graves disease, idiopathic thrombocytopenic purpura, insulin-dependent diabetes mellitus, juvenile diabetes, uveitis, Crohn's disease, ulcerative colitis, pemphigus, atopic dermatitis, autoimmune hepatitis, primary biliary cirrhosis, autoimmune pneumonitis, auto-immune carditis, myasthenia gravis, glomerulonephritis and spontaneous infertility).

[0026] The term “inflammatory diseases” or “inflammatory disorders” refers to, but is not limited to disease selected from the group of rheumatoid arthritis, conjunctivitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, bronchitis, tuberculosis, chronic cholecystitis, inflammatory bowel disease, acute pancreatitis, sepsis, asthma, chronic obstructive pulmonary disease, dermal inflammatory disorders such as psoriasis and atopic dermatitis, systemic inflammatory response syndrome (SIRS), acute respiratory distress syndrome (ARDS), cancer-associated inflammation, reduction of tumor-associated angiogenesis, diabetes, treatment of graft v. host disease and associated tissue rejection inflammatory responses, Crohn's disease, delayed- type hypersensitivity, immune-mediated and inflammatory elements of CNS disease; e.g., Alzheimer's, Parkinson's, multiple sclerosis, etc. The term “allergic diseases” or “allergic disorders” refers to, but is not limited to diseases selected from the group of asthma, allergic rhinitis, allergic sinusitis, anaphylactic syndrome, urticaria, angioedema, atopic dermatitis, allergic contact dermatitis, erythema nodosum, erythema multiforme, cutaneous necrotizing venulitis, insect bite skin inflammation and blood sucking parasitic infestation.

[0027] The term “fibrotic diseases” as used herein refers to lung fibrosis or pulmonary fibrosis (such as Asbestosis, COVID-19-related pulmonary fibrosis, drug-induced pulmonary fibrosis, hypersensitivity Pneumonitis (HP), idiopathic pulmonary fibrosis (IPF), idiopathic NSIP, pneumoconiosis, rheumatoid arthritis interstitial lung disease (RA-ILD)), liver fibrosis, heart fibrosis, mediastinal fibrosis, retroperitoneal cavity fibrosis including kidney fibrosis, bone marrow fibrosis, skin fibrosis, scleroderma or systemic sclerosis and other types of pathological fibrosis.

[0028] The term "cancer" as used herein refers to all types of animal, more specifically human cancers, neoplasm or (malignant) tumors including carcinomas, sarcomas, lymphomas, leukaemias, germ cell tumors and blastomas and thus includes solid and lymphoid cancers. Exemplary cancers that may be treated with a compound, pharmaceutical composition, or method provided herein include lymphoma, sarcoma, bladder cancer, bone cancer, brain tumor, cervical cancer, colon cancer, oesophageal cancer, gastric cancer, head and neck cancer, kidney cancer, myeloma, thyroid cancer, leukaemia, prostate cancer, breast cancer (e.g., ER positive, ER negative, chemotherapy resistant, herceptin resistant, HER2 positive, doxorubicin resistant, tamoxifen resistant, ductal carcinoma, lobular carcinoma, primary, metastatic), ovarian cancer, pancreatic cancer, liver cancer (e.g., hepatocellular carcinoma), lung cancer (e.g., non-small cell lung carcinoma, squamous cell lung carcinoma, adenocarcinoma, large cell lung carcinoma, small cell lung carcinoma, carcinoid, sarcoma), glioblastoma multiforme, glioma, or melanoma. Additional examples include, cancer of the thyroid, endocrine system, brain, breast, cervix, colon, head & neck, liver, kidney, lung, non- small cell lung, melanoma, mesothelioma, ovary, sarcoma, stomach, uterus or Medulloblastoma, Hodgkin's Disease, Non-Hodgkin's Lymphoma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, ovarian cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, primary brain tumors, cancer, malignant pancreatic insulinoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, lymphomas, thyroid cancer, neuroblastoma, oesophageal cancer, genitourinary tract cancer, malignant hypercalcemia, endometrial cancer, adrenal cortical cancer, neoplasms of the endocrine or exocrine pancreas, medullary thyroid cancer, medullary thyroid carcinoma, melanoma, colorectal cancer, papillary thyroid cancer, hepatocellular carcinoma, Paget' s Disease of the Nipple, Phyllodes Tumours, Lobular Carcinoma, Ductal Carcinoma, cancer of the pancreatic stellate cells, cancer of the hepatic stellate cells, or prostate cancer. In some embodiments, the term cancer refers to bladder cancer, bone cancer, brain cancer, breast cancer, cardiac cancer, cervical cancer, colon cancer, colorectal cancer, oesophageal cancer, fibrosarcoma, gastric cancer, gastrointestinal cancer, head, spine and neck cancer, Kaposi's sarcoma, kidney cancer, pancreatic cancer, penile cancer, testicular germ cell cancer, thymoma carcinoma, thymic carcinoma, lung cancer, ovarian cancer or prostate cancer.

[0029] In a particular embodiment, the term “inflammation condition(s)” as used herein refers to inflammatory diseases, auto-immune diseases, allergic diseases, inflammatory conditions of any tissue or organ, diseases with an inflammatory component or any other inflammatory conditions, more in particular which are responsive to cGAS inhibitor or modulator treatment, yet more in particular for which cGAS activity or activation drives, contributes, sustains, enables or the like such disease.

[0030] The term “inflammation condition(s)” as used herein comprises therefore inflammatory, allergic or autoimmune diseases or diseases with an inflammation component such as systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (OLE), lupus nephritis (LN), interferonopathies, psoriasis, insulin-dependent diabetes mellitus (IDDM), vasculitis, scleroderma, Aicardi Goutieres syndrome, dermatomyositis, sepsis, inflammatory bowel diseases, multiple sclerosis, rheumatoid arthritis, Sjogren's syndrome (SS), age related macular degeneration (AMD), Amyotrophic Lateral sclerosis (ALS), Fronto-temporal dementia (FTD), Alzheimer’s disease, Huntington’s disease and Parkinson’s disease.

[0031] The term “inflammation condition(s)” also comprises disorders with inflammation of any tissue and organs of the body, including musculoskeletal inflammation, vascular inflammation, neural inflammation, digestive system inflammation, ocular inflammation, inflammation of the reproductive system, and other inflammation such as of the cardiovascular system. Musculoskeletal inflammation refers to any inflammatory condition of the musculoskeletal system, particularly those conditions affecting skeletal joints, including joints of the hand, wrist, elbow, shoulder, jaw, spine, neck, hip, knew, ankle, and foot, and conditions affecting tissues connecting muscles to bones such as tendons. Examples of musculoskeletal inflammation include arthritis (including, for example, osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, acute and chronic infectious arthritis, arthritis associated with gout and pseudogout, and juvenile idiopathic arthritis), tendonitis, synovitis, tenosynovitis, bursitis, fibrositis (fibromyalgia), epicondylitis, myositis, and osteitis (including, for example, Paget's disease, osteitis pubis, and osteitis fibrosa cystic). Neural inflammation or inflammation of the nervous system comprises encephalitis, Guillain-Barre syndrome, meningitis, neuromyotonia, narcolepsy, multiple sclerosis, myelitis, schizophrenia and inflammation in the CNS, incl. in neurodegenerative disorders such as Parkinson’s disease, Amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. Ocular inflammation refers to inflammation of any structure of the eye, including the eye lids. Examples of ocular inflammation which may be treated with the compounds of the disclosure include blepharitis, blepharochalasis, conjunctivitis, dacryoadenitis, keratitis, keratoconjunctivitis sicca (dry eye), scleritis, trichiasis, and uveitis. Inflammation of the vasculature or lymphatic system includes atherosclerosis, arthritis, phlebitis, vasculitis, and lymphangitis. Inflammatory conditions of the digestive system comprises cholangitis, cholecystitis, enteritis, enterocolitis, gastritis, gastroenteritis, inflammatory' bowel disease (such as Crohn's disease and ulcerative colitis), ileitis, and proctitis. Inflammatory conditions of the reproductive system include cervicitis, chorioamnionitis, endometritis, epididymitis, omphalitis, oophoritis, orchitis, salpingitis, tribo - ovarian abscess, urethritis, vaginitis, vulvitis, and vulvodynia.

[0032] Autoimmune conditions having an inflammatory component are also comprised in the term “inflammation condition(s)” and such conditions include systemic lupus erythematosus, cutaneous lupus erythematosus, acute disseminated alopecia universalis, Behcet’s disease, Chagas' disease, chronic fatigue syndrome, dysautonomia, encephalomyelitis, ankylosing spondylitis, aplastic anaemia, hidradenitis suppurativa, autoimmune hepatitis, autoimmune oophoritis, celiac disease, Crohn's disease, diabetes mellites type 1 , giant cell arteritis, Goodpasture's syndrome. Grave's disease, Guillain- Barre syndrome, Hashimoto's disease, Henoch-Schonlein purpura, Kawasaki's disease, microscopic colitis, microscopic polyarteritis, mixed connective tissue disease, multiple sclerosis, myasthenia gravis, opsoclonus myoclonus syndrome, optic neuritis, Ord’s thyroiditis, pemphigus, polyarteritis nodosa, polymyalgia, rheumatoid arthritis, Reiter's syndrome, Sjogren's syndrome, Aicardi-Goutieres syndrome, temporal arteritis, Wegener’s granulomatosis, warm autoimmune haemolytic anaemia, interstitial cystitis, Lyme disease, morphea, psoriasis, sarcoidosis, scleroderma, ulcerative colitis, and vitiligo.

[0033] The term “inflammation condition(s)” also refers to allergic diseases or T-cell mediated hypersensitivity diseases having an inflammatory component such as contact hypersensitivity, contact dermatitis, urticaria, skin allergies, respiratory allergies (e.g. hay fever, allergic rhinitis) and gluten-sensitive enteropathy (Coeliac disease).

[0034] In general, the term “inflammation condition(s)” comprises any disease with an inflammatory component and thus also comprises appendicitis, dermatitis, dermatomyositis, endocarditis, fibrositis, gingivitis, glossitis, hepatitis, hidradenitis suppurativa, iritis, laryngitis, mastitis, myocarditis, nephritis, otitis, pancreatitis, parotitis, pericarditis, peritonitis, pharyngitis, pleuritis, pneumonitis, prostatitis, pyelonephritis, and stomatisi, transplant rejection (involving organs such as kidney, liver, heart, lung, pancreas (e.g., islet cells), bone marrow, cornea, small bowel, skin allografts, skin homografts, and heart valve xenografts, serum sickness, and graft vs host disease), acute pancreatitis, chronic pancreatitis, acute respiratory distress syndrome. Sezary’s syndrome, congenital adrenal hyperplasia, nonsuppurative thyroiditis, hypercalcemia associated with cancer, pemphigus, bullous dermatitis herpetiformis, severe erythema multiforme, exfoliative dermatitis, seborrheic dermatitis, seasonal or perennial allergic rhinitis, bronchial asthma, contact dermatitis, atopic dermatitis, drug hypersensitivity reactions, allergic conjunctivitis, keratitis, herpes zoster ophthalmicus, iritis and iridocyclitis, chorioretinitis, optic neuritis, symptomatic sarcoidosis, fulminating or disseminated pulmonary' tuberculosis, chemotherapy, idiopathic thrombocytopenic purpura in adults, secondary' thrombocytopenia in adults, acquired (autoimmune) haemolytic anaemia, leukaemia and lymphomas in adults, acute leukaemia of childhood, regional enteritis, autoimmune vasculitis, multiple sclerosis, chronic obstructive pulmonary disease, solid organ transplant rejection, sepsis.

[0035] Also fibrotic diseases are part of the cGAS mediated disorders or diseases. Fibrosis, also known as fibrotic scarring, is a pathological wound healing in which connective tissue replaces normal parenchymal tissue to the extent that it goes unchecked, leading to considerable tissue remodelling and the formation of permanent scar tissue. Fibrosis is the end result of chronic inflammatory reactions induced by a variety of stimuli including persistent infections, autoimmune reactions, allergic responses, chemical insults, radiation, and tissue injury. Fibrotic diseases, more in particular with an active inflammatory component, are also comprised in the term “inflammation condition(s)” and includes systemic sclerosis (SSc), interferonopathies, non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), more in particular progressive fibrosing interstitial lung disease (PF- ILD), in particular idiopathic pulmonary fibrosis (IPF).

[0036] The term “treat” or “treating” as used herein is intended to refer to administration of a compound or composition of the invention to a subject for the purpose of effecting a therapeutic benefit or prophylactic benefit, here in particular through inhibition of cGAS. Treating includes reversing, ameliorating, alleviating, inhibiting the progress of, lessening the severity of, or preventing a disease, disorder, or condition, or one or more symptoms, complications or biochemical indications of such disease, disorder or condition, here in particular mediated through cGAS. By "therapeutic benefit" is meant eradication, amelioration, reversing, alleviating, inhibiting the progress of or lessening the severity of the underlying disorder being treated. Also, a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient is afflicted with the underlying disorder in some embodiments. For prophylactic benefit, in some embodiments, the compositions are administered to a patient at risk of developing a particular disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease has not been made. For example certain methods herein treat cancer by decreasing or reducing or preventing the occurrence, growth, metastasis, or progression of cancer or decreasing a symptom of cancer. The term “prevent” or “preventing” as used herein is intended to refer to administration of a compound or composition of the invention to a subject for the purpose of effecting a therapeutic or prophylactic benefit, in particular through inhibition of cGAS whereby appearance or progression of disease, disorder or condition, or, onset or progression of one or more symptoms, complications or biochemical indications or such disease, disorder or condition is at least delayed.

[0037] The term “subject” as used herein, refers to an animal, preferably a mammal, most preferably a human, a patient, who has been the object of treatment, observation or experiment or who is in need of such treatment.

[0038] The term “therapeutically effective amount” as used herein, means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation or partial alleviation of the symptoms of the disease or disorder being treated.

[0039] The term “composition” as used herein is intended to encompass a product comprising the specified ingredients in the therapeutically effective amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.

[0040] The term “antagonist” or “inhibitor” as used herein in reference to inhibitors of the cGAS activity or activation, refers to a compound capable of producing, depending on the circumstance, a functional antagonism or inhibition of cGAS activity or activation.

[0041] It is to be noticed that the term "comprising", used in the claims, should not be interpreted as being restricted to the means listed thereafter; it does not exclude other elements or steps.

[0042] Reference throughout this specification to "one embodiment" or "an embodiment" means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, appearances of the phrases "in one embodiment" or "in an embodiment" in various places throughout this specification are not necessarily all referring to the same embodiment, but may. Furthermore, the particular features, structures or characteristics may be combined in any suitable manner, as would be apparent to one of ordinary skill in the art from this disclosure, in one or more embodiments. Where an indefinite or definite article is used when referring to a singular noun e.g. "a" or "an", "the", this includes a plural of that noun unless something else is specifically stated.

[0043] Similarly it should be appreciated that in the description of exemplary embodiments of the invention, various features of the invention are sometimes grouped together in a single embodiment, figure, or description thereof for the purpose of streamlining the disclosure and aiding in the understanding of one or more of the various inventive aspects. In each of the following definitions, the number of carbon atoms represents the maximum number of carbon atoms generally optimally present in the substituent or linker; it is understood that where otherwise indicated in the present application, the number of carbon atoms represents the optimal maximum number of carbon atoms for that particular substituent or linker.

[0044] The term “leaving group” or “LG” as used herein means a chemical group which is susceptible to be displaced by a nucleophile or cleaved off or hydrolyzed in basic or acidic conditions. In a particular embodiment, a leaving group is selected from a halogen atom (e.g., Cl, Br, I) or a sulfonate (e.g., mesylate, tosylate, triflate).

[0045] The term “protecting group” refers to a moiety of a compound that masks or alters the properties of a functional group or the properties of the compound as a whole. The chemical substructure of a protecting group varies widely. One function of a protecting group is to serve as intermediates in the synthesis of the parental drug substance. Chemical protecting groups and strategies for protection / deprotection are well known in the art. See: “Protective Groups in Organic Chemistry”, Theodora W. Greene (John Wiley & Sons, Inc., New York, 1991. Protecting groups are often utilized to mask the reactivity of certain functional groups, to assist in the efficiency of desired chemical reactions, e.g. making and breaking chemical bonds in an ordered and planned fashion. Protection of functional groups of a compound alters other physical properties besides the reactivity of the protected functional group, such as the polarity, lipophilicity (hydrophobicity), and other properties which can be measured by common analytical tools. Chemically protected intermediates may themselves be biologically active or inactive. In some embodiments the protecting group is selected from a carbamate (e.g. Boc), benzyl, p-MeO-benzyl or acetyl.

[0046] Protected compounds may also exhibit altered, and in some cases, optimized properties in vitro and in vivo, such as passage through cellular membranes and resistance to enzymatic degradation or sequestration. In this role, protected compounds with intended therapeutic effects may be referred to as prodrugs. Another function of a protecting group is to convert the parental drug into a prodrug, whereby the parental drug is released upon conversion of the prodrug in vivo. Because active prodrugs may be absorbed more effectively than the parental drug, prodrugs may possess greater potency in vivo than the parental drug. Protecting groups are removed either in vitro, in the instance of chemical intermediates, or in vivo, in the case of prodrugs. With chemical intermediates, it is not particularly important that the resulting products after deprotection, e.g. alcohols, be physiologically acceptable, although in general it is more desirable if the products are pharmacologically innocuous.

[0047] As used herein for terms such as alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl as defined herein, the notion or pre-fix Cx-yor Cx-Cymeans that the alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl consists of x to y carbon or heteroatoms composing the alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl. This does not include the carbon and / or heteroatoms of (optional) substituents, nor the carbon and / or heteroatoms of the group / molecule on which it is substituted. The term “alkyl” or “C1-18alkyl” as used herein means C1-C18 normal (primary), secondary or tertiary, linear, branched or straight hydrocarbon with no site of unsaturation. Examples are methyl, ethyl, 1-propyl (n-propyl), 2-propyl (iPr), 1-butyl, 2-methyl-1-propyl (i-Bu), 2-butyl (s- Bu), 2-dimethyl-2-propyl (t-Bu), 1-pentyl (n-pentyl), 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3- methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2- butyl, 3,3-dimethyl-2-butyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, n-dodecyl, n-tridecyl, n-tetradecyl, n-pentadecyl, n-hexadecyl, n-heptadecyl, n-octadecyl, n-nonadecyl, and n-icosyl. In particular embodiments, the term alkyl refers to C1-12alkyl (C1-12 hydrocarbons), yet more in particular to C1-9alkyl (C1-9 hydrocarbons), yet more in particular to C1-6 alkyl (C1-6 hydrocarbons) or C1-4 alkyl (C1-4 hydrocarbons) as further defined herein. Such embodiments may apply independently to terms comprising more than one alkyl moiety, e.g. embodiments of alkoxyalkyl include among others C1-4alkoxy-C1-6alkyl, C1-6alkoxy-C1-6alkyl or C1-6alkoxy-C1- 4alkyl. The term "haloalkyl" as a group or part of a group, refers to an alkyl group having the meaning as defined above wherein one, two, or three hydrogen atoms are each replaced with a halogen as defined herein. Non-limiting examples of such haloalkyl groups include chloromethyl, 1-bromoethyl, fluoromethyl, difluoromethyl, trifluoromethyl, 1,1,1-trifluoroethyl and the like. The term "hydroxyalkyl" as a group or part of a group, refers to an alkyl group having the meaning as defined above wherein one, two, or three hydrogen atoms are each replaced with an hydroxyl as defined herein, i.e. mono-, di- and tri-hydroxy-alkyl respectively. Non-limiting examples of such hydroxyalkyl groups include hydroxymethyl, 1-hydroxy-ethyl, 2-hydroxy- ethyl, 1,2-di-hydroxy ethyl, etc. The term “alkoxy" or “alkyloxy”, as a group or part of a group, refers to a group having the formula –ORbwherein Rbis C1-6alkyl as defined herein above. Non-limiting examples of suitable C1-6alkoxy include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec- butoxy, tert-butoxy, pentyloxy and hexyloxy. The term "hydroxyalkoxy" as a group or part of a group, refers to an alkyloxy (i.e. alkoxy) group having the meaning as defined above wherein one, two, or three hydrogen atoms are each replaced with an hydroxyl as defined herein, i.e. mono-, di- and tri-hydroxy-alkyloxy respectively. Non-limiting examples of such hydroxyalkyloxy groups include hydroxymethyloxy, 1-hydroxy-ethyloxy, 2-hydroxy-ethyloxy, 1,2-di-hydroxy ethyloxy, etc. The term "aminoalkoxy" as a group or part of a group, refers to an alkyloxy (i.e. alkoxy) group having the meaning as defined above wherein one, two, or three hydrogen atoms are each replaced with an amino group (-NH2) as defined herein, i.e. mono-, di- and tri-amino-alkyloxy respectively. Non-limiting examples of such aminoalkyloxy groups include aminomethyloxy, 1- amino-ethyloxy, 2-amino-ethyloxy, 1,2-di-amino-ethyloxy, etc. The term “hydroxycarbonyl-alkyl”, as a group or part of a group, refers to a group of formula -Ra-COOH, wherein Rais alkylene as defined herein. The term “haloalkoxy”, as a group or part of a group, refers to a group of formula -O-Rc, wherein Rcis haloalkyl as defined herein. Non-limiting examples of suitable haloalkoxy include fluoromethoxy, difluoromethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, 1,1,2,2- tetrafluoroethoxy, 2-fluoroethoxy, 2-chloroethoxy, 2,2-difluoroethoxy, 2,2,2-trichloroethoxy, trichloromethoxy, 2-bromoethoxy, pentafluoroethyl, 3,3,3-trichloropropoxy, 4,4,4- trichlorobutoxy. The term “cycloalkyl” or “C3-18cycloalkyl” as used herein and unless otherwise stated means a saturated hydrocarbon monovalent group having from 3 to 18 carbon atoms consisting of or comprising a C3-10monocyclic or C7-18polycyclic saturated hydrocarbon, such as for instance cyclopropyl, cyclobutyl, cyclopentyl, cyclopropylethylene, methylcyclopropylene, cyclohexyl, cycloheptyl, cyclooctyl, cyclooctylmethylene, norbornyl, fenchyl, trimethyltricycloheptyl, decalinyl, adamantyl and the like. In particular embodiments, the term cycloalkyl refers to C3- 12cycloalkyl (saturated cyclic C3-12hydrocarbons), yet more in particular to C3-9cycloalkyl (saturated cyclic C3-9hydrocarbons), still more in particular to C3-6cycloalkyl (saturated cyclic C3-6hydrocarbons) as further defined herein above. For the avoidance of doubt, fused systems of a cycloalkyl ring with a heterocyclic ring are considered as heterocycle irrespective of the ring that is bound to the core structure. Fused systems of a cycloalkyl ring with an aryl ring are considered as aryl irrespective of the ring that is bound to the core structure. Fused systems of a cycloalkyl ring with a heteroaryl ring are considered as heteroaryl irrespective of the ring that is bound to the core structure. The term “alkenyl” or “C2-18alkenyl” as used herein is C2-C18 normal (primary), secondary or tertiary, linear, branched or straight hydrocarbon with at least one site (usually 1 to 3, preferably 1) of unsaturation, namely a carbon-carbon, sp2 double bond. Examples include, but are not limited to: ethylene or vinyl (-CH=CH2), allyl (-CH2CH=CH2), and 5-hexenyl (- CH2CH2CH2CH2CH=CH2). The double bond may be in the cis or trans configuration. In particular embodiments, the term alkenyl refers to C2-12alkenyl (C2-12 hydrocarbons), yet more in particular to C2-9 alkenyl (C2-9 hydrocarbons), still more in particular to C2-6 alkenyl (C2-6 hydrocarbons) as further defined herein above with at least one site (usually 1 to 3, preferably 1) of unsaturation, namely a carbon-carbon, sp2 double bond. The term “alkenyloxy”, as a group or part of a group, refers to a group having the formula – ORdwherein Rdis alkenyl as defined herein above. The term “cycloalkenyl” as used herein refers to a non-aromatic hydrocarbon group having from 5 to 18 carbon atoms with at least one site (usually 1 to 3, preferably 1) of unsaturation, namely a carbon-carbon, sp2 double bond and consisting of or comprising a C5-10 monocyclic or C7-18 polycyclic hydrocarbon. Examples include, but are not limited to: cyclopentenyl (-C5H7), cyclopentenylpropylene, methylcyclohexenylene and cyclohexenyl (- C6H9). The double bond may be in the cis or trans configuration. In particular embodiments, the term cycloalkenyl refers to C5-12cycloalkenyl (cyclic C5-12hydrocarbons), yet more in particular to C5-9 cycloalkenyl (cyclic C5-9 hydrocarbons), still more in particular to C5-6 cycloalkenyl (cyclic C5-6 hydrocarbons) as further defined herein above with at least one site of unsaturation, namely a carbon-carbon, sp2 double bond. For the avoidance of doubt, fused systems of a cycloalkenyl ring with a heterocyclic ring are considered as heterocycle irrespective of the ring that is bound to the core structure. Fused systems of a cycloalkenyl ring with an aryl ring are considered as aryl irrespective of the ring that is bound to the core structure. Fused systems of a cycloalkenyl ring with a heteroaryl ring are considered as heteroaryl irrespective of the ring that is bound to the core structure. The term “alkynyl” or “C2-18alkynyl” as used herein refers to C2-C18 normal (primary), secondary, tertiary, linear, branched or straight hydrocarbon with at least one site (usually 1 to 3, preferably 1) of unsaturation, namely a carbon-carbon, sp triple bond. Examples include, but are not limited to: ethynyl (-C ≡CH), 3-ethyl-cyclohept-1-ynylene, and 1-propynyl (propargyl, - CH2C ^CH). In particular embodiments, the term alkynyl refers to C2-12alkynyl (C2-12hydrocarbons), yet more in particular to C2-9alkynyl (C2-9hydrocarbons) yet more in particular to C2-6alkynyl (C2-6hydrocarbons) as further defined herein above with at least one site (usually 1 to 3, preferably 1) of unsaturation, namely a carbon-carbon, sp triple bond. The term “alkynyloxy”, as a group or part of a group, refers to a group having the formula – ORewherein Reis alkynyl as defined herein above. The term “cycloalkynyl” as used herein refers to a non-aromatic hydrocarbon group having from 5 to 18 carbon atoms with at least one site (usually 1 to 3, preferably 1) of unsaturation, namely a carbon-carbon, sp triple bond and consisting of or comprising a C5-10 monocyclic or C7-18 polycyclic hydrocarbon. Examples include, but are not limited to: cyclohept-1-yne, 3-ethyl- cyclohept-1-ynylene, 4-cyclohept-1-yn-methylene and ethylene-cyclohept-1-yne. In particular embodiments, the term cycloalkynyl refers to C5-10 cycloalkynyl (cyclic C5-10 hydrocarbons), yet more in particular to C5-9 cycloalkynyl (cyclic C5-9 hydrocarbons), still more in particular to C5-6 cycloalkynyl (cyclic C5-6 hydrocarbons) as further defined herein above with at least one site (usually 1 to 3, preferably 1) of unsaturation, namely a carbon-carbon, sp triple bond. For the avoidance of doubt, fused systems of a cycloalkynyl ring with a heterocyclic ring are considered as heterocycle irrespective of the ring that is bound to the core structure. Fused systems of a cycloalkynyl ring with an aryl ring are considered as aryl irrespective of the ring that is bound to the core structure. Fused systems of a cycloalkynyl ring with a heteroaryl ring are considered as heteroaryl irrespective of the ring that is bound to the core structure. The term “alkylene” as used herein each refer to a saturated, branched or straight chain hydrocarbon group of 1-18 carbon atoms (more in particular C1-12, C1-9 or C1-6 carbon atoms), and having two monovalent group centres derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkane. Typical alkylene include, but are not limited to: methylene (-CH2-), 1,2-ethyl (-CH2CH2-), 1,3-propyl (-CH2CH2CH2-), 1,4-butyl (- CH2CH2CH2CH2-), and the like. The term “alkenylene” as used herein each refer to a branched or straight chain hydrocarbon of 2-18 carbon atoms (more in particular C2-12, C2-9 or C2-6 carbon atoms) with at least one site (usually 1 to 3, preferably 1) of unsaturation, namely a carbon-carbon, sp2 double bond, and having two monovalent centres derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkene. The term “alkynylene” as used herein each refer to a branched or straight chain hydrocarbon of 2-18 carbon atoms (more in particular C2-12, C2-9 or C2-6 carbon atoms) with at least one site (usually 1 to 3, preferably 1) of unsaturation, namely a carbon-carbon, sp triple bond, and having two monovalent centres derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkyne. The term “heteroalkyl” as used herein refers to an alkyl wherein one or more carbon atoms are replaced by one or more atoms selected from the group comprising oxygen, nitrogen or sulphur atom. The term heteroalkyl thus comprises –O-Rb, -NRo-Rb, -Ra-O-Rb, and –S-Rb, wherein Rais alkylene, Rbis alkyl, and Rois hydrogen or alkyl as defined herein. In particular embodiments, the term refers to C1-12heteroalkyl, C1-9heteroalkyl or C1-6heteroalkyl. In some embodiments heteroalkyl is selected from the group comprising alkyloxy, alkyl-oxy-alkyl, (mono- or di- )alkylamino, (mono- or di-)alkyl-amino-alkyl, alkylthio, and alkyl-thio-alkyl. The term “heteroalkenyl” as used herein refers to an acyclic alkenyl wherein one or more carbon atoms are replaced by one or more atoms selected from oxygen, nitrogen or sulphur atom. The term heteroalkenyl thus comprises –O-Rd, -NH-(Rd), -N(Rd))2, -N(Rb)(Rd), and –S- Rdwherein Rbis alkyl and Rdis alkenyl as defined herein. In particular embodiments, the term refers to C2-12heteroalkenyl, C2-9heteroalkenyl or C2-6heteroalkenyl. In some embodiments heteroalkenyl is selected from the group comprising alkenyloxy, alkenyl-oxy-alkenyl, (mono- or di-)alkenylamino, (mono- or di-)alkenyl-amino-alkenyl, alkenylthio, and alkenyl-thio-alkenyl, The term “heteroalkynyl” as used herein refers to an acyclic alkynyl wherein one or more carbon atoms are replaced by an oxygen, nitrogen or sulphur atom. The term heteroalkynyl thus comprises but is not limited to -O-Rd, -N(Rd)2, NHRd, -N(Rb)(Re), -N(Rd)(Re), and -S-Rdwherein Rbis alkyl, Reis alkynyl and Rdis alkenyl as defined herein. In particular embodiments, the term refers to C2-12heteroalkynyl, C2-9heteroalkynyl or C2-6heteroalkynyl. In some embodiments the term heteroalkynyl is selected from the group comprising alkynyloxy, alkynyl- oxy-alkynyl, (mono- or di-)alkynylamino, (mono- or di-)alkynyl-amino-alkynyl, alkynylthio, alkynyl-thio-alkynyl, The term “heteroalkylene” as used herein refers to an alkylene wherein one or more carbon atoms are replaced by one or more oxygen, nitrogen or sulphur atoms. The term “heteroalkenylene” as used herein refers to an alkenylene wherein one or more carbon atoms are replaced by one or more oxygen, nitrogen or sulphur atoms. The term “heteroalkynylene” as used herein refers to an alkynylene wherein one or more carbon atoms are replaced by one or more oxygen, nitrogen or sulphur atom. The term “aryl” as used herein means an aromatic hydrocarbon of 6-20 carbon atoms derived by the removal of hydrogen from a carbon atom of a parent aromatic ring system. Typical aryl groups include, but are not limited to 1 ring, or 2 or 3 rings fused together, derived from benzene, naphthalene, anthracene, biphenyl, and the like. In particular embodiments, the term aryl refers to a 6-14 carbon atoms membered aromatic cycle, yet more in particular refers to a 6-10 carbon atoms membered aromatic cycle. Fused systems of an aryl ring with a cycloalkyl ring, or a cycloalkenyl ring, or a cycloalkynyl ring, are considered as aryl irrespective of the ring that is bound to the core structure. Fused systems of an aryl ring with a heterocycle are considered as heterocycle irrespective of the ring that is bound to the core structure. Thus, indoline, dihydrobenzofurane, dihydrobenzo-thiophene and the like are considered as heterocycle according to the invention. Fused systems of an aryl ring with a heteroaryl ring are considered as heteroaryl irrespective of the ring that is bound to the core structure. The term “aryloxy”, as a group or part of a group, refers to a group having the formula –ORgwherein Rgis aryl as defined herein above. The term “arylalkyl” or “arylalkyl-“ as used herein refers to an alkyl in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp3 carbon atom, is replaced with an aryl. Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-1-yl, 2- phenylethen-1-yl, naphthylmethyl, 2-naphthylethyl, and the like. The arylalkyl group comprises 6 to 20 carbon atoms, e.g. the alkyl moiety of the arylalkyl group is 1 to 6 carbon atoms and the aryl moiety is 6 to 14 carbon atoms. The term “arylalkyloxy”, as a group or part of a group, refers to a group having the formula -O-Ra-Rgwherein Rgis aryl, and Rais alkylene as defined herein above. The term “arylalkenyl” or “arylalkenyl-“ as used herein refers to an alkenyl in which one of the hydrogen atoms bonded to a carbon atom, is replaced with an aryl. The arylalkenyl group comprises 6 to 20 carbon atoms, e.g. the alkenyl moiety of the arylalkenyl group is 1 to 6 carbon atoms and the aryl moiety is 6 to 14 carbon atoms. The term “arylalkynyl” or “arylalkynyl-“ as used herein refers to an alkynyl in which one of the hydrogen atoms bonded to a carbon atom, is replaced with an aryl. The arylalkynyl group comprises 6 to 20 carbon atoms, e.g. the alkynyl moiety of the arylalkynyl group is 1 to 6 carbon atoms and the aryl moiety is 6 to 14 carbon atoms. The term “arylheteroalkyl” or “arylheteroalkyl-“ as used herein refers to a heteroalkyl in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp3 carbon atom, is replaced with an aryl. The arylheteroalkyl group comprises 6 to 20 carbon atoms, e.g. the heteroalkyl moiety of the arylheteroalkyl group is 1 to 6 carbon atoms and the aryl moiety is 6 to 14 carbon atoms. In some embodiments arylheteroalkyl is selected from the group comprising aryl-O-alkyl, arylalkyl-O-alkyl, aryl-NH-alkyl, aryl-N(alkyl)2, arylalkyl-NH-alkyl, arylalkyl-N-(alkyl)2, aryl–S-alkyl, and arylalkyl-S-alkyl. The term “arylheteroalkenyl” or “arylheteroalkenyl-“ as used herein refers to a heteroalkenyl in which one of the hydrogen atoms bonded to a carbon atom, is replaced with an aryl. The arylheteroalkenyl group comprises 6 to 20 carbon atoms, e.g. the heteroalkenyl moiety of the arylheteroalkenyl group is 1 to 6 carbon atoms and the aryl moiety is 6 to 14 carbon atoms. In some embodiments arylheteroalkenyl is selected from the group comprising aryl-O-alkenyl, arylalkenyl-O-alkenyl, aryl-NH-alkenyl, aryl-N(alkenyl)2, arylalkenyl-NH-alkenyl, arylalkenyl-N- (alkenyl)2, aryl–S-alkenyl, and arylalkenyl-S-alkenyl. The term “arylheteroalkynyl” or “arylheteroalkynyl-“ as used herein refers to a heteroalkynyl in which one of the hydrogen atoms bonded to a carbon atom, is replaced with an aryl. The arylheteroalkynyl group comprises 6 to 20 carbon atoms, e.g. the heteroalkynyl moiety of the arylheteroalkynyl group is 1 to 6 carbon atoms and the aryl moiety is 6 to 14 carbon atoms. In some embodiments arylheteroalkynyl is selected from the group comprising aryl-O-alkynyl, arylalkynyl-O-alkynyl, aryl-NH-alkynyl, aryl-N(alkynyl)2, arylalkynyl-NH-alkynyl, arylalkynyl-N- (alkynyl)2, aryl–S-alkynyl, and arylalkynyl-S-alkynyl. The term “heterocycle” or “heterocyclyl” as used herein refer to non-aromatic, fully saturated or partially unsaturated ring system of 3 to 18 (ring) atoms including at least one N, O, S, or P (i.e. C3-18, for example, 3 to 7 member monocyclic (C3-7), 7 to 11 member bicyclic (C3-11), or comprising a total of 3 to 10 ring atoms (C3-10)). Each ring of the heterocycle or heterocyclyl may have 1, 2, 3 or 4 heteroatoms selected from N, O and / or S, where the N and S heteroatoms may optionally be oxidized and the N heteroatoms may optionally be quaternized; and wherein at least one carbon atom of heterocyclyl can be oxidized to form at least one C=O. The heterocycle may be attached by any heteroatom or carbon atom of the ring or ring system, where valence allows. The rings of multi-ring heterocyclyls or heterocycles may be fused, bridged and / or joined through one or more spiro atoms. Fused systems of a heterocycle or heterocyclyl with an aryl ring are considered as heterocycle or heterocyclyl irrespective of the ring that is bound to the core structure. Fused systems of a heterocycle or heterocyclyl with a heteroaryl ring are considered as heteroaryl irrespective of the ring that is bound to the core structure. Non limiting exemplary heterocycles or heterocyclic groups include piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, tetrahydropyranyl, tetrahydrofuranyl, pyrrolidinyl, aziridinyl, oxiranyl, thiiranyl, azetidinyl, oxetanyl, thietanyl, 2-imidazolinyl, pyrazolidinyl imidazolidinyl, isoxazolinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, succinimidyl, 3H-indolyl, indolinyl, isoindolinyl, chromanyl (also known as 3,4-dihydrobenzo[b]pyranyl), 2H-pyrrolyl, 1- pyrrolinyl, 2-pyrrolinyl, 3-pyrrolinyl, 4H-quinolizinyl, 2-oxopiperazinyl, 2-pyrazolinyl, 3- pyrazolinyl, tetrahydro-2H-pyranyl, 2H-pyranyl, 4H-pyranyl, 3,4-dihydro-2H-pyranyl, 3- dioxolanyl, 1,4-dioxanyl, 2,5-dioximidazolidinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, indolinyl, tetrahydrothiophenyl, tetrahydroquinolinyl, tetrahydroisoquinolin-1-yl, tetrahydroisoquinolin-2- yl, tetrahydroisoquinolin-3-yl, tetrahydroisoquinolin-4-yl, thiomorpholin-4-yl, thiomorpholin-4- ylsulfoxide, thiomorpholin-4-ylsulfone, 1,3-dioxolanyl, 1,4-oxathianyl, 1,4-dithianyl, 1,3,5- trioxanyl, 1H-pyrrolizinyl, tetrahydro-1,1-dioxothiophenyl, N-formylpiperazinyl, and morpholin- 4-yl. The term “aziridinyl” as used herein includes aziridin-1-yl and aziridin-2-yl. The term “oxyranyl” as used herein includes oxyranyl-2-yl. The term “thiiranyl” as used herein includes thiiran-2-yl. The term “azetidinyl” as used herein includes azetidin-1-yl, azetidin-2-yl and azetidin-3-yl. The term “oxetanyl” as used herein includes oxetan-2-yl and oxetan-3-yl. The term “thietanyl” as used herein includes thietan-2-yl and thietan-3-yl. The term “pyrrolidinyl” as used herein includes pyrrolidin-1-yl, pyrrolidin-2-yl and pyrrolidin-3-yl. The term “tetrahydrofuranyl” as used herein includes tetrahydrofuran-2-yl and tetrahydrofuran-3-yl. The term “tetrahydrothiophenyl” as used herein includes tetrahydrothiophen-2-yl and tetrahydrothiophen-3-yl. The term “succinimidyl” as used herein includes succinimid-1-yl and succininmid-3-yl. The term “dihydropyrrolyl” as used herein includes 2,3-dihydropyrrol-1-yl, 2,3-dihydro-1H-pyrrol-2-yl, 2,3-dihydro-1H-pyrrol-3-yl, 2,5-dihydropyrrol-1-yl, 2,5-dihydro-1H- pyrrol-3-yl and 2,5-dihydropyrrol-5-yl. The term “2H-pyrrolyl” as used herein includes 2H- pyrrol-2-yl, 2H-pyrrol-3-yl, 2H-pyrrol-4-yl and 2H-pyrrol-5-yl. The term “3H-pyrrolyl” as used herein includes 3H-pyrrol-2-yl, 3H-pyrrol-3-yl, 3H-pyrrol-4-yl and 3H-pyrrol-5-yl. The term “dihydrofuranyl” as used herein includes 2,3-dihydrofuran-2-yl, 2,3-dihydrofuran-3-yl, 2,3- dihydrofuran-4-yl, 2,3-dihydrofuran-5-yl, 2,5-dihydrofuran-2-yl, 2,5-dihydrofuran-3-yl, 2,5- dihydrofuran-4-yl and 2,5-dihydrofuran-5-yl. The term “dihydrothiophenyl” as used herein includes 2,3-dihydrothiophen-2-yl, 2,3-dihydrothiophen-3-yl, 2,3-dihydrothiophen-4-yl, 2,3- dihydrothiophen-5-yl, 2,5-dihydrothiophen-2-yl, 2,5-dihydrothiophen-3-yl, 2,5- dihydrothiophen-4-yl and 2,5-dihydrothiophen-5-yl. The term “imidazolidinyl” as used herein includes imidazolidin-1-yl, imidazolidin-2-yl and imidazolidin-4-yl. The term “pyrazolidinyl” as used herein includes pyrazolidin-1-yl, pyrazolidin-3-yl and pyrazolidin-4-yl. The term “imidazolinyl” as used herein includes imidazolin-1-yl, imidazolin-2-yl, imidazolin-4-yl and imidazolin-5-yl. The term “pyrazolinyl” as used herein includes 1-pyrazolin-3-yl, 1-pyrazolin-4- yl, 2-pyrazolin-1-yl, 2-pyrazolin-3-yl, 2-pyrazolin-4-yl, 2-pyrazolin-5-yl, 3-pyrazolin-1-yl, 3- pyrazolin-2-yl, 3-pyrazolin-3-yl, 3-pyrazolin-4-yl and 3-pyrazolin-5-yl. The term “dioxolanyl” also known as “1,3-dioxolanyl” as used herein includes dioxolan-2-yl, dioxolan-4-yl and dioxolan-5-yl. The term “dioxolyl” also known as “1,3-dioxolyl” as used herein includes dioxol- 2-yl, dioxol-4-yl and dioxol-5-yl. The term “oxazolidinyl” as used herein includes oxazolidin-2- yl, oxazolidin-3-yl, oxazolidin-4-yl and oxazolidin-5-yl. The term “isoxazolidinyl” as used herein includes isoxazolidin-2-yl, isoxazolidin-3-yl, isoxazolidin-4-yl and isoxazolidin-5-yl. The term “oxazolinyl” as used herein includes 2-oxazolinyl-2-yl, 2-oxazolinyl-4-yl, 2-oxazolinyl-5-yl, 3- oxazolinyl-2-yl, 3-oxazolinyl-4-yl, 3-oxazolinyl-5-yl, 4-oxazolinyl-2-yl, 4-oxazolinyl-3-yl, 4- oxazolinyl-4-yl and 4-oxazolinyl-5-yl. The term “isoxazolinyl” as used herein includes 2- isoxazolinyl-3-yl, 2-isoxazolinyl-4-yl, 2-isoxazolinyl-5-yl, 3-isoxazolinyl-3-yl, 3-isoxazolinyl-4-yl, 3-isoxazolinyl-5-yl, 4-isoxazolinyl-2-yl, 4-isoxazolinyl-3-yl, 4-isoxazolinyl-4-yl and 4- isoxazolinyl-5-yl. The term “thiazolidinyl” as used herein includes thiazolidin-2-yl, thiazolidin-3- yl, thiazolidin-4-yl and thiazolidin-5-yl. The term “isothiazolidinyl” as used herein includes isothiazolidin-2-yl, isothiazolidin-3-yl, isothiazolidin-4-yl and isothiazolidin-5-yl. The term “thiazolinyl” as used herein includes 2-thiazolinyl-2-yl, 2-thiazolinyl-4-yl, 2-thiazolinyl-5-yl, 3- thiazolinyl-2-yl, 3-thiazolinyl-4-yl, 3-thiazolinyl-5-yl, 4-thiazolinyl-2-yl, 4-thiazolinyl-3-yl, 4- thiazolinyl-4-yl and 4-thiazolinyl-5-yl. The term “isothiazolinyl” as used herein includes 2- isothiazolinyl-3-yl, 2-isothiazolinyl-4-yl, 2-isothiazolinyl-5-yl, 3-isothiazolinyl-3-yl, 3- isothiazolinyl-4-yl, 3-isothiazolinyl-5-yl, 4-isothiazolinyl-2-yl, 4-isothiazolinyl-3-yl, 4- isothiazolinyl-4-yl and 4-isothiazolinyl-5-yl. The term “piperidyl” also known as “piperidinyl” as used herein includes piperid-1-yl, piperid-2-yl, piperid-3-yl and piperid-4-yl. The term “dihydropyridinyl” as used herein includes 1,2-dihydropyridin-1-yl, 1,2-dihydropyridin-2-yl, 1,2- dihydropyridin-3-yl, 1,2-dihydropyridin-4-yl, 1,2-dihydropyridin-5-yl, 1,2-dihydropyridin-6-yl, 1,4-dihydropyridin-1-yl, 1,4-dihydropyridin-2-yl, 1,4-dihydropyridin-3-yl, 1,4-dihydropyridin-4- yl, 2,3-dihydropyridin-2-yl, 2,3-dihydropyridin-3-yl, 2,3-dihydropyridin-4-yl, 2,3-dihydropyridin- 5-yl, 2,3-dihydropyridin-6-yl, 2,5-dihydropyridin-2-yl, 2,5-dihydropyridin-3-yl, 2,5- dihydropyridin-4-yl, 2,5-dihydropyridin-5-yl, 2,5-dihydropyridin-6-yl, 3,4-dihydropyridin-2-yl, 3,4-dihydropyridin-3-yl, 3,4-dihydropyridin-4-yl, 3,4-dihydropyridin-5-yl and 3,4-dihydropyridin- 6-yl. The term “tetrahydropyridinyl” as used herein includes 1,2,3,4-tetrahydropyridin-1-yl, 1,2,3,4-tetrahydropyridin-2-yl, 1,2,3,4-tetrahydropyridin-3-yl, 1,2,3,4-tetrahydropyridin-4-yl, 1,2,3,4-tetrahydropyridin-5-yl, 1,2,3,4-tetrahydropyridin-6-yl, 1,2,3,6-tetrahydropyridin-1-yl, 1,2,3,6-tetrahydropyridin-2-yl, 1,2,3,6-tetrahydropyridin-3-yl, 1,2,3,6-tetrahydropyridin-4-yl, 1,2,3,6-tetrahydropyridin-5-yl, 1,2,3,6-tetrahydropyridin-6-yl, 2,3,4,5-tetrahydropyridin-2-yl, 2,3,4,5-tetrahydropyridin-3-yl, 2,3,4,5-tetrahydropyridin-3-yl, 2,3,4,5-tetrahydropyridin-4-yl, 2,3,4,5-tetrahydropyridin-5-yl and 2,3,4,5-tetrahydropyridin-6-yl. The term “tetrahydropyranyl” also known as “oxanyl” or “tetrahydro-2H-pyranyl”, as used herein includes tetrahydropyran-2- yl, tetrahydropyran-3-yl and tetrahydropyran-4-yl. The term “2H-pyranyl” as used herein includes 2H-pyran-2-yl, 2H-pyran-3-yl, 2H-pyran-4-yl, 2H-pyran-5-yl and 2H-pyran-6-yl. The term “4H-pyranyl” as used herein includes 4H-pyran-2-yl, 4H-pyran-3-yl and 4H-pyran-4-yl. The term “3,4-dihydro-2H-pyranyl” as used herein includes 3,4-dihydro-2H-pyran-2-yl, 3,4- dihydro-2H-pyran-3-yl, 3,4-dihydro-2H-pyran-4-yl, 3,4-dihydro-2H-pyran-5-yl and 3,4-dihydro- 2H-pyran-6-yl. The term “3,6-dihydro-2H-pyranyl” as used herein includes 3,6-dihydro-2H- pyran-2-yl, 3,6-dihydro-2H-pyran-3-yl, 3,6-dihydro-2H-pyran-4-yl, 3,6-dihydro-2H-pyran-5-yl and 3,6-dihydro-2H-pyran-6-yl. The term “tetrahydrothiophenyl”, as used herein includes tetrahydrothiophen-2-yl, tetrahydrothiophenyl -3-yl and tetrahydrothiophenyl -4-yl. The term “2H-thiopyranyl” as used herein includes 2H-thiopyran-2-yl, 2H-thiopyran-3-yl, 2H-thiopyran- 4-yl, 2H-thiopyran-5-yl and 2H-thiopyran-6-yl. The term “4H-thiopyranyl” as used herein includes 4H-thiopyran-2-yl, 4H-thiopyran-3-yl and 4H-thiopyran-4-yl. The term “3,4-dihydro- 2H-thiopyranyl” as used herein includes 3,4-dihydro-2H-thiopyran-2-yl, 3,4-dihydro-2H- thiopyran-3-yl, 3,4-dihydro-2H-thiopyran-4-yl, 3,4-dihydro-2H-thiopyran-5-yl and 3,4-dihydro- 2H-thiopyran-6-yl. The term “3,6-dihydro-2H-thiopyranyl” as used herein includes 3,6-dihydro- 2H-thiopyran-2-yl, 3,6-dihydro-2H-thiopyran-3-yl, 3,6-dihydro-2H-thiopyran-4-yl, 3,6-dihydro- 2H-thiopyran-5-yl and 3,6-dihydro-2H-thiopyran-6-yl. The term “piperazinyl” also known as “piperazidinyl” as used herein includes piperazin-1-yl and piperazin-2-yl. The term “morpholinyl” as used herein includes morpholin-2-yl, morpholin-3-yl and morpholin-4-yl. The term “thiomorpholinyl” as used herein includes thiomorpholin-2-yl, thiomorpholin-3-yl and thiomorpholin-4-yl. The term “dioxanyl” as used herein includes 1,2-dioxan-3-yl, 1,2-dioxan-4- yl, 1,3-dioxan-2-yl, 1,3-dioxan-4-yl, 1,3-dioxan-5-yl and 1,4-dioxan-2-yl. The term “dithianyl” as used herein includes 1,2-dithian-3-yl, 1,2-dithian-4-yl, 1,3-dithian-2-yl, 1,3-dithian-4-yl, 1,3- dithian-5-yl and 1,4-dithian-2-yl. The term “oxathianyl” as used herein includes oxathian-2-yl and oxathian-3-yl. The term “trioxanyl” as used herein includes 1,2,3-trioxan-4-yl, 1,2,3-trioxan- 5-yl, 1,2,4-trioxan-3-yl, 1,2,4-trioxan-5-yl, 1,2,4-trioxan-6-yl and 1,3,4-trioxan-2-yl. The term “azepanyl” as used herein includes azepan-1-yl, azepan-2-yl, azepan-3-yl and azepan-4-yl. The term “homopiperazinyl” as used herein includes homopiperazin-1-yl, homopiperazin-2-yl, homopiperazin-3-yl and homopiperazin-4-yl. The term “indolinyl” as used herein includes indolin-1-yl, indolin-2-yl, indolin-3-yl, indolin-4-yl, indolin-5-yl, indolin-6-yl, and indolin-7-yl. The term “quinolizinyl” as used herein includes quinolizidin-1-yl, quinolizidin-2-yl, quinolizidin-3-yl and quinolizidin-4-yl. The term “isoindolinyl” as used herein includes isoindolin-1-yl, isoindolin- 2-yl, isoindolin-3-yl, isoindolin-4-yl, isoindolin-5-yl, isoindolin-6-yl, and isoindolin-7-yl. The term “3H-indolyl” as used herein includes 3H-indol-2-yl, 3H-indol-3-yl, 3H-indol-4-yl, 3H-indol-5-yl, 3H-indol-6-yl, and 3H-indol-7-yl. The term “quinolizinyl” as used herein includes quinolizidin-1- yl, quinolizidin-2-yl, quinolizidin-3-yl and quinolizidin-4-yl. The term “quinolizinyl” as used herein includes quinolizidin-1-yl, quinolizidin-2-yl, quinolizidin-3-yl and quinolizidin-4-yl. The term “tetrahydroquinolinyl” as used herein includes tetrahydroquinolin-1-yl, tetrahydroquinolin- 2-yl, tetrahydroquinolin-3-yl, tetrahydroquinolin-4-yl, tetrahydroquinolin-5-yl, tetrahydroquinolin-6-yl, tetrahydroquinolin-7-yl and tetrahydroquinolin-8-yl. The term “tetrahydroisoquinolinyl” as used herein includes tetrahydroisoquinolin-1-yl, tetrahydroisoquinolin-2-yl, tetrahydroisoquinolin-3-yl, tetrahydroisoquinolin-4-yl, tetrahydroisoquinolin-5-yl, tetrahydroisoquinolin-6-yl, tetrahydroisoquinolin-7-yl and tetrahydroisoquinolin-8-yl. The term “chromanyl” as used herein includes chroman-2-yl, chroman-3-yl, chroman-4-yl, chroman-5-yl, chroman-6-yl, chroman-7-yl and chroman-8-yl. The term “1H-pyrrolizine” as used herein includes 1H-pyrrolizin-1-yl, 1H-pyrrolizin-2-yl, 1H- pyrrolizin-3-yl, 1H-pyrrolizin-5-yl, 1H-pyrrolizin-6-yl and 1H-pyrrolizin-7-yl. The term “3H- pyrrolizine” as used herein includes 3H-pyrrolizin-1-yl, 3H-pyrrolizin-2-yl, 3H-pyrrolizin-3-yl, 3H-pyrrolizin-5-yl, 3H-pyrrolizin-6-yl and 3H-pyrrolizin-7-yl. The term “heteroaryl” refers to an aromatic ring system of 5 to 18 (ring) atoms including at least one N, O, S, or P (i.e. C5-18), containing 1 or 2 rings which can be fused together or linked covalently, each ring typically containing 5 to 6 atoms; at least one of said rings is aromatic, where the N and S heteroatoms may optionally be oxidized and the N heteroatoms may optionally be quaternized, and wherein at least one carbon atom of said heteroaryl can be oxidized to form at least one C=O. Fused systems of a heteroaryl ring with a cycloalkyl ring, or a cycloalkenyl ring, or a cycloalkynyl ring, are considered as heteroaryl irrespective of the ring that is bound to the core structure. Fused systems of a heteroaryl ring with a heterocycle are considered as heteroaryl irrespective of the ring that is bound to the core structure. Fused systems of a hetero aryl ring with an aryl ring are considered as heteroaryl irrespective of the ring that is bound to the core structure. Non-limiting examples of such heteroaryl, include: triazol-2-yl, pyridinyl, 1H-pyrazol-5-yl, pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, oxatriazolyl, thiatriazolyl, pyrimidyl, pyrazinyl, pyridazinyl, oxazinyl, dioxinyl, thiazinyl, triazinyl, imidazo[2,1-b][1,3]thiazolyl, thieno[3,2-b]furanyl, thieno[3,2-b]thiophenyl, thieno[2,3- d][1,3]thiazolyl, thieno[2,3-d]imidazolyl, tetrazolo[1,5-a]pyridinyl, indolyl, indolizinyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, isobenzothiophenyl, indazolyl, benzimidazolyl, 1,3-benzoxazolyl, 1,2-benzisoxazolyl, 2,1-benzisoxazolyl, 1,3-benzothiazolyl, 1,2-benzoisothiazolyl, 2,1-benzoisothiazolyl, benzotriazolyl, 1,2,3-benzoxadiazolyl, 2,1,3- benzoxadiazolyl, 1,2,3-benzothiadiazolyl, 2,1,3-benzothiadiazolyl, benzo[d]oxazol-2(3H)-one, 2,3-dihydro-benzofuranyl, thienopyridinyl, purinyl, imidazo[1,2-a]pyridinyl, 6-oxo-pyridazin- 1(6H)-yl, 2-oxopyridin-1(2H)-yl, 6-oxo-pyridazin-1(6H)-yl, 2-oxopyridin-1(2H)-yl, 1,3- benzodioxolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl; preferably said heteroaryl group is selected from the group comprising pyridyl, pyrazinyl, pyrimidinyl, pyrazolyl, pyrrolyl, isoxazolyl, thiophenyl, imidazolyl, indolyl, benzimidazolyl, s-triazinyl, oxazolyl, isothiazolyl, furyl, thienyl, triazolyl and thiazolyl ; more preferably, said heteroaryl group is selected from the group comprising pyridyl, pyrazinyl, pyrimidinyl, indolyl and benzimidazolyl. The term “pyrrolyl” (also called azolyl) as used herein includes pyrrol-1-yl, pyrrol-2-yl and pyrrol-3-yl. The term “furanyl” (also called "furyl") as used herein includes furan-2-yl and furan- 3-yl (also called furan-2-yl and furan-3-yl). The term “thiophenyl” (also called "thienyl") as used herein includes thiophen-2-yl and thiophen-3-yl (also called thien-2-yl and thien-3-yl). The term “pyrazolyl” (also called 1H-pyrazolyl and 1,2-diazolyl) as used herein includes pyrazol-1-yl, pyrazol-3-yl or 1H-pyrazol-5-yl, pyrazol-4-yl and pyrazol-5-yl. The term “imidazolyl” as used herein includes imidazol-1-yl, imidazol-2-yl, imidazol-4-yl and imidazol-5-yl. The term “oxazolyl” (also called 1,3-oxazolyl) as used herein includes oxazol-2-yl, oxazol-4-yl and oxazol-5-yl. The term “isoxazolyl” (also called 1,2-oxazolyl), as used herein includes isoxazol- 3-yl, isoxazol-4-yl, and isoxazol-5-yl. The term “thiazolyl” (also called 1,3-thiazolyl),as used herein includes thiazol-2-yl, thiazol-4-yl and thiazol-5-yl (also called 2-thiazolyl, 4-thiazolyl and 5-thiazolyl). The term “isothiazolyl” (also called 1,2-thiazolyl) as used herein includes isothiazol-3-yl, isothiazol-4-yl, and isothiazol-5-yl. The term “triazolyl” as used herein includes triazol-2-yl, 1H-triazolyl and 4H-1,2,4-triazolyl, “1H-triazolyl” includes 1H-1,2,3-triazol-1-yl, 1H- 1,2,3-triazol-4-yl, 1H-1,2,3-triazol-5-yl, 1H-1,2,4-triazol-1-yl, 1H-1,2,4-triazol-3-yl and 1H-1,2,4- triazol-5-yl. “4H-1,2,4-triazolyl” includes 4H-1,2,4-triazol-4-yl, and 4H-1,2,4-triazol-3-yl. The term “oxadiazolyl” as used herein includes 1,2,3-oxadiazol-4-yl, 1,2,3-oxadiazol-5-yl, 1,2,4- oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl, 1,2,5-oxadiazol-3-yl and 1,3,4-oxadiazol-2-yl. The term “thiadiazolyl” as used herein includes 1,2,3-thiadiazol-4-yl, 1,2,3-thiadiazol-5-yl, 1,2,4- thiadiazol-3-yl, 1,2,4-thiadiazol-5-yl, 1,2,5-thiadiazol-3-yl (also called furazan-3-yl) and 1,3,4- thiadiazol-2-yl. The term “tetrazolyl” as used herein includes 1H-tetrazol-1-yl, 1H-tetrazol-5-yl, 2H-tetrazol-2-yl, and 2H-tetrazol-5-yl. The term “oxatriazolyl” as used herein includes 1,2,3,4- oxatriazol-5-yl and 1,2,3,5-oxatriazol-4-yl. The term “thiatriazolyl” as used herein includes 1,2,3,4-thiatriazol-5-yl and 1,2,3,5-thiatriazol-4-yl. The term “pyridinyl” (also called "pyridyl") as used herein includes pyridin-2-yl, pyridin-3-yl and pyridin-4-yl (also called 2-pyridyl, 3-pyridyl and 4-pyridyl). The term “pyrimidyl” as used herein includes pyrimid-2-yl, pyrimid-4-yl, pyrimid- 5-yl and pyrimid-6-yl. The term “pyrazinyl” as used herein includes pyrazin-2-yl and pyrazin-3- yl. The term “pyridazinyl as used herein includes pyridazin-3-yl and pyridazin-4-yl. The term “oxazinyl” (also called "1,4-oxazinyl") as used herein includes 1,4-oxazin-4-yl and 1,4-oxazin- 5-yl. The term “dioxinyl” (also called "1,4-dioxinyl”) as used herein includes 1,4-dioxin-2-yl and 1,4-dioxin-3-yl. The term “thiazinyl” (also called "1,4-thiazinyl”) as used herein includes 1,4- thiazin-2-yl, 1,4-thiazin-3-yl, 1,4-thiazin-4-yl, 1,4-thiazin-5-yl and 1,4-thiazin-6-yl. The term “triazinyl” as used herein includes 1,3,5-triazin-2-yl, 1,2,4-triazin-3-yl, 1,2,4-triazin-5-yl, 1,2,4- triazin-6-yl, 1,2,3-triazin-4-yl and 1,2,3-triazin-5-yl. The term “imidazo[2,1-b][1,3]thiazolyl” as used herein includes imidazo[2,1-b][1,3]thiazoi-2-yl, imidazo[2,1-b][1,3]thiazol-3-yl, imidazo[2,1-b][1,3]thiazol-5-yl and imidazo[2,1-b][1,3]thiazol-6-yl. The term “thieno[3,2- b]furanyl” as used herein includes thieno[3,2-b]furan-2-yl, thieno[3,2-b]furan-3-yl, thieno[3,2- b]furan-4-yl, and thieno[3,2-b]furan-5-yl. The term “thieno[3,2-b]thiophenyl” as used herein includes thieno[3,2-b]thien-2-yl, thieno[3,2-b]thien-3-yl, thieno[3,2-b]thien-5-yl and thieno[3,2- b]thien-6-yl. The term “thieno[2,3-d][1,3]thiazolyl” as used herein includes thieno[2,3- d][1,3]thiazol-2-yl, thieno[2,3-d][1,3]thiazol-5-yl and thieno[2,3-d][1,3]thiazol-6-yl. The term “thieno[2,3-d]imidazolyl” as used herein includes thieno[2,3-d]imidazol-2-yl, thieno[2,3- d]imidazol-4-yl and thieno[2,3-d]imidazol-5-yl. The term “tetrazolo[1,5-a]pyridinyl” as used herein includes tetrazolo[1,5-a]pyridine-5-yl, tetrazolo[1,5-a]pyridine-6-yl, tetrazolo[1,5- a]pyridine-7-yl, and tetrazolo[1,5-a]pyridine-8-yl. The term “indolyl” as used herein includes indol-1-yl, indol-2-yl, indol-3-yl,-indol-4-yl, indol-5-yl, indol-6-yl and indol-7-yl. The term “indolizinyl” as used herein includes indolizin-1-yl, indolizin-2-yl, indolizin-3-yl, indolizin-5-yl, indolizin-6-yl, indolizin-7-yl, and indolizin-8-yl. The term “isoindolyl” as used herein includes isoindol-1-yl, isoindol-2-yl, isoindol-3-yl, isoindol-4-yl, isoindol-5-yl, isoindol-6-yl and isoindol- 7-yl. The term “benzofuranyl” (also called benzo[b]furanyl) as used herein includes benzofuran-2-yl, benzofuran-3-yl, benzofuran-4-yl, benzofuran-5-yl, benzofuran-6-yl and benzofuran-7-yl. The term “isobenzofuranyl” (also called benzo[c]furanyl) as used herein includes isobenzofuran-1-yl, isobenzofuran-3-yl, isobenzofuran-4-yl, isobenzofuran-5-yl, isobenzofuran-6-yl and isobenzofuran-7-yl. The term “benzothiophenyl” (also called benzo[b]thienyl) as used herein includes 2-benzo[b]thiophenyl, 3-benzo[b]thiophenyl, 4- benzo[b]thiophenyl, 5-benzo[b]thiophenyl, 6-benzo[b]thiophenyl and -7-benzo[b]thiophenyl (also called benzothien-2-yl, benzothien-3-yl, benzothien-4-yl, benzothien-5-yl, benzothien-6- yl and benzothien-7-yl). The term “isobenzothiophenyl” (also called benzo[c]thienyl) as used herein includes isobenzothien-1-yl, isobenzothien-3-yl, isobenzothien-4-yl, isobenzothien-5-yl, isobenzothien-6-yl and isobenzothien-7-yl. The term “indazolyl” (also called 1H-indazolyl or 2- azaindolyl) as used herein includes 1H-indazol-1-yl, 1H-indazol-3-yl, 1H-indazol-4-yl, 1H- indazol-5-yl, 1H-indazol-6-yl, 1H-indazol-7-yl, 2H-indazol-2-yl, 2H-indazol-3-yl, 2H-indazol-4- yl, 2H-indazol-5-yl, 2H-indazol-6-yl, and 2H-indazol-7-yl. The term “benzimidazolyl” as used herein includes benzimidazol-1-yl, benzimidazol-2-yl, benzimidazol-4-yl, benzimidazol-5-yl, benzimidazol-6-yl and benzimidazol-7-yl. The term “1,3-benzoxazolyl” as used herein includes 1,3-benzoxazol-2-yl, 1,3-benzoxazol-4-yl, 1,3-benzoxazol-5-yl, 1,3-benzoxazol-6-yl and 1,3- benzoxazol-7-yl. The term “1,2-benzisoxazolyl” as used herein includes 1,2-benzisoxazol-3-yl, 1,2-benzisoxazol-4-yl, 1,2-benzisoxazol-5-yl, 1,2-benzisoxazol-6-yl and 1,2-benzisoxazol-7-yl. The term “2,1-benzisoxazolyl” as used herein includes 2,1-benzisoxazol-3-yl, 2,1- benzisoxazol-4-yl, 2,1-benzisoxazol-5-yl, 2,1-benzisoxazol-6-yl and 2,1-benzisoxazol-7-yl. The term “1,3-benzothiazolyl” as used herein includes 1,3-benzothiazol-2-yl, 1,3-benzothiazol- 4-yl, 1,3-benzothiazol-5-yl, 1,3-benzothiazol-6-yl and 1,3-benzothiazol-7-yl. The term “1,2- benzoisothiazolyl” as used herein includes 1,2-benzisothiazol-3-yl, 1,2-benzisothiazol-4-yl, 1,2-benzisothiazol-5-yl, 1,2-benzisothiazol-6-yl and 1,2-benzisothiazol-7-yl. The term “2,1- benzoisothiazolyl” as used herein includes 2,1-benzisothiazol-3-yl, 2,1-benzisothiazol-4-yl, 2,1-benzisothiazol-5-yl, 2,1-benzisothiazol-6-yl and 2,1-benzisothiazol-7-yl. The term “benzotriazolyl” as used herein includes benzotriazol-1-yl, benzotriazol-4-yl, benzotriazol-5-yl, benzotriazol-6-yl and benzotriazol-7-yl. The term “1,2,3-benzoxadiazolyl” as used herein includes 1,2,3-benzoxadiazol-4-yl, 1,2,3-benzoxadiazol-5-yl, 1,2,3-benzoxadiazol-6-yl and 1,2,3-benzoxadiazol-7-yl. The term “2,1,3-benzoxadiazolyl” as used herein includes 2,1,3- benzoxadiazol-4-yl, 2,1,3-benzoxadiazol-5-yl, 2,1,3-benzoxadiazol-6-yl and 2,1,3- benzoxadiazol-7-yl. The term “1,2,3-benzothiadiazolyl” as used herein includes 1,2,3- benzothiadiazol-4-yl, 1,2,3-benzothiadiazol-5-yl, 1,2,3-benzothiadiazol-6-yl and 1,2,3- benzothiadiazol-7-yl. The term “2,1,3-benzothiadiazolyl” as used herein includes 2,1,3- benzothiadiazol-4-yl, 2,1,3-benzothiadiazol-5-yl, 2,1,3-benzothiadiazol-6-yl and 2,1,3- benzothiadiazol-7-yl. The term “thienopyridinyl” as used herein includes thieno[2,3-b]pyridinyl, thieno[2,3-c]pyridinyl, thieno[3,2-c]pyridinyl and thieno[3,2-b]pyridinyl. The term “purinyl” as used herein includes purin-2-yl, purin-6-yl, purin-7-yl and purin-8-yl. The term “imidazo[1,2- a]pyridinyl”, as used herein includes imidazo[1,2-a]pyridin-2-yl, imidazo[1,2-a]pyridin-3-yl, imidazo[1,2-a]pyridin-4-yl, imidazo[1,2-a]pyridin-5-yl, imidazo[1,2-a]pyridin-6-yl and imidazo[1,2-a]pyridin-7-yl. The term “1,3-benzodioxolyl”, as used herein includes 1,3- benzodioxol-4-yl, 1,3-benzodioxol-5-yl, 1,3-benzodioxol-6-yl, and 1,3-benzodioxol-7-yl. The term “quinolinyl” as used herein includes quinolin-2-yl, quinolin-3-yl, quinolin-4-yl, quinolin-5- yl, quinolin-6-yl, quinolin-7-yl and quinolin-8-yl. The term “isoquinolinyl” as used herein includes isoquinolin-1-yl, isoquinolin-3-yl, isoquinolin-4-yl, isoquinolin-5-yl, isoquinolin-6-yl, isoquinolin- 7-yl and isoquinolin-8-yl. The term “cinnolinyl” as used herein includes cinnolin-3-yl, cinnolin- 4-yl, cinnolin-5-yl, cinnolin-6-yl, cinnolin-7-yl and cinnolin-8-yl. The term “quinazolinyl” as used herein includes quinazolin-2-yl, quinazolin-4-yl, quinazolin-5-yl, quinazolin-6-yl, quinazolin-7-yl and quinazolin-8-yl. The term “quinoxalinyl” as used herein includes quinoxalin-2-yl, quinoxalin-5-yl, and quinoxalin-6-yl. Heteroaryl and heterocycle or heterocyclyl as used herein includes by way of example and not limitation these groups described in Paquette, Leo A. “Principles of Modern Heterocyclic Chemistry” (W.A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9; “The Chemistry of Heterocyclic Compounds, A series of Monographs” (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; Katritzky, Alan R., Rees, C.W. and Scriven, E. “Comprehensive Heterocyclic Chemistry” (Pergamon Press, 1996); and J. Am. Chem. Soc. (1960) 82:5566. The term “heterocyclyloxy” or “heterocycleoxy”, as a group or part of a group, refers to a group having the formula -O-Riwherein Riis heterocyclyl as defined herein above. The term “heterocyclylalkyloxy”, as a group or part of a group, refers to a group having the formula -O-Ra-Riwherein Riis heterocyclyl, and Rais alkyl as defined herein above. The term “heteroaryloxy”, as a group or part of a group, refers to a group having the formula -O-Rkwherein Rkis heteroaryl as defined herein above. The term “heteroarylalkyloxy”, as a group or part of a group, refers to a group having the formula -O-Ra-Riwherein Riis heteroaryl, and Rais alkyl as defined herein above. The term “heterocyclylalkyl” or “heterocycle-alkyl” as a group or part of a group, refers to an alkyl in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp3 carbon atom, is replaced with a heterocyclyl. A non-limiting example of a heterocyclylalkyl or heterocycle-alkyl group is 2-piperidinyl-methylene. The heterocyclylalkyl or heterocycle-alkyl group can comprise 6 to 20 atoms, e.g. the alkyl moiety is 1 to 6 carbon atoms and the heterocyclyl moiety is 3 to 14 atoms. The term “heterocyclylalkenyl” or “heterocycle-alkenyl” as a group or part of a group refers to an alkenyl in which one of the hydrogen atoms bonded to a carbon atom, is replaced with an heterocyclyl. The heterocyclylalkenyl or heterocycle-alkenyl group can comprise 6 to 20 atoms, e.g. the alkenyl moiety is 2 to 6 carbon atoms and the heterocyclyl moiety is 3 to 14 atoms. The term “heterocyclylalkynyl” or “heterocycle-alkynyl” as a group or part of a group refers to an alkynyl in which one of the hydrogen atoms bonded to a carbon atom, is replaced with a heterocyclyl. The heterocyclylalkynyl or heterocycle-alkynyl group can comprise 6 to 20 atoms, e.g. the alkynyl moiety can comprise 2 to 6 carbon atoms and the heterocyclyl moiety can comprise 3 to 14 atoms. The term “heterocyclylheteroalkyl” or “heterocycle-heteroalkyl” as a group or part of a group refers to a heteroalkyl in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp3 carbon atom, is replaced with a heterocyclyl. The heterocyclylheteroalkyl or heterocycle-heteroalkyl group can comprise 6 to 20 atoms (i.e. C6-C20), e.g. the heteroalkyl moiety can be C1-C6 and the heterocyclyl moiety can comprise 3 to 14 atoms (i.e. be C3-C14). In some embodiments heterocyclylheteroalkyl or heterocycle-heteroalkyl is selected from the group comprising heterocyclyl-O-alkyl, heterocyclylalkyl-O-alkyl, heterocyclyl-NH-alkyl, heterocyclyl-N(alkyl)2, heterocyclylalkyl-NH-alkyl, heterocyclylalkyl-N-(alkyl)2, heterocyclyl–S- alkyl, and heterocyclylalkyl-S-alkyl. The term “heterocyclylheteroalkenyl” or “heterocycle-heteroalkenyl” as a group or part of a group refers to a heteroalkenyl in which one of the hydrogen atoms bonded to a carbon atom, is replaced with a heterocyclyl. The heterocyclylheteroalkenyl or heterocycle-heteroalkenyl group can comprise 6 to 20 atoms (i.e. C6-C20), e.g. the heteroalkenyl moiety can be C2-C6and the heterocyclyl moiety can comprise 3 to 14 atoms (i.e. be C3-C14). In some embodiments heterocyclyl-heteroalkenyl or heterocycle-heteroalkenyl is selected from the group comprising heterocyclyl-O-alkenyl, heterocyclylalkyl-O-alkenyl, heterocyclyl-NH-alkenyl, heterocyclyl- N(alkenyl)2, heterocyclylalkyl-NH-alkenyl, heterocyclylalkyl-N-(alkenyl)2, heterocyclyl–S- alkenyl, and heterocyclylalkenyl-S-alkenyl. The term “heterocyclylheteroalkynyl” or “heterocycle-heteroalkynyl” as a group or part of a group refers to a heteroalkynyl in which one of the hydrogen atoms bonded to a carbon atom, is replaced with a heterocyclyl. The heterocyclylheteroalkynyl or heterocycle-heteroalkynyl group can comprise 6 to 20 atoms (i.e. be C6-C20), e.g. the heteroalkynyl moiety can be C2-C6 and the heterocyclyl moiety can comprise 3 to 14 atoms (i.e. be C3-C14). In some embodiments heterocyclyl-heteroalkynyl is selected from the group comprising heterocyclyl-O-alkynyl, heterocyclylalkynyl-O-alkynyl, heterocyclyl-NH-alkynyl, heterocyclyl-N(alkynyl)2, heterocyclylalkynyl-NH-alkynyl, heterocyclylalkynyl-N-(alkynyl)2, heterocyclyl–S-alkynyl, and heterocyclylalkynyl-S-alkynyl. The term “heteroarylalkyl” as a group or part of a group refers to an alkyl in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp3 carbon atom, is replaced with a heteroaryl. An example of a heteroarylalkyl group is 2-pyridyl-methylene. The heteroarylalkyl group can comprise 6 to 20 atoms (i.e. C6-C20), e.g. the alkyl moiety of the heteroarylalkyl group can comprise 1 to 6 carbon atoms (i.e. C1-C6) and the heteroaryl moiety can comprise 5 to 14 atoms (i.e. C5-C14). The term “heteroarylalkenyl” as a group or part of a group refers to an alkenyl in which one of the hydrogen atoms bonded to a carbon atom, is replaced with an heteroaryl. The heteroaryl- alkenyl group can comprise 6 to 20 atoms (i.e. C6-C20), e.g. the alkenyl moiety of the heteroaryl- alkenyl group can comprise 2 to 6 carbon atoms and the heteroaryl moiety can comprise 5 to 14 atoms. The term “heteroarylalkynyl” as a group or part of a group as used herein refers to an alkynyl in which one of the hydrogen atoms bonded to a carbon atom, is replaced with a heteroaryl. The heteroarylalkynyl group comprises 6 to 20 atoms (i.e. C6-C20), e.g. the alkynyl moiety of the heteroaryl-alkynyl group is 2 to 6 carbon atoms (i.e. C2-C6) and the heteroaryl moiety is 5 to 14 atoms (i.e. C5-C14). The term “heteroarylheteroalkyl” as a group or part of a group as used herein refers to a heteroalkyl in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp3 carbon atom, is replaced with a heteroaryl. The heteroarylheteroalkyl group comprises 7 to 20 atoms (i.e. C7-C20), e.g. the heteroalkyl moiety of the heteroaryl-heteroalkyl group is 2 to 6 carbon atoms (i.e. C2-C6) and the heteroaryl moiety is 5 to 14 atoms (i.e. C5-C14). In some embodiments heteroaryl-heteroalkyl is selected from the group comprising heteroaryl-O-alkyl, heteroarylalkyl-O-alkyl, heteroaryl-NH-alkyl, heteroaryl-N(alkyl)2, heteroarylalkyl-NH-alkyl, heteroarylalkyl-N-(alkyl)2, heteroaryl–S-alkyl, and heteroarylalkyl-S-alkyl. The term “heteroarylheteroalkenyl” as a group or part of a group as used herein refers to a heteroalkenyl in which one of the hydrogen atoms bonded to a carbon atom, is replaced with an heteroaryl. The heteroarylheteroalkenyl group comprises 8 to 20 atoms (i.e. C8-C20), e.g. the heteroalkenyl moiety of the heteroarylheteroalkenyl group is 3 to 6 carbon atoms (i.e. C3- C6) and the heteroaryl moiety is 5 to 14 atoms (i.e. C5-C14). In some embodiments heteroarylheteroalkenyl is selected from the group comprising heteroaryl-O-alkenyl, heteroarylalkenyl-O-alkenyl, heteroaryl-NH-alkenyl, heteroaryl-N(alkenyl)2, heteroarylalkenyl- NH-alkenyl, heteroarylalkenyl-N-(alkenyl)2, heteroaryl–S-alkenyl, and heteroarylalkenyl-S- alkenyl. The term “heteroarylheteroalkynyl” as a group or part of a group as used herein refers to a heteroalkynyl in which one of the hydrogen atoms bonded to a carbon atom, is replaced with a heteroaryl. The heteroarylheteroalkynyl group comprises 8 to 20 atoms (i.e. C8-C20), e.g. the heteroalkynyl moiety of the heteroarylheteroalkynyl group is 2 to 6 carbon atoms (i.e. C2-C6) and the heteroaryl moiety is 5 to 14 atoms (i.e. C5-C14). In some embodiments heteroarylheteroalkynyl is selected from the group comprising heteroaryl-O-alkynyl, heteroarylalkynyl-O-alkynyl, heteroaryl-NH-alkynyl, heteroaryl-N(alkynyl)2, heteroarylalkynyl- NH-alkynyl, heteroarylalkynyl-N-(alkynyl)2, heteroaryl–S-alkynyl, and heteroarylalkynyl-S- alkynyl. By way of example, carbon bonded heteroaryl or heterocyclic rings (or heterocycles) can be bonded at position 2, 3, 4, 5, or 6 of a pyridine, position 3, 4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine, position 2, 3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a furan, tetrahydrofuran, thiophene, pyrrole or tetrahydropyrrole, position 2, 4, or 5 of an oxazole, imidazole or thiazole, position 3, 4, or 5 of an isoxazole, pyrazole, or isothiazole, position 2 or 3 of an aziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of an isoquinoline. Still more typically, carbon bonded heteroaryls and heterocyclyls include 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl, 3-pyridazinyl, 4- pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6- pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4-thiazolyl, or 5- thiazolyl. By way of example, nitrogen bonded heterocyclic rings are bonded at position 1 of an aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazolidine, 2- imidazoline, 3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, 1H-indazole, position 2 of an isoindole, or isoindoline, position 4 of a morpholine, and position 9 of a carbazole, or ß-carboline. Still more typically, nitrogen bonded heteroaryls or heterocyclyls include 1-aziridyl, 1-azetedyl, 1-pyrrolyl, 1-imidazolyl, 1- pyrazolyl, and 1-piperidinyl. As used herein and unless otherwise stated, the terms “alkoxy”, “cyclo-alkoxy”, “aryloxy”, “arylalkyloxy”, “heteroaryloxy” “heterocyclyloxy”, “alkylthio”, “cycloalkylthio”, “arylthio”, “arylalkylthio”, “heteroarylthio” and “heterocyclylthio” refer to substituents wherein an alkyl group, respectively a cycloalkyl, aryl, arylalkyl heteroaryl, or heterocyclyl (each of them such as defined herein), are attached to an oxygen atom or a sulfur atom through a single bond, such as but not limited to methoxy, ethoxy, propoxy, butoxy, thioethyl, thiomethyl, phenyloxy, benzyloxy, mercaptobenzyl and the like. The same definitions will apply for alkenyl and alkynyl instead of alkyl. The term “alkylthio", as a group or part of a group, refers to a group having the formula –S-Rbwherein Rbis alkyl as defined herein above. Non-limiting examples of alkylthio groups include methylthio (-SCH3), ethylthio (-SCH2CH3), n-propylthio, isopropylthio, n-butylthio, isobutylthio, sec-butylthio, tert-butylthio and the like. The term “alkenylthio", as a group or part of a group, refers to a group having the formula –S- Rdwherein Rdis alkenyl as defined herein above. The term “alkynylthio", as a group or part of a group, refers to a group having the formula –S- Rewherein Reis alkynyl as defined herein above. The term “arylthio", as a group or part of a group, refers to a group having the formula –S-Rgwherein Rgis aryl as defined herein above. The term “arylalkylthio", as a group or part of a group, refers to a group having the formula -S-Ra-Rgwherein Rais alkylene and Rgis aryl as defined herein above. The term “heterocyclylthio", as a group or part of a group, refers to a group having the formula –S-Riwherein Riis heterocyclyl as defined herein above. The term “heteroarylthio", as a group or part of a group, refers to a group having the formula – S-Rkwherein Rkis heteroaryl as defined herein above. The term “heterocyclylalkylthio", as a group or part of a group, refers to a group having the formula -S-Ra-Riwherein Rais alkylene and Riis heterocyclyl as defined herein above. The term “heteroarylalkylthio", as a group or part of a group, refers to a group having the formula -S-Ra-Rkwherein Rais alkylene and Rkis heteroaryl as defined herein above. The term "aminoalkyl" as a group or part of a group, refers to an alkyl group having the meaning as defined above wherein one, two, or three hydrogen atoms are each replaced with an amino group (-NH2) as defined herein, i.e. mono-, di- and tri-amino-alkyl respectively. Non-limiting examples of such aminoalkyl groups include aminomethyl, 1-amino-ethyl, 2-amino-ethyl, 1,2- di-amino-ethyl, etc. The term “mono- or di-alkylamino”, as a group or part of a group, refers to a group of formula -N(Ro)(Rb) wherein Rois hydrogen, or alkyl, Rbis alkyl. Thus, alkylamino include mono- alkyl amino group (e.g. mono-alkylamino group such as methylamino and ethylamino), and di- alkylamino group (e.g. di-alkylamino group such as dimethylamino and diethylamino). Non- limiting examples of suitable mono- or di-alkylamino groups include n-propylamino, isopropylamino, n-butylamino, i-butylamino, sec-butylamino, t-butylamino, pentylamino, n- hexylamino, di-n-propylamino, di-i-propylamino, ethylmethylamino, methyl-n-propylamino, methyl-i-propylamino, n-butylmethylamino, i-butylmethylamino, t-butylmethylamino, ethyl-n- propylamino, ethyl-i-propylamino, n-butylethylamino, i-butylethylamino, t-butylethylamino, di- n-butylamino, di-i-butylamino, methylpentylamino, methylhexylamino, ethylpentylamino, ethylhexylamino, propylpentylamino, propylhexylamino, and the like. The term “mono- or di-arylamino”, as a group or part of a group, refers to a group of formula -N(Rq)(Rr) wherein Rqand Rrare each independently selected from hydrogen, aryl, or alkyl, wherein at least one of Rqor Rris aryl. The term “mono- or di-heteroarylamino”, as a group or part of a group, refers to a group of formula -N(Ru)(Rv) wherein Ruand Rvare each independently selected from hydrogen, heteroaryl, or alkyl, wherein at least one of Ruor Rvis heteroaryl as defined herein. The term “mono- or di-heterocyclylamino”, as a group or part of a group, refers to a group of formula -N(Rw)(Rx) wherein Rwand Rxare each independently selected from hydrogen, heterocyclyl, or alkyl, wherein at least one of Rwor Rxis heterocyclyl as defined herein. As used herein and unless otherwise stated, the term halogen means any atom selected from the group consisting of fluorine (F), chlorine (Cl), bromine (Br) and iodine (I). The terminology regarding a chemical group “which optionally includes one or more heteroatoms, said heteroatoms being selected from the atoms consisting of O, S, and N” as used herein, refers to a group where one or more carbon atoms are replaced by an oxygen, nitrogen or sulphur atom and thus includes, depending on the group to which is referred, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloheteroalkyl, cycloheteroalkenyl, cycloheteroalkynyl, heteroaryl, arylheteroalkyl, heteroarylalkyl, heteroarylheteroalkyl, arylheteroalkenyl, heteroarylalkenyl, heteroarylheteroalkenyl, heteroarylheteroalkenyl, arylheteroalkynyl, heteroarylalkynyl, heteroarylheteroalkynyl, among others. This term therefore comprises, depending on the group to which is referred, as an example alkoxy, alkenyloxy, alkynyloxy, alkyl-O-alkylene, alkenyl-O-alkylene, arylalkoxy, benzyloxy, heteroarylheteroalkyl, heterocyclylheteroalkyl, heteroaryl-alkoxy, heterocyclyl-alkoxy, among others. As an example, the terminology “alkyl which optionally includes one or more heteroatoms, said heteroatoms being selected from the atoms consisting of O, S, and N” therefore refers to heteroalkyl, meaning an alkyl which comprises one or more heteroatoms in the hydrocarbon chain, whereas the heteroatoms may be positioned at the beginning of the hydrocarbon chain, in the hydrocarbon chain or at the end of the hydrocarbon chain. Examples of heteroalkyl include methoxy, methylthio, ethoxy, propoxy, CH3-O-CH2-, CH3-S-CH2-, CH3-CH2-O-CH2-, CH3-NH-, (CH3)2-N-, (CH3)2-CH2-NH- CH2-CH2-, among many other examples. As an example, the terminology “arylalkylene which optionally includes one or more heteroatoms in the alkylene chain, said heteroatoms being selected from the atoms consisting of O, S, and N” therefore refers to arylheteroalkylene, meaning an arylalkylene which comprises one or more heteroatoms in the hydrocarbon chain, whereas the heteroatoms may be positioned at the beginning of the hydrocarbon chain, in the hydrocarbon chain or at the end of the hydrocarbon chain. “Arylheteroalkylene” thus includes aryloxy, arylalkoxy, aryl-alkyl-NH- and the like and examples are phenyloxy, benzyloxy, aryl- CH2-S-CH2-, aryl-CH2-O-CH2-, aryl-NH-CH2- among many other examples. The same counts for “heteroalkenylene”, “heteroalkynylene”, and other terms used herein when referred to “which optionally includes one or more heteroatoms, said heteroatoms being selected from the atoms consisting of O, S, and N”. The terminology regarding a chemical group “wherein optionally two or more hydrogen atoms on a carbon atom or heteroatom of said group can be taken together to form a =O or =S” as used herein, refers to a group where two or more hydrogen atoms on a carbon atom or heteroatom of said group are taken together to form =O or =S. As an example, the terminology refers to “an alkyl wherein optionally two or more hydrogen atoms on a carbon atom or heteroatom of said alkyl can be taken together to form a =O or =S”, includes among other examples CH3-C(O)-CH2-, CH3-C(O)-, CH3-C(S)-CH2- and (CH3)2-CH2-C(O)-CH2-CH2-. The combination for a group “which optionally includes one or more heteroatoms, said heteroatoms being selected from the atoms consisting of O, S, and N” and “wherein optionally two or more hydrogen atoms on a carbon atom or heteroatom of said group can be taken together to form a =O or =S” can combine the two aspects described herein above and includes, if the group referred to is alkyl, among other examples CH3-C(O)O-, CH3-C(O)O- CH2-, CH3-NH-C(O)-, CH3-C(O)-NH- CH3-NH-C(O)-CH2-, CH3-NH-C(S)-CH2-, CH3-NH-C(S)- NH-CH2-, CH3-NH-S(O)2- and CH3-NH-S(O)2-NH-CH2-. The term “single bond” as used herein for a linking group i.e. in a way that a certain linking group is selected from a single bond, etc. in the formulas herein, refers to a molecule wherein the linking group is not present and therefore refers to compounds with a direct linkage via a single bond between the two moieties being linked by the linking group. As used herein with respect to a substituting group, and unless otherwise stated, the terms “substituted” such as in “substituted alkyl”, “substituted alkenyl”, substituted alkynyl”, “substituted aryl”, “substituted heteroaryl”, “substituted heterocyclyl”, “substituted arylalkyl”, “substituted heteroaryl-alkyl”, “substituted heterocyclylalkyl” and the like refer to the chemical structures defined herein, and wherein the said alkyl, alkenyl, alkynyl, group and / or the said aryl, heteroaryl, or heterocyclyl may be optionally substituted with one or more substituents (preferable 1, 2, 3, 4, 5 or 6), meaning that one or more hydrogen atoms are each independently replaced with at least one substituent. Typical substituents include, but are not limited to and in a particular embodiment said substituents are being independently selected from the group consisting of halogen, amino, hydroxyl, sulfhydryl, alkyl, alkoxy, alkenyl, alkenyloxy, alkynyl, alkynyloxy, cycloalkyl, cycloalkenyl, cycloalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, heteroaryl, heterocyclyl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, heteroarylalkyl, heterocyclylalkyl, heteroarylalkenyl, heterocyclylalkenyl and heteroarylalkynyl, heterocyclylalkynyl, -X, -Z, -O-, - OZ, =O, -SZ, -S-, =S, -NZ2, -N+Z3, =NZ, =N-OZ, -CX3(e.g. trifluoromethyl), -CN, -OCN, -SCN, -N=C=O, -N=C=S, -NO, -NO2, =N2, -N3, -NZC(O)Z, -NZC(S)Z, -NZC(O)O-, -NZC(O)OZ, - NZC(S)OZ, -NZC(O)NZZ, NZC(NZ)Z, NZC(NZ)NZZ, -C(O)NZZ, -C(NZ)Z, -S(O)2O-, -S(O)2OZ, -S(O)2Z, -OS(O)2OZ, -OS(O)2Z, -OS(O)2O-, -S(O)2NZZ, -S(O)(NZ)Z, -S(O)Z, -OP(O)(OZ)2, - P(O)(OZ)2, -P(O)(O-)2, -P(O)(OZ)(O-), -P(O)(OH) - 2, -C(O)Z, -C(O)X, -C(S)Z, -C(O)OZ, -C(O)O , -C(S)OZ, -C(O)SZ, -C(S)SZ, -C(O)NZZ, -C(S)NZZ, -C(NZ)NZZ, -OC(O)Z, -OC(S)Z, - OC(O)O-, -OC(O)OZ, -OC(S)OZ, wherein each X is independently a halogen selected from F, Cl, Br, or I; and each Z is independently –H, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, protecting group or prodrug moiety, while two Z bonded to a nitrogen atom can be taken together with the nitrogen atom to which they are bonded to form a heteroaryl, or heterocyclyl. Alkyl(ene), alkenyl(ene), and alkynyl(ene) groups may also be similarly substituted. Any substituent designation that is found in more than one site in a compound of this invention shall be independently selected. Substituents optionally are designated with or without bonds. Regardless of bond indications, if a substituent is polyvalent (based on its position in the structure referred to), then any and all possible orientations of the substituent are intended. As used herein and unless otherwise stated, the term “solvate” includes any combination which may be formed by a derivative of this invention with a suitable inorganic solvent (e.g. hydrates) or organic solvent, such as but not limited to alcohols, ketones, esters, ethers, nitriles and the like. The term “heteroatom(s)” as used herein means an atom selected from nitrogen, which can be quaternized; oxygen; and sulfur, including sulfoxide and sulfone. The term “hydroxy” as used herein means -OH. The term “carbonyl” as used herein means carbon atom bonded to oxygen with a double bond, i.e., C═O. The term “amino” as used herein means the -NH2 group. The present invention provides novel compounds which have been shown to possess cGAS inhibitory activity. Therefore, these compounds constitute a useful class of new potent compounds that can be used in the treatment and / or prevention of cGAS mediated diseases in subjects, more specifically for the treatment and / or prevention of inflammation conditions and cancer. The present invention furthermore relates to the compounds for use as medicines and to their use for the manufacture of medicaments for treating and / or preventing inflammation conditions and cancer. The present invention relates to the compounds for use as medicines for treating and / or preventing cGAS mediated diseases such as inflammation conditions and cancer in animals, mammals, more in particular in humans. The invention also relates to methods for the preparation of all such compounds and to pharmaceutical compositions comprising them in an effective amount. The present invention also relates to a method of treatment or prevention of inflammation conditions or cancer in humans by the administration of one or more such compounds, optionally in combination with one or more other medicines, to a patient in need thereof. The present invention also relates to the compounds for veterinary use and to their use as medicines for the prevention or treatment of diseases in a non-human mammal, such as inflammation conditions or cancer in non-human mammals. The compounds of the invention are compounds of formula (I) and any subgroup thereof as described herein, a stereo-isomeric form, a tautomer, a salt (in particular a pharmaceutically acceptable salt), solvate, polymorph and / or prodrug thereof, wherein: - each dotted line (---) represents an optional double bond and whereby two adjacent dotted lines cannot form a double bond at the same time; - R1is selected from the group comprising hydrogen, halogen, =O, alkyl, alkenyl, alkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, haloalkyl, haloalkenyl, haloalkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; preferably R1 is selected from the group comprising hydrogen, halogen, =O, C1-6alkyl, C2-6alkenyl, C2- 6alkynyl, hydroxyC1-6alkyl, hydroxyC2-6alkenyl, hydroxyC2-6alkynyl, aminoC1-6alkyl, aminoC2-6alkenyl, aminoC2-6alkynyl, haloC1-6alkyl, haloC2-6alkenyl, haloC2-6alkynyl, C3- 12cycloalkyl, C5-12cycloalkenyl and C5-12cycloalkynyl; wherein each of said alkyl, alkenyl, alkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, haloalkyl, haloalkenyl, haloalkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising halogen, -OH, =O, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, -C(O)OH, -NH2, -NHalkyl, and -N(alkyl)2; preferably each of said C1-6alkyl, C2-6alkenyl, C2-6alkynyl, hydroxyC1-6alkyl, hydroxyC2-6alkenyl, hydroxyC2-6alkynyl, aminoC1-6alkyl, aminoC2-6alkenyl, aminoC2-6alkynyl, haloC1-6alkyl, haloC2-6alkenyl, haloC2-6alkynyl, C3-12cycloalkyl, C5-12cycloalkenyl and C5-12cycloalkynyl is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising halogen, -OH, =O, -SH, =S, - CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, C1-6alkyl, C2-6alkenyl, C2- 6alkynyl, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, hydroxyC1-6alkyl, C3-12cycloalkyl, C5-12cycloalkenyl, C5-12cycloalkynyl, -C(O)OH, -NH2, -NHC1-6alkyl, and -N(C1- 6alkyl)2; - R2 is selected from the group comprising hydrogen, halogen, =O, hydroxyl, alkyl, alkenyl, alkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, alkyloxyalkyl, mono- or di-alkylaminoalkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, haloalkyl, haloalkenyl, haloalkynyl, alkoxy, haloalkoxy, -CONR2aR2band - CO2R2c; preferably R2 is selected from the group comprising hydrogen, halogen, =O, hydroxyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, hydroxyC1-6alkyl, hydroxyC2-6alkenyl, hydroxyC2-6alkynyl, aminoC1-6alkyl, aminoC2-6alkenyl, aminoC2-6alkynyl, C1-6alkyloxyC1- 6alkyl, mono-C1-6alkylaminoC1-6alkyl, di-C1-6alkylaminoC1-6alkyl, C3-12cycloalkyl, C5- 12cycloalkenyl, C5-12cycloalkynyl, haloC1-6alkyl, haloC2-6alkenyl, haloC2-6alkynyl, C1-6alkoxy, haloC1-6alkoxy, -CONR2aR2band -CO2R2c; wherein each of said alkyl, alkenyl, alkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, alkyloxyalkyl, mono- or di-alkylamino- alkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, haloalkyl, haloalkenyl, haloalkynyl, alkoxy and haloalkoxy is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising halogen, -OH, =O, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, -N3, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, -C(O)OH, -C(O)OR2c, -NH2, -NHalkyl, and -N(alkyl)2; - COR2d, -NR2aR2b, -NR2aCOR2d, -CONR2aR2b, and -OR2c; preferably each of said C1-6alkyl, C2-6alkenyl, C2-6alkynyl, hydroxyC1-6alkyl, hydroxyC2-6alkenyl, hydroxyC2- 6alkynyl, aminoC1-6alkyl, aminoC2-6alkenyl, aminoC2-6alkynyl, C1-6alkyloxyC1-6alkyl, mono-C1-6alkylaminoC1-6alkyl, di-C1-6alkylaminoC1-6alkyl, C3-12cycloalkyl, C5- 12cycloalkenyl, C5-12cycloalkynyl, haloC1-6alkyl, haloC2-6alkenyl, haloC2-6alkynyl, C1-6alkoxy, haloC1-6alkoxy, is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising halogen, -OH, =O, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, -N3, cyano, nitro, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, hydroxyC1-6alkyl, C3-12cycloalkyl, C5-12cycloalkenyl, C5-12cycloalkynyl, -C(O)OH, -C(O)OR2c, -NH2, - NHalkyl, and -N(alkyl)2; -COR2d, -NR2aR2b, -NR2aCOR2d, -CONR2aR2b, and -OR2c; - R2a is selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; preferably R2a is selected from the group comprising hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-12cycloalkyl, C5-12cycloalkenyl and C5-12cycloalkynyl; - R2b is selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; preferably R2b is selected from the group comprising hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-12cycloalkyl, C5-12cycloalkenyl and C5- 12cycloalkynyl; - R2c is selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; preferably R2c is selected from the group comprising hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-12cycloalkyl, C5-12cycloalkenyl and C5- 12cycloalkynyl; - R2d is selected from the group comprising hydroxyalkyl, alkyloxyalkyl, hydroxy, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; preferably R2a is selected from the group comprising hydroxy, hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3- 12cycloalkyl, C5-12cycloalkenyl and C5-12cycloalkynyl; - or R1 and R2 together with the carbon atoms to which they are attached can form a heterocyclyl (e.g. pyrrolidinyl), wherein said heterocyclyl is unsubstituted or substituted with one or more substituents each independently selected from the group comprising halogen, -OH, =O, -SH, =S, - CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, -C(O)OH, -NH2, -NHalkyl, and -N(alkyl)2; preferably wherein said heterocyclyl is unsubstituted or substituted with one or more substituents each independently selected from the group comprising halogen, -OH, =O, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, hydroxyC1-6alkyl, C3-12cycloalkyl, C5-12cycloalkenyl, C5-12cycloalkynyl,-C(O)OH, -NH2, - NHC1-6alkyl, and -N(C1-6alkyl)2; - or R2 and X together with the atoms to which they are attached can form a heterocyclyl wherein said heterocyclyl is unsubstituted or substituted with one or more substituents each independently selected from the group comprising halogen, -OH, =O, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, -C(O)OH, -NH2, -NHalkyl, and -N(alkyl)2; preferably R2 and X together with the atoms to which they are attached can form a heterocyclyl wherein said heterocyclyl is unsubstituted or substituted with one or more substituents each independently selected from the group comprising halogen, -OH, =O, -SH, =S, -CF3, - CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, hydroxyC1-6alkyl, -C(O)OH, -NH2, -NHC1-6alkyl, and - N(C1-6alkyl)2; - R3 is selected from the group comprising hydrogen, halogen, nitro, -CN, -NR3aR3b, - (CR3fR3g)q-NR3aR3b, -NR3a-(CR3fR3g)q-C(O)NR3aR3b, -NR3a-(CR3fR3g)q-CO2R3c, -NR3a- (CR3fR3g)q-OR3c, -NR3a-(CR3fR3g)q-PO(OR3i)2, -NR3a-(CR3fR3g)q-NR3aC(O)R3d, -SR3c, - S(O)R3d, -S(O)2R3c, -S(O)2-NR3aR3b, -OR3c, -(CR3fR3g)q-OR3c, , oxo, -NR3aS(O)2R3d, -(CR3fR3g)q-NR3aS(O)2R3d, -NR3aC(O)R3d, - (CR3fR3g)q-NR3aC(O)R3d, -(CR3fR3g)q-CO2R3c, -(CR3fR3g)q-C(O)R3c, -(CR3fR3g)q-C(O)NR3aR3b, hydroxyl, sulfhydryl, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, dialkylamino, alkylaminoalkyl, di-alkyl-amino-alkyl, thioalkyl, alkoxyalkyl, alkyl-thio-alkyl, alkoxyalkylamino, cycloalkyl, cycloalkenyl, cycloalkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, heteroaryl, heterocyclyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl and heterocyclylalkynyl, preferably R3 is selected from the group comprising hydrogen, halogen, nitro, -CN, -NR3aR3b, -(CR3fR3g)q-NR3aR3b, -NR3a-(CR3fR3g)q-C(O)NR3aR3b, -NR3a- (CR3fR3g)q-CO2R3c, -NR3a-(CR3fR3g)q-OR3c, -NR3a-(CR3fR3g)q-PO(OR3i)2, -NR3a-(CR3fR3g)q- NR3aC(O)R3d, -SR3c, -S(O)R3d, -S(O)2R3c, -S(O)2-NR3aR3b, -OR3c, -(CR3fR3g)q-OR3c, oxo, -NR3aS(O) R3d, -(CR3fR3g) -NR3a 3d 2 q S(O)2R , -NR3aC(O)R3d, -(CR3fR3g)q-NR3aC(O)R3d, -(CR3fR3g)q-CO2R3c, -(CR3fR3g)q-C(O)R3c, -(CR3fR3g)q-C(O)NR3aR3b, hydroxyl, sulfhydryl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkylamino, diC1-6alkylamino, C1-6alkylaminoC1-6alkyl, di-C1-6alkyl-amino-C1-6alkyl, thioC1-6alkyl, C1-6alkoxyC1-6alkyl, C1-6alkyl-thio-C1-6alkyl, C1-6alkoxyC1-6alkylamino, C3-12cycloalkyl, C5-12cycloalkenyl, C5-12cycloalkynyl, haloC1-6alkyl, haloC2-6alkenyl, haloC2-6alkynyl, aryl, heteroaryl, heterocyclyl, arylC1-6alkyl, arylC2-6alkenyl, aryl C2-6alkynyl, heteroarylC1-6alkyl, heteroarylC2-6alkenyl, heteroarylC2-6alkynyl, heterocyclylC1-6alkyl, heterocyclylC2-6alkenyl and heterocyclylC2-6alkynyl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, alkylamino, dialkylamino, alkylaminoalkyl, di-alkyl-amino-alkyl, thioalkyl, alkoxyalkyl, alkyl-thio-alkyl, alkoxyalkylamino, cycloalkyl, cycloalkenyl, cycloalkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, heteroaryl, heterocyclyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl and heterocyclylalkynyl, is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising halogen, -OH, =O, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, -C(O)OH, -C(O)R3i, -C(O)-O-CH2-O-CO-R3i, - PO-(OR3i)2, -SO2F, -NH2, -NHalkyl, and -N(alkyl)2; preferably each of said C1-6alkyl, C2- 6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkylamino, diC1-6alkylamino, C1-6alkylaminoC1- 6alkyl, di-C1-6alkyl-amino-C1-6alkyl, thioC1-6alkyl, C1-6alkoxyC1-6alkyl, C1-6alkyl-thio-C1- 6alkyl, C1-6alkoxyC1-6alkylamino, C3-12cycloalkyl, C5-12cycloalkenyl, C5-12cycloalkynyl, haloC1-6alkyl, haloC2-6alkenyl, haloC2-6alkynyl, aryl, heteroaryl, heterocyclyl, arylC1- 6alkyl, arylC2-6alkenyl, aryl C2-6alkynyl, heteroarylC1-6alkyl, heteroarylC2-6alkenyl, heteroarylC2-6alkynyl, heterocyclylC1-6alkyl, heterocyclylC2-6alkenyl and heterocyclylC2- 6alkynyl is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising halogen, -OH, =O, -SH, =S, -CF3, - CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, hydroxyC1-6alkyl, C1-6alkylthio, C3-12cycloalkyl, C5-12cycloalkenyl, C5-12cycloalkynyl, heterocyclyl, -C(O)OH, -C(O)R3i, -C(O)-O-CH2-O- CO-R3i, -PO-(OR3i)2, -SO2F, -NH2, -NHC1-6alkyl, and -N(C1-6alkyl)2; - cycle A is selected from the group comprising aryl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl and heteroaryl; cycle A is selected from the group comprising aryl, C3- 12cycloalkyl, C5-12cycloalkenyl, C5-12cycloalkynyl, heterocyclyl and heteroaryl; - Y is NR3hor O; preferably Y is NH, NC1-6alkyl or O; - each R6 is independently selected from the group comprising hydrogen, halogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, alkoxy, (mono- or di-)alkylamino, alkylthio, alkylthioalkyl, alkyloxyalkyl, (mono- or di-)alkyl-amino-alkyl, -(CR3fR3g)q-O- (CR3fR3g)v-CO2R3c, hydroxyalkyl, -(CR3fR3g)q-NR3aSO2R3d, -CO2R3c, -(CR3fR3g)q-O- (CR3fR3g)v-aryl, -(CR3fR3g)q-O-(CR3fR3g)v-heteroaryl, -CONR3aS(O)2R3d, -S(O)2R3d, - (CR3fR3g)q-O-(CR3fR3g)v-CN, -C(O)R3d, aryl, heteroaryl, heterocyclyl, -C(O)NR3aR3b, oxo, - S(O)2NR3aR3b, -OR3cand -(CR3fR3g) 6 q-O-(CR3fR3g)v-O-aryl, preferably each R is independently selected from the group comprising hydrogen, halogen, C1-6alkyl, C2- 6alkenyl, C2-6alkynyl, C3-12cycloalkyl, C5-12cycloalkenyl, C5-12cycloalkynyl, C1-6alkoxy, mono- C1-6alkylamino, di-C1-6alkylamino, C1-6alkylthio, C1-6alkylthioC1-6alkyl, C1-6alkyloxyC1-6alkyl, mono-C1-6alkyl-amino-C1-6alkyl, di-C1-6alkyl-amino-C1-6alkyl, -(CR3fR3g)q-O-(CR3fR3g)v- CO2R3c, hydroxyC1-6alkyl, -(CR3fR3g)q-NR3aSO2R3d, -CO2R3c, -(CR3fR3g)q-O-(CR3fR3g)v-aryl, -(CR3fR3g)q-O-(CR3fR3g)v-heteroaryl, -CONR3aS(O)2R3d, -S(O)2R3d, -(CR3fR3g)q-O- (CR3fR3g)v-CN, -C(O)R3d, aryl, heteroaryl, heterocyclyl, -C(O)NR3aR3b, oxo, -S(O)2NR3aR3b, -OR3cand -(CR3fR3g)q-O-(CR3fR3g)v-O-aryl, wherein each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, alkoxy, (mono- or di-)alkylamino, alkylthio, alkylthioalkyl, alkyloxyalkyl, (mono- or di-)alkyl- amino-alkyl, aryl, heteroaryl and heterocyclyl is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising halogen, -OH, =O, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, -C(O)OH, -NH2, -NHalkyl, and -N(alkyl)2; preferably each of said C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-12cycloalkyl, C5-12cycloalkenyl, C5-12cycloalkynyl, C1-6alkoxy, mono- C1-6alkylamino, di-C1-6alkylamino, C1-6alkylthio, C1-6alkylthioC1-6alkyl, C1- 6alkyloxyC1-6alkyl, mono-C1-6alkyl-amino-C1-6alkyl, di-C1-6alkyl-amino-C1-6alkyl, aryl, heteroaryl and heterocyclyl is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising halogen, -OH, =O, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, hydroxyC1-6alkyl, C3-12cycloalkyl, C5-12cycloalkenyl, C5-12cycloalkynyl, -C(O)OH, -NH2, -NHC1-6alkyl, and -N(C1-6alkyl)2; or two R6 together with the carbon atom(s) to which they are attached can form a cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl or heteroaryl; wherein each of said cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl and heteroaryl is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising -OH, halogen, -NR3aR3b, aryl, =O, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, - SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, cycloalkenyl and cycloalkynyl; preferably two R6 together with the carbon atom(s) to which they are attached can form a C3-12cycloalkyl, C5-12cycloalkenyl, C5- 12cycloalkynyl, heterocyclyl or heteroaryl; wherein each of said C3-12cycloalkyl, C5- 12cycloalkenyl, C5-12cycloalkynyl, heterocyclyl and heteroaryl is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising -OH, halogen, -NR3aR3b, aryl, =O, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, - SCF3, -SF5, cyano, nitro, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, hydroxyC1-6alkyl, C3-12cycloalkyl, C5-12cycloalkenyl and C5-12cycloalkynyl; - R3a is selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, alkoxy, (mono- or di-)alkyl-amino, alkyloxyalkyl, alkylthioalkyl, (mono- or di-)alkyl-amino-alkyl, haloalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, -SO2-alkyl, aryl, heteroaryl and heterocyclyl; preferably R3a is selected from the group comprising hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-12cycloalkyl, C5-12cycloalkenyl, C5-12cycloalkynyl, C1-6alkoxy, mono-C1-6alkyl- amino, di-C1-6alkyl-amino, C1-6alkyloxyC1-6alkyl, C1-6alkylthioC1-6alkyl, mono-C1-6alkyl- amino-C1-6alkyl, di-C1-6alkyl-amino-C1-6alkyl, haloC1-6alkyl, hydroxyC1-6alkyl, hydroxyC2-6alkenyl, hydroxyC2-6alkynyl, aminoC1-6alkyl, aminoC2-6alkenyl, aminoC2-6alkynyl, -SO2-C1-6alkyl, aryl, heteroaryl and heterocyclyl; - R3b is selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; preferably R3b is selected from the group comprising hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-12cycloalkyl, C5-12cycloalkenyl and C5- 12cycloalkynyl; - R3c is selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, alkyloxyalkyl, alkylthioalkyl, (mono- or di-)alkyl-amino-alkyl, haloalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, hydroxycarbonyl-alkyl, aminoalkyl, aminoalkenyl, aminoalkynyl, aryl, heteroaryl and heterocyclyl; preferably R3c is selected from the group comprising hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-12cycloalkyl, C5-12cycloalkenyl, C5-12cycloalkynyl, C1-6alkyloxyC1-6alkyl, C1-6alkylthioC1-6alkyl, mono-C1- 6alkyl-amino-C1-6alkyl, di-C1-6alkyl-amino-C1-6alkyl, haloC1-6alkyl, hydroxyC1-6alkyl, hydroxyC2-6alkenyl, hydroxyC2-6alkynyl, hydroxycarbonyl-C1-6alkyl, aminoC1-6alkyl, aminoC2- 6alkenyl, aminoC2-6alkynyl, aryl, heteroaryl and heterocyclyl; - R3d is selected from the group comprising alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, alkyloxyalkyl, alkoxy, (mono- or di-)alkyl-amino, (mono- or di-)alkyl-amino- alkyl, alkylthio, alkylthioalkyl, haloalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, aryl, heteroaryl and heterocyclyl; preferably R3d is selected from the group comprising C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-12cycloalkyl, C5- 12cycloalkenyl, C5-12cycloalkynyl, C1-6alkyloxyC1-6alkyl, C1-6alkoxy, mono-C1-6alkyl-amino, di-C1-6alkyl-amino, mono-C1-6alkyl-amino-C1-6alkyl, di-C1-6alkyl-amino-C1-6alkyl, C1- 6alkylthio, C1-6alkylthioC1-6alkyl, haloC1-6alkyl, hydroxyC1-6alkyl, hydroxyC2-6alkenyl, hydroxyC2-6alkynyl, aminoC1-6alkyl, aminoC2-6alkenyl, aminoC2-6alkynyl, aryl, heteroaryl and heterocyclyl; - each R3f and R3g are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, haloalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, -NH2, aminoalkyl, aminoalkenyl, aminoalkynyl, aryl, heteroaryl and heterocyclyl; preferably each R3f and R3g are independently selected from hydrogen, C1- 6alkyl, C2-6alkenyl, C2-6alkynyl, C3-12cycloalkyl, C5-12cycloalkenyl, C5-12cycloalkynyl, haloC1- 6alkyl, hydroxyC1-6alkyl, hydroxyC2-6alkenyl, hydroxyC2-6alkynyl, -NH2, aminoC1-6alkyl, aminoC2-6alkenyl, aminoC2-6alkynyl, aryl, heteroaryl and heterocyclyl; - R3h is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; preferably R3h is selected from hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-12cycloalkyl, C5-12cycloalkenyl and C5-12cycloalkynyl; - R3i is selected from hydrogen, alkyl, cycloalkyl and aryl wherein each alkyl, cycloalkyl, and aryl is optionally further substituted with one or more halogen; preferably R3i is selected from hydrogen, C1-6alkyl, C3-12cycloalkyl, and aryl wherein each C1-6alkyl, C3-12cycloalkyl and aryl is optionally further substituted with one or more halogen; - m is an integer selected from 0, 1, 2, 3, 4 or 5; preferably m is selected from 0, 1, 2 and 3; - p is an integer selected from 0, 1, 2, 3, 4 or 5; preferably p is selected from 0, 1, 2 and 3; - q is an integer selected from 0, 1, 2, 3, 4 or 5; preferably q is selected from 0, 1, 2 and 3; - v is an integer selected from 0, 1, 2, 3, 4 or 5; preferably v is selected from 0, 1, 2 and 3; - W is selected from -CO-, -SO2-, -SO(=NH)-; - L is selected from -CRLgRLh-, -NRLb-, or a single bond; - RLg is selected from the group comprising hydrogen, halogen, alkyl, alkenyl, alkynyl, hydroxyalkyl, hydroxylalkenyl, hydroxyalkynyl, -NRLaRLb, aminoalkyl, aminoalkenyl, aminoalkynyl, haloalkyl, -C(O)NRLaRLb, alkoxy, alkylamino, dialkylamino, alkylaminoalkyl, di-alkyl-amino-alkyl, thioalkyl, alkoxyalkyl, alkyl-thio-alkyl, deuterium, cycloalkyl, cycloalkenyl and cycloalkynyl; preferably RLg is selected from the group comprising hydrogen, halogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, hydroxyC1-6alkyl, hydroxyC2-6alkenyl, hydroxyC2-6alkynyl, -NRLaRLb, aminoC1-6alkyl, aminoC2-6alkenyl, aminoC2-6alkynyl, haloC1- 6alkyl, -C(O)NRLaRLb, C1-6alkoxy, C1-6alkylamino, diC1-6alkylamino, C1-6alkylaminoC1-6alkyl, di-C1-6alkyl-amino-C1-6alkyl, thioC1-6alkyl, C1-6alkoxyC1-alkyl, C1-6alkyl-thio-C1-6alkyl, deuterium, C3-12cycloalkyl, C5-12cycloalkenyl and C5-12cycloalkynyl; - RLh is selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, deuterium, cycloalkyl, cycloalkenyl and cycloalkynyl; preferably RLh is selected from hydrogen, halogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, deuterium, C3-12cycloalkyl, C5-12cycloalkenyl and C5-12cycloalkynyl; - RLa is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; preferably RLa is selected from hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-12cycloalkyl, C5-12cycloalkenyl and C5-12cycloalkynyl; - RLb is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; preferably RLb is selected from hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-12cycloalkyl, C5-12cycloalkenyl and C5-12cycloalkynyl; - or RLg and RLh together with the carbon atoms to which they are attached can form a cycloalkyl, cycloalkenyl, cycloalkynyl and heterocyclyl; preferably RLg and RLh together with the carbon atoms to which they are attached can form a C3-12cycloalkyl, C5-12cycloalkenyl, C5-12cycloalkynyl and heterocyclyl; - X is selected from the group comprising -ORXc, -NRXaRXb, aryl, heteroaryl, heterocyclyl, aminoalkyl, aminoalkenyl, aminoalkynyl, -S(O)2RXd, -NRXbS(O)2RXd, -NRXbC(O)ORXc, - OC(O)RXd, -C(O)NRXaRXb, -C(O)ORXc, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, alkyl, alkenyl, alkynyl, (mono- or di-)alkyl-amino-alkyl, thioalkyl, alkoxyalkyl, alkyl-thio-alkyl cycloalkyl, cycloalkenyl, cycloalkynyl and -N3, preferably X is selected from the group comprising -ORXc, -NRXaRXb, aryl, heteroaryl, heterocyclyl, amino-C1-6alkyl, aminoC2-6alkenyl, aminoC2-6alkynyl, -S(O)2RXd, -NRXbS(O)2RXd, -NRXbC(O)ORXc, -OC(O)RXd, - C(O)NRXaRXb, -C(O)ORXc, hydroxyC1-6alkyl, hydroxyC2-6alkenyl, hydroxyC2-6alkynyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, mono-C1-6alkyl-amino-C1-6alkyl, di-C1-6alkyl-amino-C1-6alkyl, thioC1-6alkyl, C1-6alkoxyC1-6alkyl, C1-6alkyl-thio-C1-6alkyl C3-12cycloalkyl, C5-12cycloalkenyl, C5-12cycloalkynyl, and -N3, wherein each of said heteroaryl, heterocyclyl, aryl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, hydroxyalkyl, hydroxyalkenyl and hydroxyalkynyl is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising hydroxyalkyl, - C(O)NRXaRXb, heteroaryl, heterocyclyl, heterocyclyl substituted by alkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, -OH, =O, halogen, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, -C(O)OH, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, hydroxyalkoxy, aminoalkoxy, (mono- or di-)alkyl-aminoalkoxy, -NH2, - NHalkyl, and -N(alkyl)2; preferably each of said aryl, heteroaryl, heterocyclyl, amino-C1- 6alkyl, aminoC2-6alkenyl, aminoC2-6alkynyl, hydroxyC1-6alkyl, hydroxyC2-6alkenyl, hydroxyC2-6alkynyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, mono-C1-6alkyl-amino-C1-6alkyl, di-C1-6alkyl-amino-C1-6alkyl, thioC1-6alkyl, C1-6alkoxyC1-6alkyl, C1-6alkyl-thio-C1-6alkyl C3- 12cycloalkyl, C5-12cycloalkenyl, C5-12cycloalkynyl is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising hydroxyalkyl, -C(O)NRXaRXb, heteroaryl, heterocyclyl, heterocyclyl substituted by alkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, -OH, =O, halogen, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, -C(O)OH, haloC1-6alkyl, C1- 6alkoxy, haloC1-6alkoxy, hydroxyC1-6alkyl, hydroxyC1-6alkoxy, aminoC1-6alkoxy, mono- C1-6alkyl-aminoC1-6alkoxy, di-C1-6alkyl-aminoC1-6alkoxy, -C(O)OH, -NH2, -NHC1-6alkyl, and -N(C1-6alkyl)2; - RXa is selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkyloxyalkyl, aminoalkyl, aminoalkenyl, aminoalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heteroaryl, heterocyclyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl and heterocyclylalkynyl, preferably RXa is selected from the group comprising hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, C1-6alkoxyC1-6alkyl, aminoC1-6alkyl, aminoC2-6alkenyl, aminoC2-6alkynyl, hydroxyC1-6alkyl, hydroxyC2-6alkenyl, hydroxyC2-6alkynyl, C3-12cycloalkyl, C5-12cycloalkenyl, C5-12cycloalkynyl, heteroaryl, heterocyclyl, heteroarylC1-6alkyl, heteroarylC2-6alkenyl, heteroarylC2-6alkynyl, heterocyclylC1-6alkyl, heterocyclylC2-6alkenyl and heterocyclylC2-6alkynyl, wherein each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, alkyloxyalkyl, aminoalkyl, aminoalkenyl, aminoalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, heteroaryl, heterocyclyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl and heterocyclylalkynyl is unsubstituted or is substituted with one or more substituents each independently selected from -CONRXeRXf, hydroxyalkyl, heteroaryl, heterocyclyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, -OH, =O, halogen, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, -C(O)OH, O-alkyl, haloalkyl, alkoxy, haloalkoxy, -NH2, -NHalkyl, and -N(alkyl)2; preferably each of said C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, C1-6alkoxyC1-6alkyl, aminoC1-6alkyl, aminoC2-6alkenyl, aminoC2-6alkynyl, hydroxyC1-6alkyl, hydroxyC2-6alkenyl, hydroxyC2-6alkynyl, C3- 12cycloalkyl, C5-12cycloalkenyl, C5-12cycloalkynyl, heteroaryl, heterocyclyl, heteroarylC1- 6alkyl, heteroarylC2-6alkenyl, heteroarylC2-6alkynyl, heterocyclylC1-6alkyl, heterocyclylC2-6alkenyl and heterocyclylC2-6alkynyl is unsubstituted or is substituted with one or more substituents each independently selected from -CONRXeRXf, hydroxyC1-6alkyl, heteroaryl, heterocyclyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3- 12cycloalkyl, C5-12cycloalkenyl, C5-12cycloalkynyl, -OH, =O, halogen, -SH, =S, -CF3, - CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, -C(O)OH, O-C1-6alkyl, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, -NH2, -NHC1-6alkyl, and -N(C1-6alkyl)2; - RXb is selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aminoalkyl, aminoalkenyl, aminoalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl, preferably RXb is selected from the group comprising hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, aminoC1-6alkyl, aminoC2-6alkenyl, aminoC2-6alkynyl, hydroxyC1-6alkyl, hydroxyC2-6alkenyl, hydroxyC2- 6alkynyl, C3-12cycloalkyl, C5-12cycloalkenyl and C5-12cycloalkynyl, wherein each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, hydroxyalkyl, hydroxyalkenyl and hydroxyalkynyl is unsubstituted or is substituted with one or more substituents each independently selected from -CONRXeRXf, hydroxyalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, -OH, =O, halogen, -SH, =S, -CF3, -CHF2, - OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, C(O)OH, O-alkyl, haloalkyl, alkoxy, haloalkoxy, -NH2, -NHalkyl, and -N(alkyl)2; preferably each of said C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, aminoC1-6alkyl, aminoC2-6alkenyl, aminoC2-6alkynyl, hydroxyC1-6alkyl, hydroxyC2-6alkenyl, hydroxyC2-6alkynyl, C3-12cycloalkyl, C5-12cycloalkenyl and C5-12cycloalkynyl is unsubstituted or is substituted with one or more substituents each independently selected from -CONRXeRXf, hydroxyC1-6alkyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-12cycloalkyl, C5-12cycloalkenyl, C5-12cycloalkynyl, -OH, =O, halogen, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, C(O)OH, O- C1-6alkyl, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, -NH2, -NHC1-6alkyl, and -N(C1-6alkyl)2; - each RXc is selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkyloxyalkyl, aminoalkyl, aminoalkenyl, aminoalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heteroaryl, heterocyclyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl and heterocyclylalkynyl, preferably each RXc is selected from the group comprising hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, C1-6alkoxyC1-6alkyl, aminoC1- 6alkyl, aminoC2-6alkenyl, aminoC2-6alkynyl, hydroxyC1-6alkyl, hydroxyC2-6alkenyl, hydroxyC2-6alkynyl, C3-12cycloalkyl, C5-12cycloalkenyl, C5-12cycloalkynyl, heteroaryl, heterocyclyl, heteroarylC1-6alkyl, heteroarylC2-6alkenyl, heteroarylC2-6alkynyl, heterocyclylC1-6alkyl, heterocyclylC2-6alkenyl and heterocyclylC2-6alkynyl, wherein each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, alkyloxyalkyl, aminoalkyl, aminoalkenyl, aminoalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, heteroaryl, heterocyclyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl and heterocyclylalkynyl is unsubstituted or is substituted with one or more substituents each independently selected from -CONRXaRXb, hydroxyalkyl, heteroaryl, heterocyclyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, -OH, =O, halogen, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, -C(O)OH, haloalkyl, alkoxy, haloalkoxy, - NH2, -NHalkyl, and -N(alkyl)2; preferably each of said C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, C1-6alkoxyC1-6alkyl, aminoC1-6alkyl, aminoC2-6alkenyl, aminoC2-6alkynyl, hydroxyC1-6alkyl, hydroxyC2-6alkenyl, hydroxyC2-6alkynyl, C3-12cycloalkyl, C5- 12cycloalkenyl, C5-12cycloalkynyl, heteroaryl, heterocyclyl, heteroarylC1-6alkyl, heteroarylC2-6alkenyl, heteroarylC2-6alkynyl, heterocyclylC1-6alkyl, heterocyclylC2- 6alkenyl and heterocyclylC2-6alkynyl is unsubstituted or is substituted with one or more substituents each independently selected from -CONRXaRXb, hydroxyC1-6alkyl, heteroaryl, heterocyclyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-12cycloalkyl, C5-12cycloalkenyl, C5-12cycloalkynyl, -OH, =O, halogen, -SH, =S, -CF3, -CHF2, -OCF3, - OCHF2, -SCF3, -SF5, cyano, nitro, -C(O)OH, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, - NH2, -NHC1-6alkyl, and -N(C1-6alkyl)2; - RXd is selected from the group comprising alkyl, alkenyl, alkynyl, haloalkyl, aminoalkyl, aminoalkenyl, aminoalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heteroaryl, heterocyclyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl and heterocyclylalkynyl, preferably RXd is selected from the group comprising C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, C1-6alkoxyC1-6alkyl, aminoC1-6alkyl, aminoC2-6alkenyl, aminoC2-6alkynyl, hydroxyC1-6alkyl, hydroxyC2-6alkenyl, hydroxyC2-6alkynyl, C3-12cycloalkyl, C5-12cycloalkenyl, C5-12cycloalkynyl, heteroaryl, heterocyclyl, heteroarylC1-6alkyl, heteroarylC2-6alkenyl, heteroarylC2-6alkynyl, heterocyclylC1-6alkyl, heterocyclylC2-6alkenyl and heterocyclylC2-6alkynyl, wherein each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, heteroaryl, heterocyclyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl and heterocyclylalkynyl is unsubstituted or is substituted with one or more substituents each independently selected from - CONRXaRXb, hydroxyalkyl, heteroaryl, heterocycle, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, sulfhydryl, -SCF3, -SF5, cyano, nitro, oxo, amino, -C(O)OH, halogen, hydroxyl, haloalkyl, alkoxy and haloalkoxy; preferably each of said C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, C1-6alkoxyC1-6alkyl, aminoC1-6alkyl, aminoC2- 6alkenyl, aminoC2-6alkynyl, hydroxyC1-6alkyl, hydroxyC2-6alkenyl, hydroxyC2-6alkynyl, C3-12cycloalkyl, C5-12cycloalkenyl, C5-12cycloalkynyl, heteroaryl, heterocyclyl, heteroarylC1-6alkyl, heteroarylC2-6alkenyl, heteroarylC2-6alkynyl, heterocyclylC1-6alkyl, heterocyclylC2-6alkenyl and heterocyclylC2-6alkynyl is unsubstituted or is substituted with one or more substituents each independently selected from -CONRXaRXb, hydroxyC1-6alkyl, heteroaryl, heterocycle, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3- 12cycloalkyl, C5-12cycloalkenyl, C5-12cycloalkynyl, sulfhydryl, -SCF3, -SF5, cyano, nitro, oxo, amino, -C(O)OH, halogen, hydroxyl, haloC1-6alkyl, C1-6alkoxy and haloC1-6alkoxy; - each RXe and RXf are independently selected from alkyl, alkenyl, alkynyl, haloalkyl, aminoalkyl, aminoalkenyl, aminoalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heteroaryl, heterocyclyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl and heterocyclylalkynyl, preferably each RXe and RXf are independently selected from C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, aminoC1-6alkyl, aminoC2-6alkenyl, aminoC2-6alkynyl, hydroxyC1-6alkyl, hydroxyC2-6alkenyl, hydroxyC2-6alkynyl, C3-12cycloalkyl, C5-12cycloalkenyl, C5-12cycloalkynyl, heteroaryl, heterocyclyl, heteroarylC1-6alkyl, heteroarylC2-6alkenyl, heteroarylC2-6alkynyl, heterocyclylC1-6alkyl, heterocyclylC2-6alkenyl and heterocyclylC2- 6alkynyl, wherein each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, heteroaryl, heterocyclyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl and heterocyclylalkynyl is unsubstituted or is substituted with one or more substituents each independently selected from hydroxyalkyl, heteroaryl, heterocycle, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, sulfhydryl, -SCF3, -SF5, cyano, nitro, oxo, amino, -C(O)OH, halogen, hydroxyl, haloalkyl, alkoxy and haloalkoxy; preferably each of said C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, aminoC1-6alkyl, aminoC2-6alkenyl, aminoC2-6alkynyl, hydroxyC1-6alkyl, hydroxyC2-6alkenyl, hydroxyC2-6alkynyl, C3-12cycloalkyl, C5-12cycloalkenyl, C5-12cycloalkynyl, heteroaryl, heterocyclyl, heteroarylC1-6alkyl, heteroarylC2-6alkenyl, heteroarylC2-6alkynyl, heterocyclylC1-6alkyl, heterocyclylC2- 6alkenyl and heterocyclylC2-6alkynyl is unsubstituted or is substituted with one or more substituents each independently selected from hydroxyC1-6alkyl, heteroaryl, heterocycle, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-12cycloalkyl, C5-12cycloalkenyl, C5- 12cycloalkynyl, sulfhydryl, -SCF3, -SF5, cyano, nitro, oxo, amino, -C(O)OH, halogen, hydroxyl, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy; - n is an integer selected from 1, 2, 3, or 4; preferably n is 1, 2 or 3; - each R4 is independently selected from the group comprising halogen, -SCF3, -SF5, -CF3, -OCF3, -CHF2, -OCHF2, -B(OH)2, -O-SO2-F, -SO2-F, cyano, nitro, -OR4c, -NR4aR4b, - NR4aS(O)2R4d, -NR4aSO2NR4aR4b, -NR4aC(O)R4c, -NR4aC(O)OR4c, -NR4aC(O)NR4aR4b, SR4c, -S(O)R4d, -S(O)2R4c, -S(O)2NR4aR4b, -S(O)(NR4a)R4c, -S(NR4a)(NR4a) R4c, -C(O)OR4c, -C(O)R4c, -C(O)NR3aR3b, -P(O)R4aR4b, alkyl, alkenyl, alkynyl, haloalkyl, haloalkoxy, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl and cycloalkynyl, preferably each R4 is independently selected from the group comprising halogen, -SCF3, -SF5, -CF3, -OCF3, -CHF2, -OCHF2, -B(OH)2, -O-SO2-F, -SO2- F, cyano, nitro, -OR4c, -NR4aR4b, -NR4aS(O)2R4d, -NR4aSO2NR4aR4b, -NR4aC(O)R4c, - NR4aC(O)OR4c, -NR4aC(O)NR4aR4b, SR4c, -S(O)R4d, -S(O)2R4c, -S(O)2NR4aR4b, - S(O)(NR4a)R4c, -S(NR4a)(NR4a) R4c, -C(O)OR4c, -C(O)R4c, -C(O)NR3aR3b, -P(O)R4aR4b, C1- 6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, haloC1-6alkoxy, hydroxyC1-6alkyl, hydroxyC2- 6alkenyl, hydroxyC2-6alkynyl, heteroaryl, heterocyclyl, C3-12cycloalkyl, C5-12cycloalkenyl and C5-12cycloalkynyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl haloalkoxy, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, alkoxy, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl and cycloalkynyl is unsubstituted or is substituted with one or more substituents each independently selected from -OH, =O, halogen, -SH, =S, -CF3, - CHF2, -OCF3, -OCHF2, -SCF3, -SF5, -B(OH)2, cyano, nitro, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, hydroxyalkyl, haloalkyl, alkoxy, haloalkoxy, - C(O)OH, -C(O)Oalkyl, -C(O)NH2, -C(O)NHalkyl, -C(O)N(alkyl)2, -NH2, -NHalkyl, and - N(alkyl)2; preferably each of said C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, haloC1-6alkoxy, hydroxyC1-6alkyl, hydroxyC2-6alkenyl, hydroxyC2-6alkynyl, heteroaryl, heterocyclyl, C3-12cycloalkyl, C5-12cycloalkenyl, C5-12cycloalkynyl is unsubstituted or is substituted with one or more substituents each independently selected from -OH, =O, halogen, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, -B(OH)2, cyano, nitro, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-12cycloalkyl, C5-12cycloalkenyl, C5-12cycloalkynyl, hydroxyC1-6alkyl, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, -C(O)OH, -C(O)OC1-6alkyl, - C(O)NH2, -C(O)NHC1-6alkyl, -C(O)N(C1-6alkyl)2, -NH2, -NHC1-6alkyl, and -N(C1-6alkyl)2; - or two R4 together with the carbon atom(s) to which they are attached can form a cycloalkyl, cycloalkenyl, cycloalkynyl or heterocyclyl, preferably two R4 together with the carbon atom(s) to which they are attached can form a C3-12cycloalkyl, C5-12cycloalkenyl, C5- 12cycloalkynyl or heterocyclyl, wherein each of said cycloalkyl, cycloalkenyl, cycloalkynyl and heterocyclyl is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising -OH, =O, halogen, -SH, =S, -CF3, -CHF2, -OCF3, - OCHF2, -SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, cycloalkenyl, cycloalkynyl, hydroxyalkyl, haloalkyl, alkoxy, haloalkoxy, alkoxyalkyl, haloalkoxyalkyl, hydroxyalkoxyalkyl, -C(O)OH, -C(O)Oalkyl, -C(O)NH2, -C(O)NHalkyl, -C(O)N(alkyl)2, - NH2, -NHalkyl, and -N(alkyl)2; preferably each of said C3-12cycloalkyl, C5-12cycloalkenyl, C5-12cycloalkynyl or heterocyclyl is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising -OH, =O, halogen, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-12cycloalkyl, aryl, C5-12cycloalkenyl, C5-12cycloalkynyl, hydroxyC1-6alkyl, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, C1-6alkoxyC1-6alkyl, haloC1-6alkoxyC1-6alkyl, hydroxyC1-6alkoxyC1-6alkyl, -C(O)OH, -C(O)OC1-6alkyl, -C(O)NH2, -C(O)NHC1-6alkyl, - C(O)N(C1-6alkyl)2, -NH2, -NHC1-6alkyl, and -N(C1-6alkyl)2; - R4a is selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, haloalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aminoalkyl, aminoalkenyl and aminoalkynyl; preferably R4a is selected from the group comprising hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl C3-12cycloalkyl, C5-12cycloalkenyl, C5-12cycloalkynyl, haloC1-6alkyl, hydroxyC1-6alkyl, hydroxyC2-6alkenyl, hydroxyC2-6alkynyl, aminoC1-6alkyl, aminoC2-6alkenyl and aminoC2-6alkynyl; - R4b is selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; preferably R4b is selected from the group comprising hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-12cycloalkyl, C5-12cycloalkenyl and C5- 12cycloalkynyl; - R4c is selected from the group comprising hydrogen, alkyl, alkyl substituted with deuterium, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, alkoxyalkyl and (mono- or di-)alkyl-aminoalkyl; preferably R4c is selected from the group comprising hydrogen, C1-6alkyl, C1-6alkyl substituted with deuterium, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, C1-6alkoxyC1-6alkyl, hydroxyC1-6alkyl, hydroxyC2-6alkenyl, hydroxyC2-6alkynyl, aminoC1-6alkyl, aminoC2-6alkenyl, aminoC2-6alkynyl, C3-12cycloalkyl, C5-12cycloalkenyl, C5-12cycloalkynyl, mono-C1-6alkyl-aminoC1-6alkyl and di-C1-6alkyl-aminoC1-6alkyl; - R4d is selected from the group comprising alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; preferably R4d is selected from the group comprising C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-12cycloalkyl, C5-12cycloalkenyl and C5-12cycloalkynyl; - R5 is selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkyloxyalkyl, mono- or di-alkyl-amino-alkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl; preferably R5 is selected from the group comprising hydrogen, C1- 6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, C1-6alkyloxyC1-6alkyl, mono-C1-6alkyl-amino- C1-6alkyl, di-C1-6alkyl-amino-C1-6alkyl, hydroxyC1-6alkyl, hydroxyC2-6alkenyl, hydroxyC2- 6alkynyl, aminoC1-6alkyl, aminoC2-6alkenyl, aminoC2-6alkynyl, C3-10cycloalkyl, C5- 12cycloalkenyl, C5-12cycloalkynyl, C3-10cycloalkylC1-6alkyl, C3-10cycloalkylC2-6alkenyl, C3- 10cycloalkylC2-6alkynyl, heterocyclylC1-6alkyl, heterocyclylC2-6alkenyl, heterocyclylC2- 6alkynyl; wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, alkyloxyalkyl, mono- or di-alkyl- amino-alkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, heterocyclylalkyl, heterocyclylalkenyl, and heterocyclylalkynyl, is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising -OH, =O, halogen, -SH, =S, -CF3, -CHF2, -OCF3, - OCHF2, -SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, hydroxyalkyl, haloalkyl, alkoxy, haloalkoxy, -C(O)OH, C(O)Oalkyl, - C(O)NH2, -C(O)NHalkyl, -C(O)N(alkyl)2, -NH2, -NHalkyl, and -N(alkyl)2; preferably each of said C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, C1-6alkyloxyC1-6alkyl, mono-C1-6alkyl-amino-C1-6alkyl, di-C1-6alkyl-amino-C1-6alkyl, hydroxyC1-6alkyl, hydroxyC2-6alkenyl, hydroxyC2-6alkynyl, aminoC1-6alkyl, aminoC2-6alkenyl, aminoC2-6alkynyl, C3-10cycloalkyl, C5-12cycloalkenyl, C5-12cycloalkynyl, C3-10cycloalkylC1-6alkyl, C3- 10cycloalkylC2-6alkenyl, C3-10cycloalkylC2-6alkynyl, heterocyclylC1-6alkyl, heterocyclylC2- 6alkenyl, heterocyclylC2-6alkynyl is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising -OH, =O, halogen, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-12cycloalkyl, C5-12cycloalkenyl, C5-12cycloalkynyl, hydroxyC1-6alkyl, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, -C(O)OH, C(O)OC1-6alkyl, -C(O)NH2, - C(O)NHC1-6alkyl, -C(O)N(C1-6alkyl)2, -NH2, -NHC1-6alkyl, and -N(C1-6alkyl)2; - or R3 and R5 together with the atoms to which they are attached form a heteroaryl or heterocyclyl wherein said heteroaryl or heterocyclyl is optionally substituted with one or more substituents independently selected from -OH, =O, halogen, -SH, =S, -CF3, -CHF2, - OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, phenyl, hydroxyalkyl, haloalkyl, alkoxy, haloalkoxy, -NH2, -NHalkyl, and -N(alkyl)2; preferably R3 and R5 together with the atoms to which they are attached form a heteroaryl or heterocyclyl wherein said heteroaryl or heterocyclyl is optionally substituted with one or more substituents independently selected from -OH, =O, halogen, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, - SCF3, -SF5, cyano, nitro, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, phenyl, hydroxyC1-6alkyl, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, -NH2, -NHC1-6alkyl, and -N(C1-6alkyl)2; - wherein when the moiety -W-L-X is -C(O)O-tert-butyl, then R3is not oxo or hydrogen; with the proviso that said compound is not: 1,3-dihydro-6,8-dimethoxy-4-methyl-N-(1-methylethyl)-2H-pyrrolo[3,4-c]quinoline-2- carboxamide, N-butyl-1,3-dihydro-6,8-dimethoxy-4-methyl-2H-pyrrolo[3,4-c]quinoline-2-carboxamide, 1,3-dihydro-6,8-dimethoxy-4-methyl-N-phenyl-2H-pyrrolo[3,4-c]quinoline-2-carboxamide, 1-(1,3-dihydro-6,8-dimethoxy-4-methyl-2H-pyrrolo[3,4-c]quinolin-2-yl)ethenone, N-(2-ethoxyphenyl)-1,3-dihydro-6,8-dimethoxy-4-methyl-2H-pyrrolo[3,4-c]quinoline-2- carboxamide, N-(3,4-dichlorophenyl)-1,3-dihydro-6,8-dimethoxy-4-methyl-2H-pyrrolo[3,4-c]quinoline-2- carboxamide, tert-butyl 6-(1-((tert-butoxycarbonyl)amino)propan-2-yl)-1-oxo-1,3-dihydro-2H-pyrrolo[3,4- c]quinoline-2-carboxylate, 1,3-dihydro-6,8-dimethoxy-4-methyl-N-[3-(trifluoromethyl)phenyl]-2H-pyrrolo[3,4-c]quinoline- 2-carboxamide, 2-(2-chloroacetyl)-4-methyl-8-[(2-nitro-1-pyrrolidinyl)sulfonyl]-1H-pyrrolo[3,4-c]quinoline- 1,3(2H)-dione, 1,3-dihydro-4-methyl-8-[(2-nitro-1-pyrrolidinyl)sulfonyl]-α,1,3-trioxo-2H-pyrrolo[3,4- c]quinoline-2-acetyl chloride, 2,3-dihydro-8-methyl-2-[(4-methylphenyl)sulfonyl]-4-phenyl-1H-pyrrolo[3,4-c]quinolin-1-one, 7-chloro-2,3-dihydro-2-[(4-methylphenyl)sulfonyl]-4-phenyl-1H-pyrrolo[3,4-c]quinolin-1-one, 8-bromo-2,3-dihydro-2-[(4-methylphenyl)sulfonyl]-4-phenyl-1H-pyrrolo[3,4-c]quinolin-1-one, 8-chloro-2,3-dihydro-2-[(4-methylphenyl)sulfonyl]-4-phenyl-1H-pyrrolo[3,4-c]quinolin-1-one, 8-fluoro-2,3-dihydro-2-[(4-methylphenyl)sulfonyl]-4-phenyl-1H-pyrrolo[3,4-c]quinolin-1-one, 2,3-dihydro-8-methoxy-4-(6-methyl-1H-indol-3-yl)-2-[(4-methylphenyl)sulfonyl]-1H- pyrrolo[3,4-c]quinoline, 8-(1,1-dimethylethyl)-2,3-dihydro-4-(1H-indol-3-yl)-2-[(4-methylphenyl)sulfonyl]-1H- pyrrolo[3,4-c]quinoline, 2,3-dihydro-2-[(4-methylphenyl)sulfonyl]-8-(4-morpholinylsulfonyl)-4-phenyl-1H-pyrrolo[3,4- c]quinolin-1-one, (3aS,9bS)-2-(benzo[d][1,3]dioxol-5-ylsulfonyl)-8-hydroxy-5-methyl-1,2,3,3a,5,9b-hexahydro- 4H-pyrrolo[3,4-c]quinolin-4-one, (3aS,9bS)-2-(benzo[d][1,3]dioxol-5-ylsulfonyl)-5-methyl-4-oxo-2,3,3a,4,5,9b-hexahydro-1H- pyrrolo[3,4-c]quinoline-8-carbonitrile, (3aS,9bS)-2-(benzo[d][1,3]dioxol-5-ylsulfonyl)-8-fluoro-5-methyl-1,2,3,3a,5,9b-hexahydro-4H- pyrrolo[3,4-c]quinolin-4-one, tert-butyl (3aR,9bR)-1,3,3a,4,5,9b-hexahydro-2H-pyrrolo[3,4-c]quinoline-2-carboxylate, tert-butyl (3aS,9bR)-8-(2-(trifluoromethyl)phenyl)-1,3,3a,4,5,9b-hexahydro-2H-pyrrolo[3,4- c]quinoline-2-carboxylate, In one embodiment are provided compounds of formula (I) wherein: - each dotted line (---) represents an optional double bond and whereby two adjacent dotted lines cannot form a double bond at the same time; - R1is selected from the group comprising hydrogen, halogen, =O, alkyl, alkenyl, alkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, haloalkyl, haloalkenyl, haloalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; wherein each of said alkyl, alkenyl, alkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, haloalkyl, haloalkenyl, haloalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising halogen, -OH, =O, -SH, =S, - CF3, - CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, -C(O)OH, -NH2, -NHalkyl, and - N(alkyl)2; - R2is selected from the group comprising hydrogen, halogen, =O, hydroxyl, alkyl, alkenyl, alkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, heteroalkyl (e.g., alkyloxyalkyl, mono- or di-alkylaminoalkyl), heteroalkenyl, heteroalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, haloalkyl, haloalkenyl, haloalkynyl, alkoxy, haloalkoxy, -CONR2aR2band -CO2R2c; wherein each of said alkyl, alkenyl, alkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, haloalkyl, haloalkenyl, haloalkynyl, alkoxy and haloalkoxy is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising halogen, -OH, =O, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, -C(O)OH, -NH2, - NHalkyl, and - N(alkyl)2; -COR2d, - NR2aR2b, -NR2aCOR2d, - CONR2aR2b, and -OR2c; - R2ais selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; - R2bis selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; - R2cis selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; - R2dis selected from the group comprising hydroxyalkyl, heteroalkyl (e.g. alkyloxyalkyl), hydroxy, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; - or R1and R2together with the carbon atoms to which they are attached can form a cycloalkyl, cycloalkenyl or a heterocyclyl (e.g. pyrrolidinyl), wherein each of said cycloalkyl, cycloalkenyl or heterocyclyl is unsubstituted or substituted with one or more substituents each independently selected from the group comprising halogen, -OH, =O, -SH, =S, - CF3, - CHF2, -OCF3, -OCHF2, -SCF3, - SF5, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, - C(O)OH, -NH2, -NHalkyl, and -N(alkyl)2; - R3is selected from the group comprising hydrogen, halogen, nitro, -CN, -NR3aR3b, - (CR3fR3g)q-NR3aR3b, -NR3a-(CR3fR3g)q-C(O)NR3aR3b, -NR3a-(CR3fR3g)q-NR3aC(O)R3d, -SR3c, -S(O)R3d, -S(O)2R3c, -S(O)2-NR3aR3b, -OR3c, -(CR3fR3g)q-OR3c, , oxo, -NR3aS(O)2R3d, -(CR3fR3g)q-NR3aS(O)2R3d, -NR3aC(3d O)R , - (CR3fR3g)q-NR3aC(O)R3d, -(CR3fR3g)q-CO2R3c, -(CR3fR3g)q-C(O)R3c, -(CR3fR3g)q- C(O)NR3aR3b, hydroxyl, sulfhydryl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, heteroaryl, heterocyclyl, arylalkyl, arylalkenyl, arylalkynyl, arylheteroalkyl, arylheteroalkenyl, arylheteroalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heteroarylheteroalkyl, heteroarylheteroalkenyl, heteroarylheteroalkynyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, heterocyclylheteroalkyl, heterocyclylheteroalkenyl, and heterocyclylheteroalkynyl; wherein each of said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, heteroaryl, heterocyclyl, arylalkyl, arylalkenyl, arylalkynyl, arylheteroalkyl, arylheteroalkenyl, arylheteroalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heteroarylheteroalkyl, heteroarylheteroalkenyl, heteroarylheteroalkynyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, heterocyclylheteroalkyl, heterocyclylheteroalkenyl, and heterocyclylheteroalkynyl is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising halogen, -OH, =O, -SH, =S, -CF3, - CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, -C(O)OH, - NH2, -NHalkyl, and - N(alkyl)2; - cycle A is selected from the group comprising aryl (phenyl), cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, and heteroaryl; - Y is NR3hor O; - each R6is independently selected from the group comprising hydrogen, halogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heteroalkyl (e.g. alkyloxyalkyl), heteroalkenyl, heteroalkynyl, -(CR3fR3g)q-O-(CR3fR3g)v-CO2R3c, hydroxyalkyl, -(CR3fR3g)q- NR3aSO2R3d, -CO2R3c, -(CR3fR3g)q-O-(CR3fR3g)v-aryl, -(CR3fR3g)q-O-(CR3fR3g)v-heteroaryl, - CONR3aS(O)2R3d, -S(O)2R3d, -(CR3fR3g)q-O-(CR3fR3g)v-CN, -C(O)R3d, aryl, heteroaryl, heterocyclyl, -C(O)NR3aR3b, oxo, -S(O)2NR3aR3b, -OR3cand -(CR3fR3g)q-O-(CR3fR3g)v-O- aryl; wherein each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, heteroaryl and heterocyclyl is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising halogen, -OH, =O, -SH, =S, - CF3, - CHF2, - OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, -C(O)OH, -NH2, -NHalkyl, and -N(alkyl)2; or two R6together with the carbon atom(s) to which they are attached can form a cycloalkyl, cycloalkenyl, cycloalkynyl, or heterocyclyl; wherein each of said cycloalkyl, cycloalkenyl, cycloalkynyl and heterocyclyl is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising -OH, halogen, - NR3aR3b, aryl, =O, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; - R3ais selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, haloalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, aryl, heteroaryl and heterocyclyl; - R3bis selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; - R3cis selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heteroalkyl (alkyloxyalkyl), heteroalkenyl, heteroalkynyl, haloalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, aryl, heteroaryl and heterocyclyl; - R3dis selected from the group comprising alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heteroalkyl (alkyloxyalkyl), heteroalkenyl, heteroalkynyl, haloalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, aryl, heteroaryl and heterocyclyl; - each R3fand R3gare each independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heteroalkenyl, heteroalkynyl, haloalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, aryl, heteroaryl and heterocyclyl; - R3his selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; - m is an integer selected from 0, 1, 2, 3, 4 or 5 - p is an integer selected from 0, 1,2, 3, 4 or 5; - q is an integer selected from 0, 1, 2, 3, 4 or 5; - v is an integer selected from 0, 1,2, 3, 4 or 5; - W is selected from -CO-, -SO2-, -SO(=NH)- (sulfoximinyl); - L is selected from -CRLgRLh-, -NRLb-, or a single bond; - RLgis selected from the group comprising hydrogen, halogen, alkyl, alkenyl, alkynyl, hydroxyalkyl, hydroxylalkenyl, hydroxyalkynyl, -NRLaRLb, aminoalkyl, aminoalkenyl, aminoalkynyl, haloalkyl, -C(O)NRLaRLb, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; - RLhis selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; - RLais selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; - RLbis selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; - or RLgand RLhtogether with the carbon atoms to which they are attached can form a cycloalkyl, cycloalkenyl, cycloalkynyl and heterocyclyl; - X is selected from the group comprising -ORXc, -NRXaRXb, heteroaryl, heterocyclyl, aminoalkyl aminoalkenyl, aminoalkynyl, -S(O)2RXd, -NRXbS(O)2RXd, -NRXbC(O)2RXc, - OC(O)RXd, -C(O)NRXaRXb, -CO2RXc, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl and -N3; wherein each of said heteroaryl, heterocyclyl, aryl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, hydroxyalkyl, hydroxyalkenyl and hydroxyalkynyl is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising hydroxyalkyl, -C(O)NRXaRXb, heteroaryl, heterocyclyl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, -OH, =O, halogen, -SH, =S, -CF3, -CHF2, - OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, -C(O)OH, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, -NH2, - NHalkyl, and -N(alkyl)2; - RXais selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl (alkyloxyalkyl), heteroalkenyl, heteroalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heteroaryl, heterocyclyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl and heterocyclylalkynyl; wherein each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, heteroaryl, heterocyclyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl and heterocyclylalkynyl is unsubstituted or is substituted with one or more substituents each independently selected from -CONRXaRXb, hydroxyalkyl, heteroaryl, heterocyclyl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, -OH, =O, halogen, -SH, =S, -CF3, -CHF2, - OCF3, -OCHF2, - SCF3, -SF5, cyano, nitro, -C(O)OH, O-alkyl, haloalkyl, alkoxy, haloalkoxy, -NH2, -NHalkyl, and -N(alkyl)2; - RXbis selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; wherein each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, hydroxyalkyl, hydroxyalkenyl and hydroxyalkynyl is unsubstituted or is substituted with one or more substituents each independently selected from -CONRXaRXb, hydroxyalkyl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, -OH, =O, halogen, -SH, =S, -CF3, -CHF2, - OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, - C(O)OH, O-alkyl, haloalkyl, alkoxy, haloalkoxy, -NH2, -NHalkyl, and -N(alkyl)2 - each RXcis selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl (alkyloxyalkyl), heteroalkenyl, heteroalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heteroaryl, heterocyclyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl and heterocyclylalkynyl; wherein each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, heteroaryl, heterocyclyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl and heterocyclylalkynyl is unsubstituted or is substituted with one or more substituents each independently selected from -CONRXaRXb, hydroxyalkyl, heteroaryl, heterocyclyl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, -OH, =O, halogen, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, - SCF3, -SF5, cyano, nitro, -C(O)OH, O-alkyl, haloalkyl, alkoxy, haloalkoxy, -NH2, - NHalkyl, and -N(alkyl)2; - RXdis selected from the group comprising alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heteroaryl, heterocyclyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl and heterocyclylalkynyl; wherein each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, heteroaryl, heterocyclyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl and heterocyclylalkynyl is unsubstituted or is substituted with one or more substituents each independently selected from -CONRXaRXb, hydroxyalkyl, heteroaryl, heterocycle, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, sulfhydryl, -SCF3, -SF5, cyano, nitro, oxo, amino, - C(O)OH, halogen, hydroxyl, haloalkyl, alkoxy and haloalkoxy; - n is an integer selected from 1, 2, 3, or 4; - each R4is independently selected from the group comprising halogen, -SCF3; -SF5; -CF3; -OCF3; -CHF2; -OCHF2; cyano; nitro; -OR4c, -NR4aR4b, -NR4aS(O)2R4d, -NR4aSO2NR4aR4b; -NR4aC(O)R4d, -NR4aC(O)OR4c, -NR4aC(O)NR4aR4b, SR4c, -S(O)R4d, -S(O)2R4c, - S(O)2NR4aR4b, -S(O)(NR4a)R4c; -S(NR4a)(NR4a) R4c; -C(O)OR4c, -C(O)R4c, -C(O)NR3aR3b, - P(O)R4aR4b, alkyl, alkenyl, alkynyl, haloalkyl haloalkoxy, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; wherein each of said alkyl, alkenyl, alkynyl, haloalkyl haloalkoxy, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl cycloalkyl, cycloalkenyl and cycloalkynyl is unsubstituted or is substituted with one or more substituents each independently selected from -OH, =O, halogen, -SH, =S, -CF3, - CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, hydroxyalkyl, haloalkyl, alkoxy, haloalkoxy, -C(O)OH, -C(O)Oalkyl, -C(O)NH2, -C(O)NHalkyl, C(O)N(alkyl)2, -NH2, -NHalkyl, and - N(alkyl)2; - or two R4together with the carbon(s) atom to which they are attached can form a cycloalkyl, cycloalkenyl, cycloalkynyl or heterocyclyl; wherein each of said cycloalkyl, cycloalkenyl, cycloalkynyl and heterocyclyl is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising -OH, =O, halogen, -SH, =S, -CF3, -CHF2, -OCF3, - OCHF2, -SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, hydroxyalkyl, haloalkyl, alkoxy, haloalkoxy, -C(O)OH, C(O)Oalkyl, -C(O)NH2, -C(O)NHalkyl, C(O)N(alkyl)2, -NH2, - NHalkyl, and -N(alkyl)2; - R4ais selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, haloalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aminoalkyl, aminoalkenyl and aminoalkynyl; - R4bis selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; - R4cis selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heteroalkyl, heteroalkenyl and heteroalkynyl; - R4dis selected from the group comprising alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; - R5is selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl (e.g., alkyloxyalkyl, mono- or di-alkylaminoalkyl), heteroalkenyl, heteroalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl; wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, heteroalkenyl, heteroalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, heterocyclylalkyl, heterocyclylalkenyl, and heterocyclylalkynyl, is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising -OH, =O, halogen, -SH, =S, -CF3, - CHF2, - OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, hydroxyalkyl, haloalkyl, alkoxy, haloalkoxy, -C(O)OH, C(O)Oalkyl, -C(O)NH2, - C(O)NHalkyl, C(O)N(alkyl)2, -NH2, - NHalkyl, and -N(alkyl)2; with the proviso that said compound is not: 1,3-dihydro-6,8-dimethoxy-4-methyl-N-(1-methylethyl)-2H-pyrrolo[3,4-c]quinoline-2- carboxamide N-butyl-1,3-dihydro-6,8-dimethoxy-4-methyl-2H-pyrrolo[3,4-c]quinoline-2-carboxamide 1,3-dihydro-6,8-dimethoxy-4-methyl-N-phenyl-2H-pyrrolo[3,4-c]quinoline-2-carboxamide 1-(1,3-dihydro-6,8-dimethoxy-4-methyl-2H-pyrrolo[3,4-c]quinolin-2-yl)ethenone N-(2-ethoxyphenyl)-1,3-dihydro-6,8-dimethoxy-4-methyl-2H-pyrrolo[3,4-c]quinoline-2- carboxamide N-(3,4-dichlorophenyl)-1,3-dihydro-6,8-dimethoxy-4-methyl-2H-pyrrolo[3,4-c]quinoline-2- carboxamide tert-butyl 6-(1-((tert-butoxycarbonyl)amino)propan-2-yl)-1-oxo-1,3-dihydro-2H-pyrrolo[3,4- c]quinoline-2-carboxylate 1,3-dihydro-6,8-dimethoxy-4-methyl-N-[3-(trifluoromethyl)phenyl]-2H-pyrrolo[3,4-c]quinoline- 2-carboxamide 2-(2-chloroacetyl)-4-methyl-8-[(2-nitro-1-pyrrolidinyl)sulfonyl]-1H-pyrrolo[3,4-c]quinoline- 1,3(2H)-dione 1,3-dihydro-4-methyl-8-[(2-nitro-1-pyrrolidinyl)sulfonyl]-α,1,3-trioxo-2H-pyrrolo[3,4- c]quinoline-2-acetyl chloride 2,3-dihydro-8-methyl-2-[(4-methylphenyl)sulfonyl]-4-phenyl-1H-pyrrolo[3,4-c]quinolin-1-one 7-chloro-2,3-dihydro-2-[(4-methylphenyl)sulfonyl]-4-phenyl-1H-pyrrolo[3,4-c]quinolin-1-one 8-bromo-2,3-dihydro-2-[(4-methylphenyl)sulfonyl]-4-phenyl-1H-pyrrolo[3,4-c]quinolin-1-one 8-chloro-2,3-dihydro-2-[(4-methylphenyl)sulfonyl]-4-phenyl-1H-pyrrolo[3,4-c]quinolin-1-one 8-fluoro-2,3-dihydro-2-[(4-methylphenyl)sulfonyl]-4-phenyl-1H-pyrrolo[3,4-c]quinolin-1-one 2,3-dihydro-8-methoxy-4-(6-methyl-1H-indol-3-yl)-2-[(4-methylphenyl)sulfonyl]-1H- pyrrolo[3,4-c]quinoline 8-(1,1-dimethylethyl)-2,3-dihydro-4-(1H-indol-3-yl)-2-[(4-methylphenyl)sulfonyl]-1H- pyrrolo[3,4-c]quinoline 2,3-dihydro-2-[(4-methylphenyl)sulfonyl]-8-(4-morpholinylsulfonyl)-4-phenyl-1H-pyrrolo[3,4- c]quinolin-1-one. Preferred or particular statements (features), aspect and embodiments of the compounds of this invention are set herein below. Each statement, aspect and embodiment of the invention so defined may be combined with any other statement, aspect and / or embodiment, unless clearly indicated to the contrary. In particular, any feature indicated as being preferred, particular or advantageous may be combined with any other features or statements indicated as being preferred, particular or advantageous. Hereto, the present invention is in particular captured by any one or any combination of one or more of the below statements and embodiments, with any other statement, aspect and / or embodiment. The compound according to any one of the formulas, statements, embodiments or claims, wherein R1is selected from hydrogen, alkyl, or hydroxyalkyl; preferably R1is selected from hydrogen, C1-6alkyl, or hydroxyC1-6alkyl. In an embodiment, R1is selected from hydrogen, alkyl and hydroxyalkyl, such as C1-4-alkyl and hydroxyC1-4-alkyl. In a further embodiment, R1is selected from hydrogen, methyl, hydroxymethyl, ethyl and (i- or n-) propyl. In a further embodiment, R1is a C1-4-alkyl, such as methyl, and stereo chemically defined in S-configuration. The compound according to any one of the formulas, statements, embodiments or claims, wherein - R2is selected from the group comprising hydrogen, -CONR2aR2b, aminoalkyl, alkyl, hydroxyalkyl and heteroalkyl; preferably R2is selected from the group comprising hydrogen, -CONR2aR2b, aminoC1-6alkyl, C1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, mono-C1-6alkylaminoC1-6alkyl and di-C1-6alkylaminoC1-6alkyl; - R2ais selected from hydrogen or alkyl; preferably R2ais selected from hydrogen or C1-6alkyl and - R2bis selected from hydrogen or alkyl; preferably R2bis selected from hydrogen or C1-6alkyl. In some embodiments, R2is selected from the group comprising hydrogen, -CONR2aR2b, aminoalkyl, alkyl, hydroxyalkyl, alkoxy, alkoxyalkyl, (mono- or di-alkyl)amino, (mono- or di- alkyl)amino-alkyl, alkylthio and alkylthioalkyl; R2ais selected from hydrogen or alkyl; and R2bis selected from hydrogen or alkyl; preferably R2is selected from the group comprising hydrogen, -CONR2aR2b, aminoC1-6alkyl, C1-6alkyl, hydroxyC1-6alkyl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, mono- C1-6alkylamino, di-C1-6alkylamino, mono-C1-6alkylamino-C1-6alkyl, di-C1-6alkylamino-C1-6alkyl, C1-6alkylthio and C1-6alkylthioC1-6alkyl; R2ais selected from hydrogen or C1-6alkyl; and R2bis selected from hydrogen or C1-6alkyl. In some embodiments, R2is a C1-4alkyl, such as methyl. In further embodiments, R2is stereochemically defined in S-configuration. The compound according to any one of the formulas, statements, embodiments or claims, wherein - R3is selected from the group comprising hydrogen, -NR3aR3b, -NR3a-(CR3fR3g)q-CONR3a, - NR3a-(CR3fR3g)q-NR3aCOR3d, -SR3c, OR3c, alkyl, , oxo, -NR3aSO2R3d, halogen, -NR3aCOR3dand heteroalkyl (e.g. alkoxy, alkoxyalkyl, (mono- or di-alkyl)amino, (mono- or di-alkyl)amino-alkyl, alkylthio and alkylthioalkyl); preferably R3is selected from the group comprising hydrogen, -NR3aR3b, -NR3a-(CR3fR3g)q-CONR3a, - NR3a-(CR3fR3g)q-NR3aCOR3d, -SR3c, OR3c, C1-6alkyl, , oxo, -NR3aSO R3d, halogen, -NR3aCOR3d 2 , C1-6alkoxy, C1-6alkoxyC1- 6alkyl, mono-C1-6alkylamino, di-C1-6alkylamino, mono-C1-6alkylamino-C1-6alkyl, di-C1- 6alkylamino-C1-6alkyl, C1-6alkylthio and C1-6alkylthioC1-6alkyl;cycle A is selected from the group comprising aryl (phenyl), 3- to 7-membered cycloalkyl, 4- to 12-membered heterocyclyl, 5- to 12-membered heteroaryl; - Y is NR3hor O; - each R6is independently selected from the group comprising hydrogen, -(CR3fR3g)q-O- (CR3fR3g)v-CO2R3c, hydroxyalkyl, -(CR3fR3g)q-NR3aSO2R3d, -CO2R3c, -(CR3fR3g)q-O- (CR3fR3g)v-heteroaryl, -CONR3aSO2R3d, -SO2R3d, -(CR3fR3g)q-O-(CR3fR3g)v-CN, -COR3d, heteroaryl, heteroalkyl (e.g. alkoxy, alkoxyalkyl, (mono- or di-alkyl)amino, (mono- or di- alkyl)amino-alkyl, alkylthio and alkylthioalkyl), aryl (phenyl), halo, alkyl, -CONR3aR3b, oxo, -SO2NR3aR3b, -OR3c, and -(CR3fR3g)q-O-(CR3fR3g)v-O-aryl; wherein each of said alkyl, aryl, heteroalkyl, or heteroaryl is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising halogen, hydroxyl, alkoxy, haloalkyl and haloalkoxy; preferably each R6is independently selected from the group comprising hydrogen, -(CR3fR3g)q-O-(CR3fR3g)v-CO2R3c, hydroxyC1-6alkyl, -(CR3fR3g)q- NR3aSO2R3d, -CO2R3c, -(CR3fR3g)q-O-(CR3fR3g)v-heteroaryl, -CONR3aSO2R3d, -SO2R3d, - (CR3fR3g)q-O-(CR3fR3g)v-CN, -COR3d, heteroaryl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, mono-C1-6alkylamino, di-C1-6alkylamino, mono-C1-6alkylamino-C1-6alkyl, di-C1-6alkylamino-C1-6alkyl, C1-6alkylthio and C1-6alkylthioC1-6alkyl; aryl, halo, C1-6alkyl, -CONR3aR3b, oxo, -SO2NR3aR3b, -OR3c, and -(CR3fR3g)q-O-(CR3fR3g)v-O-aryl; wherein each of said C1-6alkyl, aryl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, mono-C1-6alkylamino, di-C1-6alkylamino, mono-C1-6alkylamino-C1-6alkyl, di-C1-6alkylamino-C1-6alkyl, C1-6alkylthio and C1-6alkylthioC1-6alkyl, or heteroaryl is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising halogen, hydroxyl, C1-6alkoxy, haloC1-6alkyl and halo C1-6alkoxy; or two R6together with the carbon atom(s) to which they are attached can form a heterocyclyl or cycloalkyl; wherein each of said heterocyclyl or cycloalkyl is unsubstituted or is substituted with one or more substituents each independently selected from -OH, halogen, -NR3aR3b, heteroalkyl (e.g. alkoxy, alkoxyalkyl, (mono- or di-alkyl)amino, (mono- or di-alkyl)amino-alkyl, alkylthio and alkylthioalkyl), alkoxy, haloalkyl and haloalkoxy; preferably two R6together with the carbon atom(s) to which they are attached can form a heterocyclyl or cycloalkyl; wherein each of said heterocyclyl or cycloalkyl is unsubstituted or is substituted with one or more substituents each independently selected from -OH, halogen, -NR3aR3b, C1-6alkoxy, C1-6alkoxyC1-6alkyl, mono-C1-6alkylamino, di-C1-6alkylamino, mono-C1-6alkylamino-C1-6alkyl, di-C1-6alkylamino-C1-6alkyl, C1-6alkylthio and C1-6alkylthioC1- 6alkyl, haloC1-6alkyl and haloC1-6alkoxy - R3ais selected from hydrogen, alkyl, cycloalkyl, or hydroxyalkyl; preferably R3ais selected from hydrogen, C1-6alkyl, C3-10cycloalkyl, or hydroxyC1-6alkyl; - R3bis selected from hydrogen or alkyl; preferably R3bis selected from hydrogen or C1-6alkyl; - R3cis selected from the group comprising alkyl, heteroalkyl (alkyloxyalkyl), haloalkyl, hydroxyalkyl, and hydrogen; preferably R3cis selected from the group comprising C1-6alkyl, C1-6alkyloxyC1-6alkyl, haloC1-6alkyl, hydroxyC1-6alkyl, and hydrogen; - R3dis selected from alkyl, heteroalkyl, cycloalkyl, or aryl; preferably R3dis selected from hydrogen, C1-6alkyl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, mono-C1-6alkylamino, di-C1- 6alkylamino, mono-C1-6alkylamino-C1-6alkyl, di-C1-6alkylamino-C1-6alkyl, C1-6alkylthio and C1-6alkylthioC1-6alkyl, C3-10cycloalkyl, or aryl - each R3fand R3gare each independently selected from hydrogen or alkyl; preferably each R3fand R3gare each independently selected from hydrogen or C1-6alkyl; - R3his hydrogen or alkyl; preferably R3his hydrogen or C1-6alkyl; - m is an integer selected from 0, 1, 2, 3, or 4; - p is an integer selected from 0, 1 or 2; - q is an integer selected from 0, 1 or 2; and - v is an integer selected from 0, 1 or 2. The compound according to any one of the formulas, statements, embodiments or claims, wherein, R3is selected from hydrogen, -NR3aR3b, -(CR3fR3g)q-NR3aR3b, -NR3a-(CR3fR3g)q- C(O)NR3aR3b, -NR3a-(CR3fR3g)q-CO2R3c, -NR3a-(CR3fR3g)q-OR3c, -NR3a-(CR3fR3g)q-PO(OR3i)2, - NR3a-(CR3fR3g)q-NR3aC(O)R3d, -SR3c, -OR3c, -(CR3fR3g)q-OR3c, oxo, -NR3aS(O)2R3d, -(CR3fR3g)q-NR3aS(O)2R3d, -NR3aC(O)R3d, - (CR3fR3g)q-NR3aC(O)R3d, -(CR3fR3g)q-CO2R3c, -(CR3fR3g)q-C(O)R3c, -(CR3fR3g)q-C(O)NR3aR3b, hydroxyl, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, dialkylamino, alkylaminoalkyl, di-alkyl- amino-alkyl, thioalkyl, alkoxyalkyl, alkyl-thio-alkyl and alkoxyalkylamino, cycloalkyl; preferably R3is selected from hydrogen, -NR3aR3b, -(CR3fR3g)q-NR3aR3b, -NR3a-(CR3fR3g)q-C(O)NR3aR3b, - NR3a-(CR3fR3g)q-CO2R3c, -NR3a-(CR3fR3g)q-OR3c, -NR3a-(CR3fR3g)q-PO(OR3i)2, -NR3a- (CR3fR3g)q-NR3aC(O)R3d, -SR3c, -OR3c, -(CR3fR3g)q-OR3c, , oxo, -NR3aS(O)2R3d, -(CR3fR3g)q-NR3aS(O)2R3d, -NR3aC(O)R3d, - (CR3fR3g)q-NR3aC(O)R3d, -(CR3fR3g)q-CO2R3c, -(CR3fR3g)q-C(O)R3c, -(CR3fR3g)q-C(O)NR3aR3b, hydroxyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkylamino, di-C1-6alkylamino, C1- 6alkylaminoC1-6alkyl, di-C1-6alkyl-amino-C1-6alkyl, thioC1-6alkyl, C1-6alkoxyC1-6alkyl, C1-6alkyl- thio-C1-6alkyl and C1-6alkoxyC1-6alkylamino, C3-10cycloalkyl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, alkylamino, dialkylamino, alkylaminoalkyl, di-alkyl-amino-alkyl, thioalkyl, alkoxyalkyl, alkyl-thio-alkyl, alkoxyalkylamino and cycloalkyl is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising halogen, -OH, =O, -SH, =S, alkyl, alkoxy, haloalkoxy, hydroxyalkyl, alkoxy, alkylthio, cycloalkyl, -C(O)OH, -C(O)R3i, -C(O)-O-CH2-O-CO-R3i, -PO-(OR3i)2, -NH2, -NHalkyl, and -N(alkyl)2; preferably wherein each of said C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkylamino, di-C1-6alkylamino, C1-6alkylaminoC1-6alkyl, di-C1-6alkyl-amino-C1-6alkyl, thio C1-6alkyl, C1-6alkoxyC1-6alkyl, C1-6alkyl-thio-C1-6alkyl and C1-6alkoxyC1-6alkylamino, C3-10cycloalkyl is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising halogen, -OH, =O, -SH, =S, C1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, hydroxyC1-6alkyl, C1-6alkoxy, C1-6alkylthio, C3-10cycloalkyl, - C(O)OH, -C(O)R3i, -C(O)-O-CH2-O-CO-R3i, -PO-(OR3i)2, -NH2, -NHC1-6alkyl, and -N(C1-6alkyl)2; - cycle A is selected from the group comprising aryl, C3-7cycloalkyl, C4-12heterocyclyl and C5-12heteroaryl; - Y is NR3hor O; - each R6 is independently selected from the group comprising hydrogen, halogen, alkyl, cycloalkyl, alkoxy, (mono- or di-)alkylamino, alkylthio, alkylthioalkyl, alkyloxyalkyl, (mono- or di-)alkyl-amino-alkyl, -(CR3fR3g)q-O-(CR3fR3g)v-CO2R3c, hydroxyalkyl, -(CR3fR3g)q- NR3aSO2R3d, -C(O)OR3c, -(CR3fR3g)q-O-(CR3fR3g)v-aryl, -(CR3fR3g)q-O-(CR3fR3g)v- heteroaryl, -CONR3aS(O)2R3d, -S(O)2R3d, -(CR3fR3g)q-O-(CR3fR3g)v-CN, -C(O)R3d, aryl, heteroaryl, heterocyclyl, -C(O)NR3aR3b, oxo, -S(O)2NR3aR3b, -OR3cand -(CR3fR3g)q-O- (CR3fR3g) 6 v-O-aryl; preferably each R is independently selected from the group comprising hydrogen, halogen, C1-6alkyl, C3-10cycloalkyl, C1-6alkoxy, mono-C1-6alkylamino, di- C1- 6alkylamino, C1-6alkylthio, C1-6alkylthioC1-6alkyl, C1-6alkyloxyC1-6alkyl, mono-C1- 6alkylaminoC1-6alkyl, di-C1-6alkylaminoC1-6alkyl, -(CR3fR3g)q-O-(CR3fR3g)v-CO2R3c, hydroxy C1-6alkylaminoC1-6alkyl, -(CR3fR3g)q-NR3aSO2R3d, -C(O)OR3c, -(CR3fR3g)q-O-(CR3fR3g)v-aryl, -(CR3fR3g)q-O-(CR3fR3g)v-heteroaryl, -CONR3aS(O)2R3d, -S(O)2R3d, -(CR3fR3g)q-O- (CR3fR3g)v-CN, -C(O)R3d, aryl, heteroaryl, heterocyclyl, -C(O)NR3aR3b, oxo, -S(O)2NR3aR3b, -OR3cand -(CR3fR3g)q-O-(CR3fR3g)v-O-aryl, wherein each of said alkyl, cycloalkyl, alkoxy, (mono- or di-)alkylamino, alkylthio, alkylthioalkyl, alkyloxyalkyl, (mono- or di-)alkyl-amino-alkyl, aryl, heteroaryl and heterocyclyl is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising halogen, -OH, =O, -SH, =S, -CF3, - CHF2, -OCF3, -OCHF2, alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, -C(O)OH, -NH2, -NHalkyl, and -N(alkyl)2; preferably each of said C1-6alkyl, C3-10cycloalkyl, C1-6alkoxy, mono-C1-6alkylamino, di-C1-6alkylamino, C1- 6alkylthio, C1-6alkylthioC1-6alkyl, C1-6alkyloxyC1-6alkyl, mono-C1-6alkylaminoC1-6alkyl, di- C1-6alkylaminoC1-6alkyl, aryl, heteroaryl and heterocyclyl is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising halogen, -OH, =O, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, C1-6alkyl, haloC1- 6alkyl, C1-6alkoxy, haloC1-6alkoxy, hydroxyC1-6alkyl, C3-10cycloalkyl, C5-10cycloalkenyl, C4-10cycloalkynyl, -C(O)OH, -NH2, -NHC1-6alkyl, and -N(C1-6alkyl)2; - R3a is selected from the group comprising hydrogen, alkyl, cycloalkyl, alkoxy, (mono- or di- )alkyl-amino, alkyloxyalkyl, alkylthioalkyl, (mono- or di-)alkyl-amino-alkyl, hydroxyalkyl and aminoalkyl; preferably hydrogen, C1-6alkyl, C3-10cycloalkyl, C1-6alkoxy, mono-C1-6alkyl- amino, di-C1-6alkyl-amino, C1-6alkyloxyC1-6alkyl, C1-6alkylthioC1-6alkyl, mono-C1-6alkylaminoC1-6alkyl, di-C1-6alkylaminoC1-6alkyl, hydroxyC1-6alkyl and aminoC1-6alkyl; - R3b is selected from the group comprising hydrogen and alkyl; preferably R3b is selected from the group comprising hydrogen and C1-6alkyl; - R3c is selected from the group comprising hydrogen, alkyl, alkyloxyalkyl, alkylthioalkyl, (mono- or di-)alkyl-amino-alkyl, hydroxyalkyl, hydroxycarbonyl-alkyl and aminoalkyl; preferably R3c is selected from the group comprising hydrogen, C1-6alkyl, C1-6alkyloxyC1-6alkyl, C1-6alkylthioC1-6alkyl, mono-C1-6alkylaminoC1-6alkyl, di-C1-6alkylaminoC1-6alkyl, hydroxyC1-6alkyl, hydroxycarbonyl-C1-6alkyl and aminoC1-6alkyl; - R3d is selected from the group comprising alkyl, cycloalkyl, alkyloxyalkyl, alkoxy, (mono- or di-)alkyl-amino, (mono- or di-)alkyl-amino-alkyl, alkylthio, alkylthioalkyl, hydroxyalkyl and aminoalkyl; preferably R3d is selected from the group comprising C1-6alkyl, C3-10cycloalkyl, C1-6alkyloxyC1-6alkyl, C1-6alkoxy, mono-C1-6alkylamino, di-C1-6alkylamino, mono-C1-6alkylaminoC1-6alkyl, di-C1-6alkylaminoC1-6alkyl, C1-6alkylthio, C1-6alkylthioC1-6alkyl, hydroxyC1-6alkyl and aminoC1-6alkyl; - each R3f and R3g are each independently selected from hydrogen, alkyl, cycloalkyl, hydroxyalkyl -NH , and aminoalkyl; pref 3f 3g 2 erably each R and R are each independently selected from hydrogen, C1-6alkyl, C3-10cycloalkyl, hydroxyC1-6alkyl -NH2, and aminoC1- 6alkyl; - R3h is selected from hydrogen and alkyl; preferably R3h is selected from hydrogen and C1- 6alkyl; - R3i is selected from hydrogen, alkyl, cycloalkyl and aryl wherein each alkyl, cycloalkyl, and aryl is optionally further substituted with one or more halogen; preferably R3i is selected from hydrogen, C1-6alkyl, C3-10cycloalkyl and aryl wherein each C1-6alkyl, C3-10cycloalkyl, and aryl is optionally further substituted with one or more halogen; - m is an integer selected from 0, 1, 2, 3 or 4; - p is an integer selected from 0, 1 or 2; - q is an integer selected from 0, 1 or 2; or - v is an integer selected from 0, 1 or 2. The compound according to any one of the formulas, statements, embodiments or claims, wherein R3is selected from hydrogen, alkyl, -NR3xR3yand -OR3z; preferably R3is selected from hydrogen, C1-6alkyl, -NR3xR3yand -OR3zwherein: - alkyl is optionally substituted by one, two or three substituents independently selected from halogen, -OH, =O, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, alkylthio, cycloalkyl, cycloalkenyl, cycloalkynyl, -C(O)OH, -C(O)R3i, -C(O)-O-CH2-O-CO-R3i, -PO-(OR3i)2, -NH2, -NHalkyl, and -N(alkyl)2; preferably C1-6alkyl is optionally substituted by one, two or three substituents independently selected from halogen, -OH, =O, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, hydroxyC1-6alkyl, C1-6alkylthio, C3-10cycloalkyl, C5-10cycloalkenyl, - C(O)OH, -C(O)R3i, -C(O)-O-CH2-O-CO-R3i, -PO-(OR3i)2, -NH2, -NHC1-6alkyl, and -N(C1- 6alkyl)2; - each R3x, R3yand R3zare independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl and heterocyclyl; preferably each R3x, R3yand R3zare independently selected from hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-10cycloalkyl and heterocyclyl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl and heterocyclyl are optionally further substituted by one, two or three substituents independently selected from halogen, -OH, =O, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, cycloalkynyl, -C(O)OH, -C(O)R3i, -C(O)-O-CH2-O-CO-R3i, -PO-(OR3i)2, -NH2, -NHalkyl, and -N(alkyl)2; preferably each C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-10cycloalkyl and heterocyclyl are optionally further substituted by one, two or three substituents independently selected from halogen, -OH, =O, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, - SCF3, -SF5, cyano, nitro, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, C1-6alkoxy, haloC1- 6alkoxy, hydroxyC1-6alkyl, C1-6alkoxy, C1-6alkylthio, C3-10cycloalkyl, C5-10cycloalkenyl, - C(O)OH, -C(O)R3i, -C(O)-O-CH2-O-CO-R3i, -PO-(OR3i)2, -NH2, -NHC1-6alkyl, and -N(C1- 6alkyl)2; - or, R3xand R3ytogether form a heterocycle optionally substituted with one, two or three substituents independently selected from comprising halogen, -OH, =O, -SH, =S, -CF3, - CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, -C(O)OH, -NH2, -NHalkyl, and -N(alkyl)2; preferably R3xand R3ytogether form a heterocycle optionally substituted with one, two or three substituents independently selected from comprising halogen, -OH, =O, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, hydroxyC1-6alkyl, C3-10cycloalkyl, C5- 10cycloalkenyl, C5-10cycloalkynyl, -C(O)OH, -NH2, -NHC1-6alkyl, and -N(C1-6alkyl)2. The compound according to any one of the formulas, statements, embodiments or claims, wherein R3is selected from hydrogen, alkyl, -NR3xR3yand -OR3z; preferably R3is selected from hydrogen, C1-6alkyl, -NR3xR3yand -OR3zwherein: - alkyl is optionally substituted by one, two or three substituents independently selected from halogen, -OH, =O, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, alkylthio, cycloalkyl, cycloalkenyl, cycloalkynyl, -C(O)OH, -C(O)R3i, -C(O)-O-CH2-O-CO-R3i, -PO-(OR3i)2, -NH2, -NHalkyl, and -N(alkyl)2; preferably C1-6alkyl is optionally substituted by one, two or three substituents independently selected from halogen, -OH, =O, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, hydroxyC1-6alkyl, C1-6alkylthio, C3-10cycloalkyl, C5-10cycloalkenyl, - C(O)OH, -C(O)R3i, -C(O)-O-CH2-O-CO-R3i, -PO-(OR3i)2, -NH2, -NHC1-6alkyl, and -N(C1- 6alkyl)2; - each R3x, R3yand R3zare independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl and heterocyclyl; preferably each R3x, R3yand R3zare independently selected from hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-10cycloalkyl and heterocyclyl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl and heterocyclyl are optionally further substituted by one, two or three substituents independently selected from halogen, -OH, =O, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, cycloalkynyl, -C(O)OH, -C(O)R3i, -C(O)-O-CH2-O-CO-R3i, -PO-(OR3i)2, -NH2, -NHalkyl, and -N(alkyl)2; preferably each C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-10cycloalkyl and heterocyclyl are optionally further substituted by one, two or three substituents independently selected from halogen, -OH, =O, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, - SCF3, -SF5, cyano, nitro, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, C1-6alkoxy, haloC1- 6alkoxy, hydroxyC1-6alkyl, C1-6alkoxy, C1-6alkylthio, C3-10cycloalkyl, C5-10cycloalkenyl, - C(O)OH, -C(O)R3i, -C(O)-O-CH2-O-CO-R3i, -PO-(OR3i)2, -NH2, -NHC1-6alkyl, and -N(C1- 6alkyl)2; - or, R3xand R3ytogether form a heterocycle optionally substituted with one, two or three substituents independently selected from comprising halogen, -OH, =O, -SH, =S, -CF3, - CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, -C(O)OH, -NH2, -NHalkyl, and -N(alkyl)2; preferably R3xand R3ytogether form a heterocycle optionally substituted with one, two or three substituents independently selected from comprising halogen, -OH, =O, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, hydroxyC1-6alkyl, C3-10cycloalkyl, C5- 10cycloalkenyl, C5-10cycloalkynyl, -C(O)OH, -NH2, -NHC1-6alkyl, and -N(C1-6alkyl)2. The compound according to any one of the formulas, statements, embodiments or claims, wherein R3is selected from hydrogen, amino, -NHC1-6alkyl, -N(C1-6alkyl)2, -NR3a-(CR3fR3g)q- C(O)NR3aR3b, -NR3a-(CR3fR3g)q-CO2R3c, -NR3a-(CR3fR3g)q-OR3c, -NR3a-(CR3fR3g)q-PO(OR3i)2, - NR3a-(CR3fR3g)q-NR3aC(O)R3d, -OR3c, -(CR3fR3g)q-OR3c, , oxo, -NR3aS(O) R3d, -NR3aC(O3d 2 )R , hydroxyl, C1-6alkyl, C2-6alkenyl, C2- 6alkynyl, C1-6alkoxy, C1-6alkylamino, diC1-6alkylamino and C3-12cycloalkyl; wherein each of said C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkylamino, diC1- 6alkylamino or C3-12cycloalkyl is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising halogen, -OH, =O, -CF3, -CHF2, - OCF3, -OCHF2, cyano, nitro, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, hydroxyC1- 4alkyl, C3-10cycloalkyl, heterocyclyl, -C(O)OH, -PO-(OH)2, -PO-(OC1-4alkyl)2, -NH2, -NHC1- 4alkyl, and -N(C1-4alkyl)2; cycle A is selected from the group comprising aryl, C3-12cycloalkyl, heterocyclyl and heteroaryl; preferably cycle A is selected from: aryl, C3-10cycloalkyl, Y is NH, NC1-6alkyl or O; each R6 is independently selected from the group comprising hydrogen, halogen, C1-6alkyl, C1- 6alkoxy, C1-6alkyloxyC1-6alkyl, -(CR3fR3g)q-O-(CR3fR3g)v-CO2R3c, hydroxyC1-6alkyl, -CO2R3c, - (CR3fR3g)q-O-(CR3fR3g)v-heteroaryl, -CONR3aS(O)2R3d, -C(O)R3d, -C(O)NR3aR3b, oxo, -OR3c, wherein each of said C1-6alkyl, C1-6alkoxy, C1-6alkyloxyC1-6alkyl, hydroxyC1-6alkyl, is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising halogen, -OH, =O, -CF3, -CHF2, -OCF3, -OCHF2, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, hydroxyC1-4alkyl, -C(O)OH, -NH2, -NHalkyl, and - N(alkyl)2; R3a is selected from the group comprising hydrogen, C1-6alkyl, hydroxyC1-6alkyl, aminoC1-6alkyl, -SO2-C1-6alkyl; R3b is selected from the group comprising hydrogen, C1-6alkyl; R3c is selected from the group comprising hydrogen, C1-6alkyl, haloC1-6alkyl, hydroxyC1-6alkyl, hydroxycarbonyl-C1-6alkyl, aminoC1-6alkyl; R3d is selected from the group comprising C1-6alkyl, hydroxyC1-6alkyl, aminoC1-6alkyl; each R3f and R3g are independently selected from hydrogen, C1-6alkyl, hydroxyC1-6alkyl, -NH2; R3h is hydrogen; R3i is hydrogen or C1-6alkyl, m is an integer selected from 0, 1, 2, or 3; p is an integer selected from 0, or 1; q is an integer selected from 0, 1, or 2; v is an integer selected from 0, 1, or 2. The compound according to any one of the formulas, statements, embodiments or claims, wherein R3is selected from -NH2, -NHMe and -N(Me)2. The compound according to any one of the formulas, statements, embodiments or claims, wherein R3is not oxo. The compound according to any one of the formulas, statements, embodiments or claims, wherein R3is not hydrogen. The compound according to any one of the formulas, statements, embodiments or claims, wherein W is -CO-. The compound according to any one of the formulas, statements, embodiments or claims, wherein - L is -CRLgRLh- or -NRLb-; - RLgis selected from the group comprising hydrogen, alkyl, hydroxyalkyl, -NRLaRLb, aminoalkyl, heteroalkyl, haloalkyl and -C(O)NRLaRLb; - RLhis selected from hydrogen or alkyl; - RLais selected from hydrogen or alkyl; and - RLbis selected from hydrogen or alkyl. The compound according to any one of the formulas, statements, embodiments or claims, wherein - RLgis selected from the group comprising hydrogen, alkyl, hydroxyalkyl, -NRLaRLb, aminoalkyl, alkoxy, alkylamino, dialkylamino, alkylaminoalkyl, di-alkyl-amino-alkyl, thioalkyl, alkoxyalkyl, alkyl-thio-alkyl, haloalkyl -C(O)NRLaRLband deuterium; preferably RLgis selected from the group comprising hydrogen, C1-6alkyl, hydroxyC1-6alkyl, -NRLaRLb, aminoC1-6alkyl, C1-6alkoxy, C1-6alkylamino, di-C1-6alkylamino, C1-6alkylaminoC1-6alkyl, di- C1-6alkyl-amino-C1-6alkyl, thioC1-6alkyl, C1-6alkoxyC1-6alkyl, C1-6alkyl-thio-C1-6alkyl, haloC1- 6alkyl, -C(O)NRLaRLband deuterium; - RLhis selected from hydrogen, deuterium or alkyl; preferably RLhis selected from hydrogen, deuterium or C1-6alkyl; - RLais selected from hydrogen or alkyl; preferably RLais selected from hydrogen or C1-6alkyl; and - RLbis selected from hydrogen or alkyl; preferably RLbis selected from hydrogen or C1-6alkyl. The compound according to any one of the formulas, statements, embodiments or claims, wherein L is -CRLgRLh-, RLgis hydrogen, deuterium or C1-4alkyl (e.g. methyl) and RLhis hydrogen or deuterium. In a further embodiment L is methylene or deuterated methylene (- CD2-). In some embodiments, such as where L is -CRLgRLh-, X is selected from -ORXcand -NRXaRXb. In some embodiments (such as but not limited to where L is -CRLgRLh-, and / or X is selected from -ORXcand -NRXaRXb, or, where the compound has structural formula (VI) or (VII)), - RXais selected from the group comprising hydrogen, alkyl, alkyloxyalkyl, aminoalkyl, hydroxyalkyl, cycloalkyl and heterocyclyl, wherein each of said alkyl, alkyloxyalkyl, aminoalkyl, hydroxyalkyl, cycloalkyl and heterocyclyl is unsubstituted or is substituted with one or more substituents each independently selected from hydroxyalkyl, heteroaryl, heterocyclyl, alkyl, cycloalkyl, -OH, =O, halogen, -SH, =S, -C(O)OH, O-alkyl, alkoxy, -NH2, -NHalkyl, and -N(alkyl)2; - RXbis selected from the group comprising hydrogen, alkyl, aminoalkyl, hydroxyalkyl, and cycloalkyl, wherein each of said alkyl, aminoalkyl, hydroxyalkyl, and cycloalkyl, is unsubstituted or is substituted with one or more substituents each independently selected from hydroxyalkyl, alkyl, cycloalkyl, -OH, =O, halogen, -SH, =S, -C(O)OH, alkoxy, -NH2, - NHalkyl, and -N(alkyl)2; - each RXcis selected from the group comprising hydrogen, alkyl, alkyloxyalkyl, aminoalkyl, hydroxyalkyl, cycloalkyl and heterocyclyl, wherein each of said alkyl, alkyloxyalkyl, aminoalkyl, hydroxyalkyl, cycloalkyl and heterocyclyl is unsubstituted or is substituted with one or more substituents each independently selected from -CONRXaRXb, hydroxyalkyl, heteroaryl, heterocyclyl, alkyl, deuterium, cycloalkyl, -OH, =O, halogen, -SH, =S, -C(O)OH, O-alkyl, alkoxy, -NH2, - NHalkyl, and -N(alkyl)2. The compound according to any one of the formulas, statements, embodiments or claims, wherein X is selected from -ORXc, -NH2, , , , , aminoC1-6alkyl, -C(O)ONH2, hydroxyC1-6alkyl; wherein each of said groups is substituted or unsubstituted with one or more substituents each independently selected from the group comprising hydroxyC1-6alkyl, -C(O)NRXaRXb, heteroaryl, heterocyclyl, heterocyclyl substituted by C1-6alkyl, C1-6alkyl, C3-10cycloalkyl, -OH, =O, halogen, -SH, =S, -CF3, -CHF2, -OCF3, - OCHF2, -SCF3, -SF5, cyano, nitro, -C(O)OH, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, hydroxyC1-6alkyl, hydroxyC1-6alkoxy, aminoC1-6alkoxy, (mono- or di-)C1-6alkyl-aminoC1-6alkoxy, -NH2, -NHC1-6alkyl, and -N(C1-6alkyl)2. The compound according to any one of the formulas, statements, embodiments or claims, wherein L is a single bond and X is a heterocycle or heteroaryl, wherein said heterocycle and heteroaryl are optionally substituted by one or more substituents independently selected from hydroxyC1-6alkyl, -C(O)NRXaRXb, heteroaryl, heterocyclyl, heterocyclyl substituted by C1-6alkyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-10cycloalkyl, -OH, =O, halogen, -SH, =S, -CF3, -CHF2, - OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, -C(O)OH, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, hydroxyC1-6alkoxy, aminoC1-6alkoxy, mono-aminoC1-6alkoxy, di-aminoC1-6alkoxy, -NH2, -NHC1- 6alkyl, and -N(C1-6alkyl)2; and wherein RXaand RXbare as defined for any of the embodiments, statements or claims described herein. In some embodiments, L is a single bond and X is a heterocycle or heteroaryl, wherein said heterocycle and heteroaryl are optionally substituted by one or more substituent R7, wherein each R7is independently selected from hydroxyC1-6alkyl, -C(O)NRXaRXb, heteroaryl, heterocyclyl, heterocyclyl substituted by C1-6alkyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3- 10cycloalkyl, -OH, =O, halogen, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, -C(O)OH, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, hydroxyC1-6alkoxy, aminoC1-6alkoxy, mono-aminoC1-6alkoxy, di-aminoC1-6alkoxy, -NH2, -NHC1-6alkyl, and -N(C1-6alkyl)2; and wherein RXaand RXbare as defined for any of the embodiments, statements or claims described herein. In some embodiments, - the moiety L-X is according to ; - Z is N or O; - cycle B is a heterocyclyl or heteroaryl; - u is 0, 1, 2 or 3; and, - each R7is independently selected from hydroxyalkyl, -C(O)NRXaRXb, heteroaryl, heterocyclyl, heterocyclyl substituted by one or more alkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, -OH, =O, halogen, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, -C(O)OH, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, hydroxyalkoxy, aminoalkoxy, (mono- or di-)alkyl-aminoalkoxy, -NH2, -NHalkyl, and -N(alkyl)2; preferably each R7is independently selected from hydroxyC1-6alkyl, -C(O)NRXaRXb, heteroaryl, heterocyclyl, heterocyclyl substituted by one or more C1-6alkyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-10cycloalkyl, C5-10cycloalkenyl, C5-10cycloalkynyl, -OH, =O, halogen, -SH, =S, -CF3, -CHF2, - OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, -C(O)OH, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, hydroxyC1-6alkyl, hydroxyC1-6alkoxy, aminoC1-6alkoxy, mono-C1-6alkyl-aminoC1-6alkoxy, di-C1-6alkyl-aminoC1-6alkoxy, -NH2, -NHC1-6alkyl, and -N(C1-6alkyl)2. In some embodiments, such as where W is -CO- and / or L is a single bond, X is a heteroaryl optionally substituted by one of more R7. In some embodiments, moiety -L-X is according to wherein cycle B is selected from In some embodiments, u is 0, 1 or 2. In some embodiments, each R7is independently selected from hydroxyalkyl, alkyl, -OH, halogen, -SH, =S, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, hydroxyalkoxy, aminoalkoxy, (mono- or di-)alkyl-aminoalkoxy, -NH2, -NHalkyl, and -N(alkyl)2. In some embodiments, each R7is independently selected from C1-4alkyl (methyl), halogen, C1-4alkoxy (methoxy), halo-C1-4alkoxy, hydroxy-C1-4alkyl, hydroxy-C1-4alkoxy, C1-4aminoalkoxy, (mono- or di-)-C1-4alkyl-amino-C1-4alkoxy, -NH2, -NH(C1-4alkyl), and -N(C1-4alkyl)2.The compound according to any one of the formulas, statements, embodiments or claims, wherein - X is selected from the group comprising -ORXc, -NRXaRXb, heteroaryl, heterocyclyl, aminoalkyl -SO2RXd, -CONRXaRXb, -C(O)ORXc, hydroxyalkyl, and alkyl; wherein each of said heterocyclyl, heteroaryl and alkyl is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising halogen, -OH, =O, alkoxy, hydroxyalkyl, alkyl, haloalkyl, amino, mono- or di-alkylamino, -CONRXaRXb, heteroaryl, and carboxyl; preferably X is selected from the group comprising -ORXc, - NRXaRXb, heteroaryl, heterocyclyl, aminoC1-6alkyl, -SO2RXd, -CONRXaRXb, -C(O)ORXc, hydroxyeC1-6alkyl, and C1-6alkyl; wherein each of said heterocyclyl, heteroaryl and C1-6alkyl is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising halogen, -OH, =O, C1-6alkoxy, hydroxyC1-6alkyl, C1- 6alkyl, haloC1-6alkyl, amino, mono-C1-6alkylamino, di-C1-6alkylamino, -CONRXaRXb, heteroaryl, and carboxyl; - RXais selected from hydrogen, hydroxyalkyl, alkyl, or heteroalkyl (alkyloxyalkyl); preferably RXais selected from hydrogen, hydroxyC1-6alkyl, C1-6alkyl, or C1-6alkyloxyC1-6alkyl; - RXbis selected from hydrogen or alkyl; preferably RXbis selected from hydrogen or C1- 6alkyl; - each RXcis selected from the group comprising hydrogen, alkyl, aminoalkyl, hydroxyalkyl, cycloalkyl, heteroalkyl (alkyloxyalkyl, mono- or di-alkyl aminoalkyl) and heteroarylalkyl, wherein each of said alkyl and cycloalkyl is unsubstituted or is substituted with one or more substituents each independently selected from -CONRXaRXb, -NH2 or hydroxyalkyl; preferably each RXcis selected from the group comprising hydrogen, C1-6alkyl, aminoC1- 6alkyl, hydroxyC1-6alkyl, C3-10cycloalkyl, C1-6alkyloxyC1-6alkyl, mono-C1-6alkylaminoC1- 6alkyl, di-C1-6alkylaminoC1-6alkyl and heteroarylC1-6alkyl, wherein each of said C1-6alkyl and C3-10cycloalkyl is unsubstituted or is substituted with one or more substituents each independently selected from -CONRXaRXb, -NH2or hydroxyC1-6alkyl; and - RXdis selected from the group comprising alkyl, alkyl, cycloalkyl, and heteroaryl; preferably RXdis selected from the group comprising C1-6alkyl ,C3-10cycloalkyl and heteroaryl. The compound according to any one of the formulas, statements, embodiments or claims, wherein - W is -CO-; - L is -CH2- or -NH-; and - X is selected from the group comprising -ORXc, -NRXaRXb, heteroaryl, heterocyclyl, aminoalkyl -SO2RXd, -CONRXaRXb, -C(O)ORXc, hydroxyalkyl, and alkyl; wherein each of said heterocyclyl, heteroaryl and alkyl is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising halogen, -OH, =O, alkoxy, hydroxyalkyl, alkyl, haloalkyl, amino, mono- or di-alkylamino, -CONRXaRXb, heteroaryl, and carboxyl; - each RXaand RXcis independently selected from hydrogen, alkyl, hydroxyalkyl, aminoalkyl, heteroalkyl, cycloalkyl, heteroaryl, heterocyclyl, heteroarylalkyl and heterocyclylalkyl; wherein each of said alkyl, hydroxyalkyl, aminoalkyl, heteroalkyl, cycloalkyl, heteroaryl, heterocyclyl, heteroarylalkyl and heterocyclylalkyl is unsubstituted or is substituted with one or more substituents each independently selected from -CONRXaRXb, hydroxyalkyl, heteroaryl, heterocyclyl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, -OH, =O, halogen, -SH, =S, -CF3, -CHF2, -OCF3, - OCHF2, - SCF3, -SF5, cyano, nitro, -C(O)OH, O-alkyl, haloalkyl, alkoxy, haloalkoxy, -NH2, - NHalkyl, and -N(alkyl)2; - RXbis selected from hydrogen or alkyl; and - RXdis selected from the group comprising alkyl, hydroxyalkyl, aminoalkyl, heteroalkyl, cycloalkyl, heteroaryl, heterocyclyl, heteroarylalkyl and heterocyclylalkyl; wherein each of said alkyl, hydroxyalkyl, aminoalkyl, heteroalkyl, cycloalkyl, heteroaryl, heterocyclyl, heteroarylalkyl and heterocyclylalkyl is unsubstituted or is substituted with one or more substituents each independently selected from -CONRXaRXb, hydroxyalkyl, heteroaryl, heterocyclyl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, -OH, =O, halogen, -SH, =S, -CF3, -CHF2, -OCF3, - OCHF2, -SCF3, -SF5, cyano, nitro, -C(O)OH, O-alkyl, haloalkyl, alkoxy, haloalkoxy, -NH2, -NHalkyl, and -N(alkyl)2. The compound according to any one of the formulas, statements, embodiments or claims, wherein - each R4is independently selected from the group comprising halogen, -CF3, -OCF3, -CHF2, -OCHF2, alkyl, -OR4c, haloalkyl, -CN, haloalkoxy, hydroxyalkyl, heteroalkyl (alkyloxyalkyl) and cycloalkyl, or two R4together with the carbon atom(s) to which they are attached can form a cycloalkyl, or a cycloalkenyl; - R4cis selected from the group comprising alkyl, alkoxy, hydroxyalkyl and haloalkyl; and - n is an integer selected from 1, 2, 3, or 4. The compound according to any one of the formulas, statements, embodiments or claims, wherein - each R4is independently selected from the group comprising -CF3, -OCF3, -CHF2, -B(OH)2, -O-SO2-F, -SO2-F, -OCHF2, alkyl, -OR4c, haloalkyl, -CN, haloalkoxy, hydroxyalkyl, haloalkoxy, hydroxyalkyl, alkyloxyC1-6alkyl and cycloalkyl; preferably each R4is independently selected from the group comprising halogen, -CF3, -OCF3, -CHF2, -OCHF2, -B(OH)2, -O-SO2-F, -SO2-F, alkyl, -OR4c, -NR4aC(O)R4c, haloC1-6alkyl, -CN, haloC1-6alkoxy, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl and C3-10cycloalkyl; - or two R4together with the carbon atom(s) to which they are attached can form a cycloalkyl, a cycloalkenyl or heterocyclyl; preferably two R4together with the carbon atom(s) to which they are attached can form a C3-10cycloalkyl, a C5-10cycloalkenyl, or a heterocyclyl; - R4cis selected from the group comprising alkyl, alkyl substituted with deuterium, alkoxyalkyl, hydroxyalkyl and haloalkyl; preferably R4cis selected from the group comprising C1-6alkyl, -CD3, C1-6alkoxyC1-6alkyl, hydroxyC1-6alkyl and haloC1-6alkyl; and - n is an integer selected from 1, 2, 3, or 4. The compound according to any one of the formulas, statements, embodiments or claims, wherein R5is selected from the group comprising hydrogen, alkyl, haloalkyl, heteroalkyl (e.g., alkyloxyalkyl), hydroxyalkyl, aminoalkyl, cycloalkylalkyl, and heterocyclylalkyl; preferably R5is selected from the group comprising hydrogen, C1-6alkyl, haloC1-6alkyl, C1-6alkyloxyC1-6alkyl, mono-amino-C1-6alkyl, di-amino-C1-6alkyl, hydroxyC1-6alkyl, aminoC1-6alkyl, C3- 10cycloalkylalkyl, and heterocyclylalkyl. In some embodiments, R5is selected from the group comprising hydrogen, alkyl, alkyloxyalkyl, hydroxyalkyl, aminoalkyl; preferably R5is selected from the group comprising hydrogen, C1- 4alkyl, C1-4alkyloxyC1-4alkyl, hydroxyC1-4alkyl, aminoC1-4alkyl. The compound according to any one of the formulas, statements, embodiments or claims, having structural formula (II), (III), or (IV) wherein each of R1, R2, R3, R4, R5, n, L and X have the same meaning as that defined in any one of the formulas, statements, embodiments or claims herein. The compound according to any one of the formulas, statements, embodiments or claims, having structural formula (IIa), (IIIa), (IVa), (IIb), (IIIb), (IVb), (IIc), (IIIc), (IVc), (IId), (IIId), (IVd), (IIe), (IIIe), or (IVe),

[0048] wherein - r is an integer selected from 0, 1, 2 or 3; s is an integer selected from 0, 1, or 2; t is an integer selected from 0, or 1; - R4.1, R4.2, R4.3, R4.4, have each independently the meaning of R4; and - each of R1, R2, R3, R4, R5, L and X have the same meaning as that defined in any one of the formulas, statements, embodiments or claims herein. In some embodiments, R4.1is halogen, such as chlorine. In some embodiments, R4.3is C1-4 alkoxy, such as methoxy. In further embodiments, compounds are according to formula (IIc), (IId), (IVc) or (IVd), wherein R4.1is halogen (chlorine), R4.3is C1-4 alkoxy (methoxy), R4.2(when present) is halogen, s is 0 and t is 0. The compound according to any one of the formulas, statements, embodiments or claims, having structural formula (V), (VI), or (VII), wherein each of R1, R3, R4, n, RXa, RXb, RXc, RLg, and X have the same meaning as that defined in any one of the formulas, statements, embodiments or claims herein. The compound according to any one of the formulas, statements, embodiments or claims, having structural formula (Va), (VIa), (VIIa), (Vb), (VIb), (VIIb), (Vc), (VIc), (VIIc), (Vd), (VId), (VIId), (Ve), (VIe), or (VIIe), wherein - r is an integer selected from 0, 1, 2 or 3; preferably r is an integer selected from 1 or 2; - s is an integer selected from 0, 1, or 2; preferably s is an integer selected from 0 or 1; - t is an integer selected from 0, or 1; - R4.1, R4.2, R4.3, R4.4, have each independently the meaning of R4; and - each of R1, R3, R4, RXa, RXb, RXc, RLg, and X have the same meaning as that defined in any one of the formulas, statements, embodiments or claims. In some embodiments, the compound is according to any of formula (Vc), (VIc), (Vd)) or (VId) wherein R4.1is halogen (chlorine), R4.3is C1-4alkoxy (methoxy), R4.2(when present) is halogen, s is 0 and t is 0, and wherein RXa, RXb, RXc, RLg, and X have the same meaning as that defined in any one of the formulas, statements, embodiments or claims. The compound according to any one of the formulas, statements, embodiments or claims, having structural formula (VIII), (IX), (X), (XI) and (XII) wherein each of R1, R3, R4, n, and RLg, have the same meaning as that defined in any one of the formulas, statements, embodiments or claims herein. The compound according to any one of the formulas, statements, embodiments or claims, having structural formula (VIIIa), (IXa), (Xa), (VIIIb), (IXb), (Xb), (VIIIc), (IXc), (Xc), (VIIId), (IXd), (Xd), (VIIIe), (IXe) or (Xe), wherein - r is an integer selected from 0, 1, 2 or 3; s is an integer selected from 0, 1, or 2; t is an integer selected from 0, or 1; - R4.1, R4.2, R4.3, R4.4, have each independently the meaning of R4; and - each of R1, R3, R4, and RLg, have the same meaning as that defined in any one of the formulas, statements, embodiments or claims herein. Also provided is a compound having a structure according to structural formula (VIIIa), (IXa), (VIIIb), (IXb), (VIIIc), (IXc), (VIIId) and (IXd) wherein - r is an integer selected from 1, 2 or 3; s is an integer selected from 0, 1, or 2; t is an integer selected from 0, or 1; - R4.1, R4.2, R4.3have each independently the meaning of R4; and - each of R1, R3, R4, and RLg, have the same meaning as that defined in any one of the formulas, statements, embodiments or claims herein. The compound according to any one of the formulas, statements, embodiments or claims, having structural formula (XIII), (XIIIa), (XIV), (XIVa), (XV) (XVa) or (XVI) wherein each of W, moiety1 2 3 3a 3b 4 7 R , R , R , R , R , R , n, R and u have the same meaning as that defined in any one of the formulas, statements, embodiments or claims herein. The compound according to any one of the formulas, statements, embodiments or claims, having structural formula (XIIIb), (XIIIc), (XIIId), (XIIIe), or (XIIIf)

[0049] wherein - r is an integer selected from 0, 1, 2 or 3; s is an integer selected from 0, 1, or 2; t is an integer selected from 0, or 1; - R4.1, R4.2, R4.3, R4.4, have each independently the meaning of R4; and - wherein each of moiety , R1, R2, R3, R3a, R3b, R4, n, R7and u have the same meaning as that defined in any one of the formulas, statements, embodiments or claims herein. In a particular embodiment, the compounds of the invention are selected from the compounds listed in Table 1 or as described with their chemical name in Table 1 or in the examples. A pharmaceutical composition comprising a compound according to any one of the formulas, statements, embodiments or claims herein and a pharmaceutically acceptable carrier, solvent, adjuvant or diluent. A compound according to any one of the formulas, statements, embodiments or claims herein, or a pharmaceutical composition according to any one of the statements, embodiments or claims herein, for use as a medicament. The present compounds used in the current invention may also exist in their stereochemically isomeric form, defining all possible compounds made up of the same atoms bonded by the same sequence of bonds but having different three-dimensional structures, which are not interchangeable. Unless otherwise mentioned or indicated, the chemical designation of compounds encompasses the mixture of all possible stereochemically isomeric forms, which said compounds might possess. Said mixture may contain all diastereomers and / or enantiomers of the basic molecular structure of said compound. All stereochemically isomeric forms of the compounds used in the present invention either in pure form or in admixture with each other are intended to be embraced within the scope of the present invention including any racemic mixtures or racemates. More generally, the invention relates to the compounds of the formulae described herein and embodiments, statements and aspects thereof being useful as agents having biological activity or as diagnostic agents. Any of the uses mentioned with respect to the present invention may be restricted to a non-medical use, a non-therapeutic use, a non-diagnostic use, or exclusively an in vitro use, or a use related to cells remote from an animal. Compounds of the present disclosure are small molecule cGAS inhibitors or modulators. Small molecule cGAS inhibitors are useful, e.g., for the treatment of inflammation conditions, including with no limitations inflammatory disorders, auto-immune disorders, allergic diseases, inflammation of certain tissues or organs, fibrotic diseases and any other condition in which there is inflammation, more in particular associated with cGAS activity or activation. In a particular embodiment, the compounds of the invention are useful for the prevention or treatment of inflammatory, allergic or autoimmune diseases or diseases with an inflammation component such as systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), lupus nephritis (LN), interferonopathies, psoriasis, insulin-dependent diabetes mellitus (IDDM), vasculitis, scleroderma, Aicardi Goutieres syndrome, dermatomyositis, sepsis, inflammatory bowel diseases, multiple sclerosis, rheumatoid arthritis, Sjogren's syndrome (SS), age related macular degeneration (AMD), Amyotrophic Lateral sclerosis (ALS), Fronto- temporal dementia (FTD), Alzheimer’s disease, Huntington’s disease and Parkinson’s disease. In other embodiments, cGAS inhibitors are useful for the treatment of cancers, such as cancers selected from bladder cancer, bone cancer, brain cancer, breast cancer, cardiac cancer, cervical cancer, colon cancer, colorectal cancer, oesophageal cancer, fibrosarcoma, gastric cancer, gastrointestinal cancer, head, spine and neck cancer, Kaposi's sarcoma, kidney cancer, pancreatic cancer, penile cancer, testicular germ cell cancer, thymoma carcinoma, thymic carcinoma, lung cancer, ovarian cancer or prostate cancer. In some embodiments, solid cancers are characterized by the overexpression, genetic activation or the like of cGAS. cGAS inhibitors may also be useful to treat cancers that have developed resistance to prior treatments. This may include, for instance, the treatment of cancers that have developed resistance to chemotherapy, or to targeted therapy or to immunotherapy. Small molecule cGAS inhibitors may also be useful to treat a metastasized cancer. In some instances, the metastasized cancer is selected from metastasized uveal melanoma, oesophageal cancer, liver cancer, breast cancer, hepatocellular carcinoma, lung adenocarcinoma, glioma, colon cancer, gastric cancer, medulloblastoma, ovarian cancer, oesophageal squamous cell carcinoma, sarcoma, Ewing sarcoma, head and neck cancer, prostate cancer and meningioma. The compounds of the invention according to any one of the formulas, statements, embodiments or claims herein or a pharmaceutical composition according to any one of the statements, embodiments or claims herein, are for use in treating or preventing a cGAS mediated disease, more in particular a disease with inappropriate activation of the cGAS- STING pathway or of the type I interferon (IFN) response. In a particular embodiment, a compound according to any one of the formulas, statements, embodiments or claims herein or a pharmaceutical composition according to any one of the statements, embodiments or claims herein, is for use in treating an inflammation condition or a disorder selected from inflammatory disorder, an autoimmune disorder, an allergic disease, a fibrotic disease or cancer. More in particular, the compound or pharmaceutical composition is for use according to any one of the formulas, statements, embodiments or claims herein, wherein the disorder is selected from the group comprising systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), lupus nephritis (LN), interferonopathies, psoriasis, insulin-dependent diabetes mellitus (IDDM), vasculitis, scleroderma, Aicardi Goutieres syndrome, dermatomyositis, sepsis, inflammatory bowel diseases, multiple sclerosis, rheumatoid arthritis, Sjogren's syndrome (SS), age related macular degeneration (AMD), Amyotrophic Lateral sclerosis (ALS), Fronto- temporal dementia (FTD), Alzheimer’s disease, Huntington’s disease and Parkinson’s disease. The current inventions also relates to a method for treating or preventing a cGAS mediated disease in a subject in need thereof, the method comprising administering to a subject in need of such treatment an effective amount of one or more compounds according to any one of the formulas, statements, embodiments or claims herein or a pharmaceutical composition according to any one of the statements, embodiments or claims herein. In a particular embodiment, the method relates to inhibiting the cGAS / STING pathway or an aberrant type I interferon (IFN) response in a subject, the method comprising, comprising administering to a subject in need of such treatment an effective amount of one or more compounds according to any one of the formulas, statements, embodiments or claims herein or a pharmaceutical composition according to any one of the statements, embodiments or claims herein. In a particular embodiment, the inventions provides a method of treating an inflammation condition, the method comprising administering to a subject in need of such treatment an effective amount of one or more compounds according to any one of the formulas, statements, embodiments or claims herein or a pharmaceutical composition according to any one of the statements, embodiments or claims herein. It also provides a method for treating or preventing a disease according to any one of the statements, embodiments or claims herein, wherein the disorder is selected from the group comprising systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), lupus nephritis (LN), interferonopathies, psoriasis, insulin-dependent diabetes mellitus (IDDM), vasculitis, scleroderma, Aicardi Goutieres syndrome, dermatomyositis, sepsis, inflammatory bowel diseases, multiple sclerosis, rheumatoid arthritis, Sjogren's syndrome (SS), age related macular degeneration (AMD), Amyotrophic Lateral sclerosis (ALS), Fronto-temporal dementia (FTD), Alzheimer’s disease, Huntington’s disease and Parkinson’s disease. Small molecule cGAS inhibitors and pharmaceutical compositions comprising them may also be useful when combined, upon simultaneous administration, or subsequent administration, with other agents used for the treatment of diseases such as inflammatory disorders, auto- immune disorders, allergic diseases, fibrotic diseases, neurodegenerative diseases and cancer. Co-administration includes administering two active agents simultaneously, approximately simultaneously (e.g., within about 1, 5, 10, 15, 20, or 30 minutes of each other), or sequentially in any order. In some embodiments, co-administration can be accomplished by co-formulation, i.e., preparing a single pharmaceutical composition including both active agents. In other embodiments, the active agents can be formulated separately. In another embodiment, the active and / or adjunctive agents may be linked or conjugated to one another. In some embodiments, the additional medicine or therapeutic agent is an anti-inflammatory agent, anti-fibrotic agent or anti-allergic agent, or more general are selected from agents used for treating or preventing inflammation conditions such as anti- inflammatory agents, anti- fibrotic agents, anti-allergic agents / anti-histamines, bronchodilators, beta2 agonists / betamimetics, adrenergic agonists, anticholinergic agents, methotrexate, mycophenolate mofetil, leukotriene modulators, JAK inhibitors, anti-interleukin antibodies, cytokine / chemokine receptor modulators (i.e. cytokine receptor antagonists), anti-TNF antibodies such as Adalimumab (Humira™), and anti-BAFF agents (such as Belimumab and Etanercept). Examples of anti-inflammatory agents are NSAIDs and corticosteroids. NSAIDs are for example selected from ibuprofen, naproxen, diclofenac, meloxicam, celecoxib, acetylsalicylic acid (Aspirin™), indomethacin, mefenamic acid and etoricoxib. Corticosteroids can as an example be selected from Flunisolide, Beclomethasone, Triamcinolone, Budesonide, Fluticasone, Mometasone, Ciclesonide, Rofleponide and Dexametasone. Antiallergic agents / anti-histamines can for example be selected from Epinastine, Cetirizine, Azelastine, Fexofenadine, Levocabastine, Loratadine, Ebastine, Desloratidine and Mizolastine. Anti-fibrotic agents are for example selected from Pirfenidone and tyrosine kinase inhibitors such as Nintedanib. Beta 2 agonists / betamimetics may be either long acting beta 2 Agonists (LABAs) or short acting beta agonists (SABAs). And are for example selected from Bambuterol, Bitolterol, Carbuterol, Clenbuterol, Fenoterol, Formoterol, Flexoprenalin, Ibuterol, Pirbuterol, Procaterol, Reproterol, Salmeterol, Sulfonterol, Terbutalin, Tolubuterol, Olodaterol, and Salbutamol, in particular Olodaterol. Anticholinergic agents are as an example selected from ipratropium salts, tiotropium salts, glycopyrronium salts, and theophylline, wherein tiotropium bromide is preferred in particular. Leukotriene modulators can for example be selected from Montelukast, Pranlukast, Zafirlukast, Ibudilast and Zileuton. JAK inhibitors can for example be selected from Baricitinib, Cerdulatinib, Fedratinib, Filgotinib, Gandotinib, Lestaurtinib, Momelotinib, Pacritinib, Peficitinib, Ruxolitinib, Tofacitinib, and Upadacitinib. Examples of anti-interleukin antibodies are anti-IL23 antibodies such as Risankizumab, anti-l L17 antibodies, anti-ILl antibodies, anti-l L4 antibodies, anti-IL13 antibodies, anti-IL-5 antibodies, anti-l L-6 antibodies such as Tocilizumab (Actemra™), anti-l L-12 antibodies, anti- l L-15 antibodies. In certain embodiments, the second agent is an anti-cancer agent. In certain embodiments, the second agent is a chemotherapeutic. "Anti-cancer agent" refers to a composition (e.g. compound, drug, antagonist, inhibitor, modulator, vaccine, cells) having antineoplastic properties or the ability to inhibit the growth or proliferation of cells or in general an agent having utility in treating or preventing cancer and comprises chemotherapeutic agents, immunotherapeutic agents, radiotherapeutic agents, cancer vaccines and the like. In some embodiments, an anticancer agent is an agent approved by the FDA or EMA or similar regulatory agency of a country other than the USA or Europe, for treating cancer. Examples of anti-cancer agents include, but are not limited to MEK inhibitors, EGFR inhibitors, RAS inhibitors, inhibitors of B-RAF, alkylating agents, nitrogen mustards, ethylenimine and methylmelamines, alkyl sulfonates, nitrosoureas, triazenes, anti-metabolites, pyrimidine analogues, purine analogues, plant alkaloids, topoisomerase inhibitors, antitumor antibiotics, platinum-based compounds, anthracenedione, substituted urea, methyl hydrazine derivative, adrenocortical suppressant, epipodophyllotoxins, inhibitors of mitogen-activated protein kinase signaling, mTOR inhibitors, agents that arrest cells in the G2-M phases and / or modulate the formation or stability of microtubules, antioestrogen, antiandrogen, monoclonal antibodies (e.g., anti-CD20, anti-HER2, anti-CD52, anti-HLA-DR, and anti-VEGF monoclonal antibodies such as Alemtuzumab, Bevacizumab, Bretuximab vedotin, Cetuximab, Gemtuzumab ozogamicin, Ibritumomab tiuxetan, Ipilimumab, Ofatumumab, Panitumumab, Rituximab, Tositumomab, Trastuzumab, Nivolumab, Pembrolizumab, Avelumab, durvalumab and pidilizumab), immunotoxins (e.g., anti-CD33 monoclonal antibody-calicheamicin conjugate, anti-CD22 monoclonal antibody-pseudomonas exotoxin conjugate, etc.), radioimmunotherapy (e.g., anti- CD20 monoclonal antibody conjugated toU 1ln,90Y, or etc. ) and the like. Within the group of anti-cancer agents, “Chemotherapeutic" or "chemotherapeutic agent" refers to a chemical composition or compound having antineoplastic properties or the ability to inhibit the growth or proliferation of cells. In a further embodiment, the compounds described herein can be co-administered with conventional radiotherapeutic agents including, but not limited to, radionuclides such as47Sc,64Cu,67Cu,9Sr,86Y,87Y,90Y,105Rh,mAg,mIn,117mSn,149Pm,153Sm,166Ho,177Lu,86Re,188Re,211At, and212Bi, optionally conjugated to antibodies directed against tumor antigens. The compounds of the invention can inhibit cGAS activity. The compounds have been shown to inhibit cGAS activity in cellular models and in an animal model The compounds of the invention can optionally be bound covalently to an insoluble matrix and used for affinity chromatography (separations, depending on the nature of the groups of the compounds, for example compounds with pendant aryl are useful in hydrophobic affinity separations). When using one or more derivatives of the formulae as defined herein: - the active ingredients of the compound(s) may be administered to the animal or mammal (including a human) to be treated by any means well known in the art, i.e. orally, intranasally, subcutaneously, intramuscularly, intradermally, intravenously, intra-arterially, parenterally or by catheterization. - the therapeutically effective amount of the preparation of the compound(s), especially for the treatment of diseases mediated by activity of cGAS in humans and other mammals (such as cancer, metabolic diseases and certain congenital disorders), preferably is a cGAS inhibiting amount of the compounds of the formulae, statements, aspects and embodiments as defined herein and corresponds to an amount which ensures a plasma level that is able to inhibit the cGAS activity and is in a particular embodiment between 1ng / ml and 100 mg / ml, more in particular between 1ng / ml and 1mg / ml, still more in particular between 1ng / ml and 1µg / ml. Suitable dosages of the compounds or compositions of the invention should be used to treat or prevent the targeted diseases in a subject. Depending upon the pathologic condition to be treated and the patient’s condition, the said effective amount may be divided into several sub-units per day or may be administered at more than one day intervals. According to a particular embodiment of the invention, the compounds of the invention may be employed in combination with other therapeutic agents for the treatment or prophylaxis of diseases mediated by activity of cGAS in humans and other mammals. The invention therefore relates to the use of a composition comprising: (a) one or more compounds of the formulae and aspects, statements and embodiments herein, and (b) one or more further therapeutic or preventive agents that are used for the prevention or treatment of inflammatory disorders, auto-immune disorders, allergic diseases, fibrotic diseases and cancer and in general for inflammatory conditions also including diabetic diseases, metabolic diseases, cardiovascular diseases and neurodegenerative disorders as biologically active agents in the form of a combined preparation for simultaneous, separate or sequential use. The compound or composition can be administered concurrently with, prior to, or subsequent to the one or more additional therapeutic agents, which are different from the compound described herein and may be useful as, e.g., combination therapies. Examples of such further therapeutic agents for use in combinations include anti-inflammatory agents, anti-auto-immune disorder agents, anti-allergic agents, anti-fibrotic agents, anti-diabetic agents, agents used for cardiovascular diseases, metabolic diseases, or neurodegenerative diseases and anti-cancer agents as described herein. The pharmaceutical composition or combined preparation according to this invention may contain the compounds of the present invention over a broad content range depending on the contemplated use and the expected effect of the preparation. Generally, the content of the derivatives of the present invention of the combined preparation is within the range of 0.1 to 99.9% by weight, preferably from 1 to 99% by weight, more preferably from 5 to 95% by weight. Those of skill in the art will also recognize that the compounds of the invention may exist in many different protonation states, depending on, among other things, the pH of their environment. While the structural formulae provided herein depict the compounds in only one of several possible protonation states, it will be understood that these structures are illustrative only, and that the invention is not limited to any particular protonation state - any and all protonated forms of the compounds are intended to fall within the scope of the invention. The term "pharmaceutically acceptable salts" as used herein means the therapeutically active non-toxic salt forms which the compounds of formulae herein are able to form. Therefore, the compounds of this invention optionally comprise salts of the compounds herein, especially pharmaceutically acceptable non-toxic salts containing, for example, Na+, Li+, K+, Ca2+and Mg2+. Such salts may include those derived by combination of appropriate cations such as alkali and alkaline earth metal ions or ammonium and quaternary amino ions with an acid anion moiety, typically a carboxylic acid. The compounds of the invention may bear multiple positive or negative charges. The net charge of the compounds of the invention may be either positive or negative. Any associated counter ions are typically dictated by the synthesis and / or isolation methods by which the compounds are obtained. Typical counter ions include, but are not limited to ammonium, sodium, potassium, lithium, halides, acetate, trifluoroacetate, etc., and mixtures thereof. It will be understood that the identity of any associated counter ion is not a critical feature of the invention, and that the invention encompasses the compounds in association with any type of counter ion. Moreover, as the compounds can exist in a variety of different forms, the invention is intended to encompass not only forms of the compounds that are in association with counter ions (e.g., dry salts), but also forms that are not in association with counter ions (e.g., aqueous or organic solutions). Metal salts typically are prepared by reacting the metal hydroxide with a compound of this invention. Examples of metal salts which are prepared in this way are salts containing Li+, Na+, and K+. A less soluble metal salt can be precipitated from the solution of a more soluble salt by addition of the suitable metal compound. In addition, salts may be formed from acid addition of certain organic and inorganic acids to basic centres, typically amines, or to acidic groups. Examples of such appropriate acids include, for instance, inorganic acids such as hydrohalogen acids, e.g. hydrochloric or hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, 2-hydroxypropanoic, 2-oxopropanoic, lactic, pyruvic, oxalic (i.e. ethanedioic), malonic, succinic (i.e. butanedioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic (i.e. 2-hydroxybenzoic), p-aminosalicylic and the like. Furthermore, this term also includes the solvates which the compounds of formulae herein as well as their salts are able to form, such as for example hydrates, alcoholates and the like. Finally, it is to be understood that the compositions herein comprise compounds of the invention in their unionized, as well as zwitterionic form, and combinations with stoichiometric amounts of water as in hydrates. Also included within the scope of this invention are the salts of the parental compounds with one or more amino acids, especially the naturally-occurring amino acids found as protein components. The amino acid typically is one bearing a side chain with a basic or acidic group, e.g., lysine, arginine or glutamic acid, or a neutral group such as glycine, serine, threonine, alanine, isoleucine, or leucine. The compounds of the invention also include physiologically acceptable salts thereof. Examples of physiologically acceptable salts of the compounds of the invention include salts derived from an appropriate base, such as an alkali metal (for example, sodium), an alkaline earth (for example, magnesium), ammonium and NX4+(wherein X is C1-C4 alkyl). Physiologically acceptable salts of an hydrogen atom or an amino group include salts of organic carboxylic acids such as acetic, benzoic, lactic, fumaric, tartaric, maleic, malonic, malic, isethionic, lactobionic and succinic acids; organic sulfonic acids, such as methanesulfonic, ethanesulfonic, benzenesulfonic and p-toluenesulfonic acids; and inorganic acids, such as hydrochloric, sulfuric, phosphoric and sulfamic acids. Physiologically acceptable salts of a compound containing a hydroxy group include the anion of said compound in combination with a suitable cation such as Na+and NX4+(wherein X typically is independently selected from H or a C1-C4 alkyl group). However, salts of acids or bases which are not physiologically acceptable may also find use, for example, in the preparation or purification of a physiologically acceptable compound. All salts, whether or not derived form a physiologically acceptable acid or base, are within the scope of the present invention. As used herein and unless otherwise stated, the term ‘’enantiomer‘’ means each individual optically active form of a compound of the invention, having an optical purity or enantiomeric excess (as determined by methods standard in the art) of at least 80% (e.g. at least 90% of one enantiomer and at most 10% of the other enantiomer), preferably at least 90% and more preferably at least 98%. The term "isomers" as used herein means all possible isomeric forms, including tautomeric and stereochemical forms, which the compounds of formulae herein may possess, but not including position isomers. Typically, the structures shown herein exemplify only one tautomeric or resonance form of the compounds, but the corresponding alternative configurations are contemplated as well. Unless otherwise stated, the chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers (since the compounds of formulae herein may have at least one chiral centre) of the basic molecular structure, as well as the stereochemically pure or enriched compounds. More particularly, stereogenic centres may have either the R- or S-configuration, and multiple bonds may have either cis- or trans-configuration. Pure isomeric forms of the said compounds are defined as isomers substantially free of other enantiomeric or diastereomeric forms of the same basic molecular structure. In particular, the term "stereoisomerically pure" or "chirally pure" relates to compounds having a stereoisomeric excess of at least about 80% (e.g. at least 90% of one isomer and at most 10% of the other possible isomers), preferably at least 90%, more preferably at least 94% and most preferably at least 97%. The terms "enantiomerically pure" and "diastereomerically pure" should be understood in a similar way, having regard to the enantiomeric excess, respectively the diastereomeric excess, of the mixture in question. Separation of stereoisomers is accomplished by standard methods known to those in the art. One enantiomer of a compound of the invention can be separated substantially free of its opposing enantiomer by a method such as formation of diastereomers using optically active resolving agents ("Stereochemistry of Carbon Compounds," (1962) by E. L. Eliel, McGraw Hill; Lochmuller, C. H., (1975) J. Chromatogr., 113:(3) 283-302). Separation of isomers in a mixture can be accomplished by any suitable method, including: (1) formation of ionic, diastereomeric salts with chiral compounds and separation by fractional crystallization or other methods, (2) formation of diastereomeric compounds with chiral derivatizing reagents, separation of the diastereomers, and conversion to the pure enantiomers, or (3) enantiomers can be separated directly under chiral conditions. Under method (1), diastereomeric salts can be formed by reaction of enantiomerically pure chiral bases such as brucine, quinine, ephedrine, strychnine, a-methyl-b-phenylethylamine (amphetamine), and the like with asymmetric compounds bearing acidic functionality, such as carboxylic acid and sulfonic acid. The diastereomeric salts may be induced to separate by fractional crystallization or ionic chromatography. For separation of the optical isomers of amino compounds, addition of chiral carboxylic or sulfonic acids, such as camphorsulfonic acid, tartaric acid, mandelic acid, or lactic acid can result in formation of the diastereomeric salts. Alternatively, by method (2), the substrate to be resolved may be reacted with one enantiomer of a chiral compound to form a diastereomeric pair (Eliel, E. and Wilen, S. (1994) Stereochemistry of Organic Compounds, John Wiley & Sons, Inc., p. 322). Diastereomeric compounds can be formed by reacting asymmetric compounds with enantiomerically pure chiral derivatizing reagents, such as menthyl derivatives, followed by separation of the diastereomers and hydrolysis to yield the free, enantiomerically enriched compound. A method of determining optical purity involves making chiral esters, such as a menthyl ester or Mosher ester, a-methoxy-a-(trifluoromethyl)phenyl acetate (Jacob III. (1982) J. Org. Chem. 47:4165), of the racemic mixture, and analysing the NMR spectrum for the presence of the two atropisomeric diastereomers. Stable diastereomers can be separated and isolated by normal- and reverse-phase chromatography following methods for separation of atropisomeric naphthyl-isoquinolines (Hoye, T., WO 96 / 15111).Under method (3), a racemic mixture of two asymmetric enantiomers is separated by chromatography using a chiral stationary phase. Suitable chiral stationary phases are, for example, polysaccharides, in particular cellulose or amylose derivatives. Commercially available polysaccharide based chiral stationary phases are ChiralCeITMCA, OA, OB5, OC5, OD, OF, OG, OJ and OK, and ChiralpakTMAD, AS, OP(+) and OT(+). Appropriate eluents or mobile phases for use in combination with said polysaccharide chiral stationary phases are hexane and the like, modified with an alcohol such as ethanol, isopropanol and the like. ("Chiral Liquid Chromatography" (1989) W. J. Lough, Ed. Chapman and Hall, New York; Okamoto, (1990) "Optical resolution of dihydropyridine enantiomers by High-performance liquid chromatography using phenylcarbamates of polysaccharides as a chiral stationary phase", J. of Chromatogr. 513:375-378). The terms cis and trans are used herein in accordance with Chemical Abstracts nomenclature and include reference to the position of the substituents on a ring moiety. The absolute stereochemical configuration of the compounds of the formulae described herein may easily be determined by those skilled in the art while using well-known methods such as, for example, X-ray diffraction. The present invention also includes isotopically labelled compounds, which are identical to those recited in the formulas recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that may be incorporated into compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine and chlorine, such as2H,3H,13C,11C,14C,15N,18O,17O,31P,32P,35S,18F, and36CI, respectively. Compounds of the present invention and pharmaceutically acceptable salts of said compounds or which contain the aforementioned isotopes and / or other isotopes of other atoms are within the scope of this invention. Certain isotopically labelled compounds of the present invention, for example those into which radioactive isotopes such as3H and14C are incorporated, are useful in drug and / or substrate tissue distribution assays. Tritiated, i.e.,3H, and carbon-14, i.e.,14C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e.,2H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. lsotopically labelled compounds of the formulas of this invention may generally be prepared by carrying out the procedures disclosed in the examples and preparations described herein, by substituting a readily available isotopically labelled reagent for a non-isotopically labelled reagent. Also encompassed within the invention are modifications of the compounds of the formula (I) or other formulas, embodiments, aspects or parts thereof or metabolites thereof using PROTAC technology (Schapira M. et al, Nat. Rev. Drug Discov. 2019, 18(12), 949-963). Specifically, the PROTAC technology designs a bifunctional small molecule, one end of which is a compound of the general formula (I) or other formulas, embodiments, aspects or parts thereof or metabolites thereof, and the other end of which is connected with a ligand of E3 ubiquitin ligase through a connecting chain, to form a target-induced protein degradation complex. Because this degradation has a catalytic effect, a lower dosage can achieve efficient degradation. The compound of the general formula (I) or other formulas, embodiments, aspects or parts thereof or metabolites thereof can be connected via a linker arm (e.g. long- chain ethylene glycol with the length of 2-10, long-chain propylene glycol with the length of 2- 10 and long-chain fatty alkane with the length of 2-10) to a ligand of E3 ubiquitin ligase such as e.g. thalidomide analogues. The compounds of the invention may be formulated with conventional carriers and excipients, which will be selected in accord with ordinary practice. Tablets will contain excipients, glidants, fillers, binders and the like. Aqueous formulations are prepared in sterile form, and when intended for delivery by other than oral administration generally will be isotonic. Formulations optionally contain excipients such as those set forth in the "Handbook of Pharmaceutical Excipients" (1986) and include ascorbic acid and other antioxidants, chelating agents such as EDTA, carbohydrates such as dextrin, hydroxyalkylcellulose, hydroxyalkylmethylcellulose, stearic acid and the like. Subsequently, the term "pharmaceutically acceptable carrier" as used herein means any material or substance with which the active ingredient is formulated in order to facilitate its application or dissemination to the locus to be treated, for instance by dissolving, dispersing or diffusing the said composition, and / or to facilitate its storage, transport or handling without impairing its effectiveness. The pharmaceutically acceptable carrier may be a solid or a liquid or a gas which has been compressed to form a liquid, e.g. the compositions of this invention can suitably be used as concentrates, emulsions, solutions, granulates, dusts, sprays, aerosols, suspensions, ointments, creams, tablets, pellets or powders. Suitable pharmaceutical carriers for use in the said pharmaceutical compositions and their formulation are well known to those skilled in the art, and there is no particular restriction to their selection within the present invention. They may also include additives such as wetting agents, dispersing agents, stickers, adhesives, emulsifying agents, solvents, coatings, antibacterial and antifungal agents (for example phenol, sorbic acid, chlorobutanol), isotonic agents (such as sugars or sodium chloride) and the like, provided the same are consistent with pharmaceutical practice, e.g. carriers and additives which do not create permanent damage to mammals. The pharmaceutical compositions of the present invention may be prepared in any known manner, for instance by homogeneously mixing, coating and / or grinding the active ingredients, in a one-step or multi-steps procedure, with the selected carrier material and, where appropriate, the other additives such as surface-active agents. may also be prepared by micronisation, for instance in view to obtain them in the form of microspheres usually having a diameter of about 1 to 10 gm, namely for the manufacture of microcapsules for controlled or sustained release of the active ingredients. Suitable surface-active agents, also known as emulgent or emulsifier, to be used in the pharmaceutical compositions of the present invention are non-ionic, cationic and / or anionic materials having good emulsifying, dispersing and / or wetting properties. Suitable anionic surfactants include both water-soluble soaps and water-soluble synthetic surface-active agents. Suitable soaps are alkaline or alkaline-earth metal salts, unsubstituted or substituted ammonium salts of higher fatty acids (C10-C22), e.g. the sodium or potassium salts of oleic or stearic acid, or of natural fatty acid mixtures obtainable from coconut oil or tallow oil. Synthetic surfactants include sodium or calcium salts of polyacrylic acids; fatty sulphonates and sulphates; sulphonated benzimidazole derivatives and alkylarylsulphonates. Fatty sulphonates or sulphates are usually in the form of alkaline or alkaline-earth metal salts, unsubstituted ammonium salts or ammonium salts substituted with an alkyl or acyl group having from 8 to 22 carbon atoms, e.g. the sodium or calcium salt of lignosulphonic acid or dodecylsulphonic acid or a mixture of fatty alcohol sulphates obtained from natural fatty acids, alkaline or alkaline-earth metal salts of sulphuric or sulphonic acid esters (such as sodium lauryl sulphate) and sulphonic acids of fatty alcohol / ethylene oxide adducts. Suitable sulphonated benzimidazole derivatives preferably contain 8 to 22 carbon atoms. Examples of alkylarylsulphonates are the sodium, calcium or alcoholamine salts of dodecylbenzene sulphonic acid or dibutyl-naphthalenesulphonic acid or a naphthalene-sulphonic acid / formaldehyde condensation product. Also suitable are the corresponding phosphates, e.g. salts of phosphoric acid ester and an adduct of p-nonylphenol with ethylene and / or propylene oxide, or phospholipids. Suitable phospholipids for this purpose are the natural (originating from animal or plant cells) or synthetic phospholipids of the cephalin or lecithin type such as e.g. phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerine, lysolecithin, cardiolipin, dioctanylphosphatidyl-choline, dipalmitoylphoshatidyl -choline and their mixtures. Suitable non-ionic surfactants include polyethoxylated and polypropoxylated derivatives of alkylphenols, fatty alcohols, fatty acids, aliphatic amines or amides containing at least 12 carbon atoms in the molecule, alkylarenesulphonates and dialkylsulphosuccinates, such as polyglycol ether derivatives of aliphatic and cycloaliphatic alcohols, saturated and unsaturated fatty acids and alkylphenols, said derivatives preferably containing 3 to 10 glycol ether groups and 8 to 20 carbon atoms in the (aliphatic) hydrocarbon moiety and 6 to 18 carbon atoms in the alkyl moiety of the alkylphenol. Further suitable non-ionic surfactants are water-soluble adducts of polyethylene oxide with poylypropylene glycol, ethylenediaminopolypropylene glycol containing 1 to 10 carbon atoms in the alkyl chain, which adducts contain 20 to 250 ethyleneglycol ether groups and / or 10 to 100 propyleneglycol ether groups. Such compounds usually contain from 1 to 5 ethyleneglycol units per propyleneglycol unit. Representative examples of non-ionic surfactants are nonylphenol -polyethoxyethanol, castor oil polyglycolic ethers, polypropylene / polyethylene oxide adducts, tributylphenoxypolyethoxyethanol, polyethyleneglycol and octylphenoxypolyethoxyethanol. Fatty acid esters of polyethylene sorbitan (such as polyoxyethylene sorbitan trioleate), glycerol, sorbitan, sucrose and pentaerythritol are also suitable non-ionic surfactants. Suitable cationic surfactants include quaternary ammonium salts, particularly halides, having 4 hydrocarbon groups optionally substituted with halo, phenyl, substituted phenyl or hydroxy; for instance quaternary ammonium salts containing as N-substituent at least one C8-22alkyl (e.g. cetyl, lauryl, palmityl, myristyl, oleyl and the like) and, as further substituents, unsubstituted or halogenated lower alkyl, benzyl and / or hydroxy-lower alkyl. A more detailed description of surface-active agents suitable for this purpose may be found for instance in "McCutcheon's Detergents and Emulsifiers Annual" (MC Publishing Crop., Ridgewood, New Jersey, 1981), "Tensid-Taschenbucw', 2 d ed. (Hanser Verlag, Vienna, 1981) and "Encyclopaedia of Surfactants, (Chemical Publishing Co., New York, 1981). Compounds of the invention and their pharmaceutically acceptable salts (hereafter collectively referred to as the active ingredients) may be administered by any route appropriate to the condition to be treated, suitable routes including oral, rectal, nasal, topical (including ocular, buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural). The preferred route of administration may vary with for example the condition of the recipient. While it is possible for the active ingredients to be administered alone it is preferable to present them as pharmaceutical formulations. The formulations, both for veterinary and for human use, of the present invention comprise at least one active ingredient, as above described, together with one or more pharmaceutically acceptable carriers therefore and optionally other therapeutic ingredients. The carrier(s) optimally are "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. The formulations include those suitable for oral, rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural) administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product. Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste. A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active or dispersing agent. Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein. For infections of the eye or other external tissues e.g. mouth and skin, the formulations are optionally applied as a topical ointment or cream containing the active ingredient(s) in an amount of, for example, 0.075 to 20% w / w (including active ingredient(s) in a range between 0.1% and 20% in increments of 0.1% w / w such as 0.6% w / w, 0.7% w / w, etc.), preferably 0.2 to 15% w / w and most preferably 0.5 to 10% w / w. When formulated in an ointment, the active ingredients may be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with an oil-in-water cream base. If desired, the aqueous phase of the cream base may include, for example, at least 30% w / w of a polyhydric alcohol, e.g. an alcohol having two or more hydroxyl groups such as propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG400) and mixtures thereof. The topical formulations may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogues. The oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier (otherwise known as an emulgent), it desirably comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Optionally, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make up the so-called emulsifying wax, and the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations. The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the active compound in most oils likely to be used in pharmaceutical emulsion formulations is very low. Thus the cream should optionally be a non- greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono- or dibasic alkyl esters such as di- isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and / or liquid paraffin or other mineral oils can be used. Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active ingredient. The active ingredient is optionally present in such formulations in a concentration of 0.5 to 20%, advantageously 0.5 to 10% particularly about 1.5% w / w. Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatine and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier. Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate. Formulations suitable for nasal administration wherein the carrier is a solid include a coarse powder having a particle size for example in the range 20 to 500 microns (including particle sizes in a range between 20 and 500 microns in increments of 5 microns such as 30 microns, 35 microns, etc.), which is administered in the manner in which snuff is taken, e.g. by rapid inhalation through the nasal passage from a container of the powder held close up to the nose. Suitable formulations wherein the carrier is a liquid, for administration as for example a nasal spray or as nasal drops, include aqueous or oily solutions of the active ingredient. Formulations suitable for aerosol administration may be prepared according to conventional methods and may be delivered with other therapeutic agents. Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate. Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non- aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described. Preferred unit dosage formulations are those containing a daily dose or unit daily sub-dose, as herein above recited, or an appropriate fraction thereof, of an active ingredient. It should be understood that in addition to the ingredients particularly mentioned above the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents. Compounds of the invention can be used to provide controlled release pharmaceutical formulations containing as active ingredient one or more compounds of the invention ("controlled release formulations") in which the release of the active ingredient can be controlled and regulated to allow less frequency dosing or to improve the pharmacokinetic or toxicity profile of a given invention compound. Controlled release formulations adapted for oral administration in which discrete units comprising one or more compounds of the invention can be prepared according to conventional methods. Additional ingredients may be included in order to control the duration of action of the active ingredient in the composition. Control release compositions may thus be achieved by selecting appropriate polymer carriers such as for example polyesters, polyamino acids, polyvinyl pyrrolidone, ethylene-vinyl acetate copolymers, methylcellulose, carboxymethylcellulose, protamine sulphate and the like. The rate of drug release and duration of action may also be controlled by incorporating the active ingredient into particles, e.g. microcapsules, of a polymeric substance such as hydrogels, polylactic acid, hydroxymethylcellulose, polymethyl methacrylate and the other above-described polymers. Such methods include colloid drug delivery systems like liposomes, microspheres, microemulsions, nanoparticles, nanocapsules and so on. Depending on the route of administration, the pharmaceutical composition may require protective coatings. Pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation thereof. Typical carriers for this purpose therefore include biocompatible aqueous buffers, ethanol, glycerol, propylene glycol, polyethylene glycol and the like and mixtures thereof. In view of the fact that, when several active ingredients are used in combination, they do not necessarily bring out their joint therapeutic effect directly at the same time in the mammal to be treated, the corresponding composition may also be in the form of a medical kit or package containing the two ingredients in separate but adjacent repositories or compartments. In the latter context, each active ingredient may therefore be formulated in a way suitable for an administration route different from that of the other ingredient, e.g. one of them may be in the form of an oral or parenteral formulation whereas the other is in the form of an ampoule for intravenous injection or an aerosol. Another embodiment of this invention relates to various precursor or “pro-drug” forms of the compounds of the present invention. It may be desirable to formulate the compounds of the present invention in the form of a chemical species which itself is not significantly biologically- active, but which when delivered to the animal, mammal or human will undergo a chemical reaction catalyzed by the normal function of the body of the fish, inter alia, enzymes present in the stomach or in blood serum, said chemical reaction having the effect of releasing a compound as defined herein. The term “pro-drug” thus relates to these species which are converted in vivo into the active pharmaceutical ingredient. The pro-drugs of the compounds of the present invention can have any form suitable to the formulator, for example, esters are non-limiting common pro-drug forms. In the present case, however, the pro-drug may necessarily exist in a form wherein a covalent bond is cleaved by the action of an enzyme present at the target locus. For example, a C-C covalent bond may be selectively cleaved by one or more enzymes at said target locus and, therefore, a pro-drug in a form other than an easily hydrolysable precursor, inter alia an ester, an amide, and the like, may be used. The counterpart of the active pharmaceutical ingredient in the pro-drug can have different structures such as an amino acid or peptide structure, alkyl chains, sugar moieties and others as known in the art. For the purpose of the present invention the term “therapeutically suitable pro-drug” is defined herein as “a compound modified in such a way as to be transformed in vivo to the therapeutically active form, whether by way of a single or by multiple biological transformations, when in contact with the tissues of the animal, mammal or human to which the pro-drug has been administered, and without undue toxicity, irritation, or allergic response, and achieving the intended therapeutic outcome ”. More specifically the term “prodrug”, as used herein, relates to an inactive or significantly less active derivative of a compound such as represented by the structural formulae herein described, which undergoes spontaneous or enzymatic transformation within the body in order to release the pharmacologically active form of the compound. For a comprehensive review, reference is made to Rautio J. et al. (“Prodrugs: design and clinical applications” Nature Reviews Drug Discovery, 2008, doi: 10.1038 / nrd2468). The compounds of the invention can be prepared while using a series of chemical reactions well known to those skilled in the art, altogether making up the process for preparing said compounds and exemplified further. The processes described further are only meant as examples and by no means are meant to limit the scope of the present invention. The present invention relates to methods for the preparation of the compounds, comprising the steps of: - coupling a pyrrolidine-containing compound of formula (A1) with an electrophile of formula LG-W-L-X-PG and further removing PG (if different than Me) thereby obtaining compound of formula (A2), wherein R1, R2, R3, R4, W, L, X and n have the meaning according to any one of the formula or embodiments presented herein, wherein PG is a protecting group and LG is a leaving group; or - reacting a compound of formula (A3) with a nucleophile, preferably of formula HR3, and further removing PG (if different than Me) thereby obtaining compound of formula (A2), wherein R1, R2, R3, R4, W, L, X and n have the meaning according to any one of the formula or embodiments presented herein, wherein PG is a protecting group and LG is a leaving group; or - coupling a pyridone-containing compound of formula (A4) with an electrophile, preferably of formula R5-LG and further removing PG (if different than Me) thereby obtaining compound of formula (A5) or (A6), wherein R1, R2, R3, R5, W, L, X and n have the meaning according to any one of the formula or embodiments presented herein, wherein PG is a protecting group, LG is a leaving group and wherein group -OR5corresponds to group - OR3cas defined in any one the formula, statements or embodiments presented herein; or

[0050] - reacting a compound of formula (A7) with a nucleophile, preferably of formula HX-PG and further removing PG thereby obtaining compound of formula (A2), wherein R1, R2, R3, R4, W, L, X and n have the meaning according to any one of the formula or embodiments presented herein, wherein PG is a protecting group and LG is a leaving group; or - reacting a halogen-containing compound of formula (A8) with an appropriate coupling agent, preferably a suitable R4.4reagent (e.g. boronic acid or ester, organozinc, stannanes) by procedures known to the skilled in the art (Suzuki coupling, Negishi coupling, Stille coupling and the like) and further removing PG thereby obtaining compound of formula (A2a), wherein R1, R2, R3, R4, R4.4W, L, X and n have the meaning according to any one of the formula, statements or embodiments presented herein, wherein PG is a protecting group and X1is a halogen; Representative compounds of the present invention can be synthesized in accordance with the general synthetic methods described below and illustrated in the schemes that follow. Since the schemes are an illustration, the invention should not be construed as being limited by the specific chemical reaction and specific conditions described in the schemes and examples. The general schemes depicted above should therefore be considered as non- limiting examples. It will be understood that compounds of the invention may be obtained through other methods, which are known to people skilled in the art. The various starting material used in the schemes are commercially available or may be prepared by methods well within the skill persons versed in the art. The variables are as defined herein and within the skill of persons verses in the art. Abbreviations used in the instant specification, particularly in the schemes and examples, are as follows: The compounds of the present invention may be prepared according to the general procedure outlined in scheme 1. Scheme 1: all R1, R2, R3, R4, W, L, X and n are as described for the compounds of the present invention and its embodiments and formulae. PG = protecting group, LG = leaving group, X1= halogen. Anilines of general formula 1 commercially available or synthesized by procedures known to the skilled in the art or as set forth in the examples below, may be halogenated with an suitable halogenating agent (e.g. Bromine, N-bromosuccinimide, N-chlorosuccinimide, N- iodosuccinimide and the like) in a polar aprotic solvent (e.g. dichloromethane, tetrahydrofuran and the like) at a temperature ranging from 0 to 25°C to provide the desired intermediates of general formula 2. Tricycles of general formula 6 may be obtained by reaction of intermediates of general formula 2 with boronate derivatives of general formula 3 wherein PG is a protecting group (e.g. Boc, PMB and the like), synthesized by procedures known to the skilled in the art or as set forth in the examples below, in the presence of Pd catalysts such as Pd(PPh3)4and a base (e.g. K2CO3, KOAc and the like) in a suitable solvent (e.g. dioxane, water and the like). Alternatively, intermediates of general formula 2 may be converted into boronate derivatives of general formula 4 by reaction with bis(pinacolato)diboron in combination with corresponding Pd catalysts (e.g. Pd(dppf)Cl2,Pd2(dba)3and the like), ligands such as PCy3and bases (e.g 20 .KOAc and the like) in polar aprotic solvents such as dioxane. Boronate derivatives of general formula 4 may be reacted further with ester derivatives of general formula 5 wherein LG is a leaving group (OTf, Br and the like) and PG is a protecting group (e.g. Boc and the like), synthesized by procedures known to the skilled in the art or as set forth in the examples below, to afford tricycles of general formula 6. Derivatives of general formula 7 wherein LG is a leaving group such as OTf may be obtained from tricycles of general formula 6 following reactions known to the skilled in the art or as set forth in the examples below. Intermediates of general formula 7 may be reduced with appropriate reducing agents (e.g Et3SiH, H2, HCOOH and the like) in presence of Pd catalysts (e.g Pd(PPh3)4, Pd(OAc)2, Pd(dppf)Cl2 and the like) and bases (e.g pyridine, Et3N and the like) in polar protic or aprotic solvents (e.g THF, dioxane, DMF, MeOH and the like) to give compounds of general formula 8. Removal of the N-protecting group may be performed following procedures known to the skilled in the art (e.g. treatment in presence of an acid such as HCl or TFA if PG = Boc). More information can be found in T.W. Greene and P.G. M. Wuts in Protective Groups in Organic Chemistry, 3rded., John Wiley and Sons, 1999. Compounds of interest having a general formula 11 may be obtained from intermediates of general formula 9 via a 2-step sequence involving coupling with an appropriate coupling agent of general formula 10 wherein LG is a leaving group (e.g Cl, Br, OR and the like) and PG is a protecting group (e.g Boc, Ac and the like), commercially available or synthesized following procedures known to the skilled in the art or as set forth in the examples below, in combination with bases (e.g DIEA, Et3N and the like) in polar aprotic solvents (e.g DCM, DMF and the like) at a temperature ranging from -10 to 25°C and protecting group removal performed following procedures known to the skilled in the art (e.g. treatment in presence of an acid such as HCl or TFA if PG = Boc or a base (e.g. K2CO3, LiOH and the like) if PG = Ac). In another embodiment, the compounds of the present invention may be prepared according to the general procedure outlined in scheme 2. Scheme 2: all R1, R2, R3, R4, R5, W, L, X and n are as described for the compounds of the present invention and its embodiments and formulae. PG = protecting group, LG = leaving group, X1= halogen. Intermediates of general formula 12 may be obtained from intermediates of general formula 6, synthesized as described in Scheme 1, via a 2-step sequence involving N-protecting group removal and coupling reaction as described in Scheme 1. Intermediates of general formula 12 may be converted into compounds of interest having formula 14 or 15 by reaction with alkylating agents of formula 13 (commercially available or synthesized) wherein LG is a leaving group such as Cl, Br, I and OTs in a polar aprotic solvent (e.g. DMF and the like) in presence of a base (e.g. Cs2CO3 and the like) at a temperature raising from 20 to 120°C followed by protecting group removal. Alternatively, intermediates of general formula 12 may be converted into derivatives of general formula 16 wherein LG is a leaving group (e.g. Cl, OTf and the like) following reactions known to the skilled in the art or as set forth in the examples below. If LG = OTf, intermediates of general formula 17 may be synthesized from derivatives of general formula 16 by reaction with appropriate coupling agents selected from, but not limited, to boronic acids, boronic esters, boroxines, organotin reagents in presence of Pd catalysts (e.g Pd(PPh3)4, Pd(dppf)Cl2 and the like) and a base (e.g pyridine or K2CO3 and the like) in a polar aprotic solvent such as THF or Dioxane or in an apolar aprotic solvent such as toluene or by displacement of the leaving group with an appropriate nucleophile (e.g amine the like) following procedures known to the skilled in the art or as set forth in the examples below. If LG = Cl, intermediates of general formula 16 may be reacted with appropriate coupling agents (e.g sulfonamides, amides and the like) in presence of Pd catalysts such as Pd2dba3, ligands such as Xantphos and a base (e.g K3PO4 and the like) in a suitable solvent (e.g dioxane and the like) to provide compounds of general formula 17. Compounds of interest having a general formula 11 may be obtained after removal of the protecting group as described in Scheme 1. In another embodiment, the compounds of the present invention may be prepared according to the general procedure outlined in scheme 3. Scheme 3: all R1, R2, R3, R4, W, L, X and n are as described for the compounds of the present invention and its embodiments and formulae. LG = leaving group. Intermediates of general formula 9, synthesized as described in Scheme 1, may be reacted with electrophiles of general formula 18 (commercially available or synthesized) wherein LG is a leaving group (e.g Cl and the like) following procedures known to the skilled in the art or as set forth in the examples below to afford compounds of formula 19. Derivatives of general formula 17 may be obtained by displacement of the leaving group with an appropriate nucleophile (e.g amine and the like) as described in Scheme 2. Compounds of interest having a general formula 11 may be obtained after removal of the protecting group as described in Scheme 1.

[0051] The following examples are provided for the purpose of illustrating the present invention and by no means should be interpreted to limit the scope of the present invention.

[0052] Table 1 : Structures of example compounds of the invention, and their respective codes and their name generated with ChemBioDraw 20.0.

[0053] Structures of example compounds that contain stereocentres are drawn and named with absolute stereochemistry, if known. In case of unknown absolute stereochemistry the compounds can be either racemic, a mixture of diastereomers, a pure diastereomer of unknown stereochemistry, or a pure enantiomer of unknown stereochemistry. EXAMPLES

[0054] Part A represents the preparation of the compounds (intermediates and final compounds) whereas Part B represents the pharmacological examples.

[0055] Part A: Experimental chemistry Procedures

[0056] All starting materials which are not explicitly described were either commercially available (the details of suppliers such as for example Acros, Avocado, Aldrich, Fluka, FluoroChem, MatrixScientific, Maybridge, Merck, Sigma, etc. can be found in the SciFinder® Database for example) or the synthesis thereof has already been described precisely in the specialist literature (experimental guidelines can be found in the Reaxys® Database or the SciFinder® Database respectively, for example) or can be prepared using the conventional methods known to the person skilled in the art.

[0057] The reactions were, if necessary, carried out under an inert atmosphere (mostly argon and N2). The number of equivalents of reagents and the amounts of solvents employed as well as the reaction temperatures and times can vary slightly between different reactions carried out by analogous methods. The work-up and purification methods were adapted according to the characteristic properties of each compound and can vary slightly for analogous methods. The yields of the compounds prepared are not optimized.

[0058] The indication ..equivalents" ("eq." or “eq” or “equiv.”) means molar equivalents, „RT“ or “rt” means room temperature T (23 ± 7 °C), „M“ are indications of concentration in mol / l, „sol.“ means solution, "cone." means concentrated. The mixing ratios of solvents are usually stated in the volume I volume ratio.

[0059] Microwave irradiation reactions were carried out by using either an Anton Paar Monowave 450 or a CEM microwave synthesizer Discover 2.0 reactor.

[0060] Key analytical characterization was carried out by means of1H-NMR spectroscopy and / or mass spectrometry (MS, m / z for [M+H]+and / or [M-H]') for all the exemplary compounds and selected intermediate products. In certain cases, where e.g. regioisomers and / or diastereomers could be / were formed during the reaction, additional analytics, such as, e.g.13C NMR and NOE (nuclear overhauser effect) NMR experiments were performed.

[0061] NMR data were recorded using a Bruker Avance III HD 400 MHz (TopSpin 3.6.5 software), a BrukerAvance Neo 400 MHz (TopSpin 4.1.4 software), a Bruker Avance III 400 MHz (TopSpin 3.6.2 software), or a Bruker Avance III HD 400 MHz Prodigy (TopSpin 3.2 software).1H data were calibrated using tetramethylsilane as an internal calibration reference. The b-values are expressed in parts per million (ppm). The following acronyms were used: s (singlet), d (doublet), t (triplet), q (quartet), quint (quintet), m (multiplet), br (broadened).

[0062] Structures of example compounds that contain stereocentres are drawn and named with absolute stereochemistry, if known. In case of unknown absolute stereochemistry the compounds can be either racemic, a mixture of diastereomers, a pure diastereomer of unknown stereochemistry, or a pure enantiomer of unknown stereochemistry.

[0063] The LC-MS analyses mentioned in the experimental part were performed using the instruments, columns and chromatographic conditions outlined in the table below.

[0064] Preparative HPLC purifications were performed on a Waters 2545 (Mass lynx 4.2 software, 2998 PDA detector, 3767 / 2767 autosampler, Detection wavelength range 200 - 400 nm), an Ingos LCP5020 (Chromulan v0.91 software, LCD5000 detector, Detection wavelength fixed at 260 nm), a Gilson (GX-271) (Trilution software, DAD (171) detector, Detection wavelength fixed at 215 nm and 254 nm), a Shimadzu (LC-20AP) (LC Solution software, UV / VIS (SPD-20AV) detector, Detection wavelength fixed at 215 nm and 254 nm), or a Waters (Empower software, 2996 PDA detector, Max plot). EXAMPLES OF THE PREPARATION OF INTERMEDIATES Synthesis of Intermediate 01 Step-1: To an ice-cooled solution of Boc-L-alanine methyl ester (50.0 g, 246.30 mmol) in anhydrous THF (1600 mL) was added LiHMDS (1.0 M solution in THF, 246.3 mL) and the mixture was stirred at 0 °C for 30 min. Next, methyl acrylate (26.5 mL, 295.57 mmol) was added and the resulting reaction mixture was stirred at 0 °C for 1 h, after which the reaction mixture was allowed to warm to RT and stirring was continued at this temperature for another 3 h. Subsequently, the mixture was quenched with a satd. aq. NH4Cl solution and diluted with EtOAc. The organic layer was separated and the aqueous layer was extracted with EtOAc. The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by flash column chromatography (0-20% EtOAc / Hexane) to give 1-(tert- butyl) 3-methyl (5S)-5-methyl-4-oxopyrrolidine-1,3-dicarboxylate (36.0 g, 57%) as a yellow oil. UPLC-MS (Method A): Rt = 2.38 min (95%); m / z 256 [M-H]-. Step-2: To a solution of 1-(tert-butyl) 3-methyl (5S)-5-methyl-4-oxopyrrolidine-1,3- dicarboxylate (20.0 g, 77.82 mmol) and DIEA (38.5 mL, 233.46 mmol) in DCM (120 mL) at -78 °C was added dropwise a solution of trifluoromethanesulfonic anhydride (14.2 mL, 85.60 mmol) in DCM (80 mL) and the resulting reaction mixture was stirred at this temperature for 30 minutes. Next, the mixture was stirred for an additional 18 h allowing the temperature to reach RT. The reaction mixture was subsequently poured onto a satd. aq. NaHCO3 solution. The phases were separated, the organic layer was dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by flash column chromatography (0-20% EtOAc / Hexane) to give 1-(tert-butyl) 3-methyl (S)-5-methyl-4-(((trifluoromethyl)sulfonyl)oxy)- 2,5-dihydro-1H-pyrrole-1,3-dicarboxylate (16.2 g, 53%) as a yellow oil. UPLC-MS (Method A): Rt = 2.21 min (96%); m / z 375 [M+H-Me]+.1H NMR (400 MHz, DMSO-d6) δ ppm 4.66 - 4.61 (m, 1H), 4.40 - 4.18 (m, 2H), 3.75 (s, 3H), 1.43 - 1.37 (m, 12H). The intermediates listed in the table below were prepared following a similar procedure to the one described above using an appropriate ester protected amino acid. Synthesis of Intermediates 02-05 Step-1: To a solution of 2,3-dichloro-4-methoxyaniline (21.0 g, 110.53 mmol) (obtained as described in WO2016042172) in DCM (400 mL) was added dropwise a solution of N- bromosuccinimide (19.7 g, 110.53 mmol) in DCM (760 mL) under nitrogen atmosphere, and the resulting reaction mixture was stirred at RT for 10 min. Then, the mixture was quenched by addition of water (1000 mL) and the organic layer was separated by filtering through a phase separator, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash column chromatography (10-15% EtOAc / Hexane) to give 6-bromo-2,3-dichloro-4- methoxyaniline (16.0 g, 55%) as a pale brown solid. LC-MS (Method D): Rt = 1.69 min (86%); m / z 269.7 [M+H]+.1H NMR (400 MHz, DMSO-d6) δ ppm 7.29 (s, 1H), 5.20 (s, 2H), 3.78 (s, 3H). Step-2: To a degassed (Ar sparging) solution of 6-bromo-2,3-dichloro-4-methoxyaniline (10.00 g, 37.18 mmol), bis(pinacolato)diboron (14.16 g, 55.76 mmol) and potassium acetate (10.93 g, 111.52 mmol) in anhydrous 1,4-dioxane (100 mL) was added Pd2(dba)3(1.70 g, 1.86 mmol) and tricyclohexylphosphine (1.05 g, 3.72 mmol), and the resulting reaction mixture was stirred at 110°C for 4 h under argon atmosphere. After cooling to RT, the mixture was filtered through a pad of celite. The filtrate was concentrated in vacuo to give crude 2,3-dichloro-4-methoxy-6- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) aniline (7.6 g) which was used as such in the next step. UPLC-MS (Method A): Rt = 1.65 min; m / z 236 [M+H]+[m / z of corresponding boronic acid]. Step-3: To a degassed (Ar sparging) solution of crude 2,3-dichloro-4-methoxy-6-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (7.6 g, 23.90 mmol), 1-(tert-butyl) 3-methyl (S)-5- methyl-4-(((trifluoromethyl)sulfonyl)oxy)-2,5-dihydro-1H-pyrrole-1,3-dicarboxylate (11.2 g, 28.68 mmol) and K2CO3(9.9 g, 71.70 mmol) in a mixture of 1,4-dioxane / H2O (120 mL; 5:1 v / v) was added Pd(PPh3)4 (1.4 g, 1.20 mmol), and the resulting reaction mixture was stirred at 80°C for 3 h under argon atmosphere. After cooling to RT, the mixture was filtered through a pad of celite, which was washed thoroughly with EtOAc (3 x 75 mL). The combined filtrate was concentrated in vacuo and the residue was purified by flash column chromatography (40-60% EtOAc / Hexane) to give tert-butyl (S)-6,7-dichloro-8-methoxy-1-methyl-4-oxo-1,3,4,5- tetrahydro-2H-pyrrolo[3,4-c]quinoline-2-carboxylate (5.0 g, 52% two steps) as a pale brown solid. UPLC-MS (Method A): Rt = 2.01 min (94%); m / z 399 [M+H]+.1H NMR (400MHz, DMSO- d6) δ ppm 11.19 (br s, 1H), 7.31-7.24 (m, 1H), 5.54-5.46 (m, 1H), 4.54-4.41 (m, 2H), 3.98-3.92 (m, 3H), 1.52-1.47 (m, 12 H). Step-4: To an ice-cooled solution of tert-butyl (S)-6,7-dichloro-8-methoxy-1-methyl-4-oxo- 1,3,4,5-tetrahydro-2H-pyrrolo[3,4-c]quinoline-2-carboxylate (7.0 g, 17.59 mmol) in a mixture of 1,4-dioxane / MeOH (70 mL; 1:1 v / v) was added dropwise hydrochloric acid (66.0 mL, 264.00 mmol; 4M solution in 1,4-dioxane), and the resulting reaction mixture was stirred at RT for 4 h. The mixture was concentrated in vacuo and the residue was triturated with n-pentane (2 x 50.0 mL) and dried further under reduced pressure to give crude (S)-6,7-dichloro-8-methoxy-1- methyl-1,2,3,5-tetrahydro-4H-pyrrolo[3,4-c]quinolin-4-one hydrochloride (5.5 g) which was used as such in the next step. UPLC-MS (Method A): Rt = 1.51 min; m / z 299 [M+H]+. Step-5: To a solution of (S)-6,7-dichloro-8-methoxy-1-methyl-1,2,3,5-tetrahydro-4H- pyrrolo[3,4-c]quinolin-4-one hydrochloride (5.50 g, 16.39 mmol) and DIEA (11.5 mL, 65.77 mmol) in anhydrous DCM (50.0 mL) was added dropwise a solution of acetoxyacetyl chloride (1.7 mL, 15.62 mmol) in anhydrous DCM (2.0 mL) at -10 °C, and the resulting reaction mixture was stirred at this temperature for 10 min under nitrogen atmosphere. The mixture was quenched by addition of cold water (25.0 mL) and diluted with DCM (150.0 mL). The organic layer was washed sequentially with water (2 x 200.0 mL) and brine (200.0 mL), dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash column chromatography (40 g silica column, 40-50% EtOAc / DCM) to give (S)-2-(6,7-dichloro-8- methoxy-1-methyl-4-oxo-1,3,4,5-tetrahydro-2H-pyrrolo[3,4-c]quinolin-2-yl)-2-oxoethyl acetate (4.95 g, 70% two steps) as a pale brown solid. LC-MS (Method D): Rt = 3.03 min (90%); m / z 398.9 [M+H]+.1H NMR (400MHz, DMSO-d6) δ ppm 11.23 (s, 1H), 7.36 -7.31 (m, 1H), 5.76-5.74 (m, 1H), 4.96-4.63 (m, 4H), 3.97 (s, 3H), 2.12 (s, 3H), 1.52-1.50 (m, 3H). Step-6: To an ice-cooled solution of (S)-2-(6,7-dichloro-8-methoxy-1-methyl-4-oxo-1,3,4,5- tetrahydro-2H-pyrrolo[3,4-c]quinolin-2-yl)-2-oxoethyl acetate (2.20 g, 5.53 mmol) in anhydrous DCM (25.0 mL) was added dropwise anhydrous pyridine (4.5 mL, 55.28 mmol) followed by trifluoromethanesulfonic anhydride (1.20 mL, 7.19 mmol) under argon atmosphere. The resulting reaction mixture was stirred for 16 h allowing the temperature to reach RT. Subsequently, the mixture was concentrated in vacuo and co-evaporated with anhydrous toluene (3 x 25.0 ml) to give crude (S)-2-(6,7-dichloro-8-methoxy-1-methyl-4- (((trifluoromethyl)sulfonyl)oxy)-1,3-dihydro-2H-pyrrolo[3,4-c]quinolin-2-yl)-2-oxoethyl acetate (4.0 g) as a dark brown solid which was used as such in the next step. UPLC-MS (Method A): Rt = 2.17 min; m / z 531 [M+H]+.1H NMR (400MHz, DMSO-d6) δ ppm 7.63-7.56 (m, 1H), 6.02- 6.01 (m, 1H), 5.18-5.06 (m, 2H), 5.00-4.83 (m, 2H), 4.10 (s, 3H), 2.13 (s, 3H), 1.62-1.56 (m, 3H). Step-7: To an ice-cooled solution of tert-butyl (S)-6,7-dichloro-8-methoxy-1-methyl-4-oxo- 1,3,4,5-tetrahydro-2H-pyrrolo[3,4-c]quinoline-2-carboxylate (7.00 g, 17.58 mmol) in DCM (90.0 mL) was added pyridine (13.89 g, 175.89 mmol) and trifluoromethanesulfonic anhydride (6.45 g, 22.86 mmol), and the resulting reaction mixture was stirred for 16 h allowing the temperature to reach RT. Subsequently, the mixture was concentrated in vacuo and co-evaporated with toluene (2 x 50.0 mL) to give tert-butyl (S)-6,7-dichloro-8-methoxy-1-methyl-4- (((trifluoromethyl) sulfonyl) oxy)-1,3-dihydro-2H-pyrrolo[3,4-c] quinoline-2-carboxylate (9.00 g, 88%) as a brown sticky solid which was used as such in the next step. LC-MS (Method J): Rt = 2.71 min (92%); m / z 531 [M+H]+. Step-8: To a solution of tert-butyl (S)-6,7-dichloro-8-methoxy-1-methyl-4- (((trifluoromethyl)sulfonyl)oxy)-1,3-dihydro-2H-pyrrolo[3,4-c]quinoline-2-carboxylate (9.00 g, 16.94 mmol) in THF (180.0 mL) was added Pd(PPh3)4 (0.97 g, 0.85 mmol) and the mixture was heated to 60 °C. Next, pyridine (13.6 mL, 169.38 mmol) and triethyl silane (27.3 mL, 169.38 mmol) were added and the resulting reaction mixture was stirred at 60 °C for 3 h. After cooling to RT, the mixture was filtered through a pad of celite and the filtrate was concentrated in vacuo. The residue was purified by flash column chromatography (10-20% EtOAc / Pet ether) to give tert-butyl (S)-6,7-dichloro-8-methoxy-1-methyl-1,3-dihydro-2H-pyrrolo[3,4-c] quinoline- 2-carboxylate (3.80 g, 60%) as an off-white solid. LC-MS (Method J): Rt = 2.58 min (95%); m / z 383 [M+H]+.1H NMR (400 MHz, DMSO-d6) δ ppm 8.87 (s, 1 H), 7.44 (s, 0.5 H), 7.38 (s, 0.5 H), 5.68 (qd, 0.5 H), 5.60 (qd, 0.5 H), 4.71 – 4.88 (m, 2 H), 4.07 (s, 3 H), 1.46 – 1.60 (m, 12 H). Step-9: To an ice-cooled solution of tert-butyl (S)-6,7-dichloro-8-methoxy-1-methyl-1,3- dihydro-2H-pyrrolo[3,4-c] quinoline-2-carboxylate (1.90 g, 4.97 mmol) in 1,4-dioxane (40.0 mL) was added hydrochloric acid (6.2 mL, 24.80 mmol; 4M solution in 1,4-dioxane), and the resulting reaction mixture was stirred at RT for 2 h. The mixture was concentrated in vacuo and the residue was treated with a satd. aq. NaHCO3 solution (20.0 mL) and extracted with MeOH / DCM (10 / 90 v / v; 2 x 30.0 mL). The combined organic layers were washed with brine (20.0 mL), dried over Na2SO4, filtered, and concentrated in vacuo to give (S)-6,7-dichloro-8- methoxy-1-methyl-2,3-dihydro-1H-pyrrolo[3,4-c]quinoline as an off-white solid (1.30 g, 92%). LC-MS (Method I): Rt = 1.32 min (97%); m / z 283 [M+H]+.1H NMR (400 MHz, CDCl3) δ ppm 8.82 (s, 1 H), 7.00 (s, 1 H), 4.99 (qd, 1 H), 4.53 (dd, 1 H), 4.40 (d, 1 H), 4.04 (s, 3 H), 1.53 (d, 3 H). Step-10: To an ice-cooled solution of (S)-6,7-dichloro-8-methoxy-1-methyl-2,3-dihydro-1H- pyrrolo[3,4-c] quinoline (1.00 g, 3.53 mmol) in anhydrous DCM (20.0 mL) was added DIEA (1.30 mL, 7.06 mmol) and 2-bromoacetyl bromide (784 mg, 3.89 mmol), and the resulting reaction mixture was stirred at 0 °C for 30 min under N2-atmosphere. Subsequently, the mixture was diluted with DCM (50.0 mL), washed with water (50.0 mL) and brine (50.0 mL), dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash column chromatography (2% MeOH / DCM) to give (S)-2-bromo-1-(6,7-dichloro-8-methoxy-1-methyl- 1,3-dihydro-2H-pyrrolo[3,4-c] quinolin-2-yl) ethan-1-one (800 mg, 56%). LC-MS (Method J): Rt = 1.93 min (90%); m / z 403 [M+H]+. The intermediates listed in the tables below were prepared following a similar procedure to the one above using commercially available or described starting materials (use of appropriate reagents and purification methods known to the skilled in the art).

[0065] Synthesis of Intermediate 06 Step-1: To a solution of 3-amino-4-bromobenzonitrile (2.50 g, 12.43 mmol) in DMF (22.2 mL), heated at 60°C, was added N-chloro succinimide (1.69 g, 12.43 mmol) and the resulting reaction mixture was stirred at this temperature for 3 h. After cooling to RT, the mixture was poured onto a mixture of water and ice (200 mL). The thus formed solid was filtered and dried on high vacuum. The solid was purified by flash column chromatography (80 g silica column, 0-40% EtOAc / PE) to give 3-amino-4-bromo-2-chloro-benzonitrile (1.20 g, 42%) as a white solid. LC-MS (Method S): Rt = 1.29 min; m / z 229 [M-H]-.1H NMR (400 MHz, DMSO-d6) δ ppm 7.61 (d, 1 H), 7.06 (d, 1 H), 6.03 (s, 2 H). Synthesis of Intermediate 07 Step-1: To a solution of (tert-butoxycarbonyl)glycine (243 mg, 1.39 mmol) in anhydrous DCM (14.0 mL) was added HATU (632 mg, 1.66 mmol) and DIEA (0.36 mL, 2.08 mmol) and the mixture was stirred for 15 min under N2 atmosphere. Next, (S)-6,7-dichloro-8-methoxy-1- methyl-1,2,3,5-tetrahydro-4H-pyrrolo[3,4-c]quinolin-4-one hydrochloride (465 mg, 1.39 mmol) (obtained as described above) was added and the resulting reaction mixture was stirred at RT for 1 h. The mixture was concentrated in vacuo and the residue was purified by flash column chromatography (50-100% EtOAc / Hexane) to give tert-butyl (S)-(2-(6,7-dichloro-8-methoxy-1- methyl-4-oxo-1,3,4,5-tetrahydro-2H-pyrrolo[3,4-c]quinolin-2-yl)-2-oxoethyl)carbamate (502 mg, 79%) as a pale brown solid. LC-MS (Method P): Rt = 3.18 min; m / z 456.1 [M+H]+;1H NMR (400 MHz, DMSO-d6): δ 11.20 (br. s, 1H), 7.34 (s, 0.67H), 7.32 (s, 0.33H), 5.88-5.81 (m, 0.33H), 5.80-5.69 (m, 0.67H), 4.90-4.60 (m, 2H), 3.97 (s, 3H), 3.94-3.74 (m, 2H), 1.55 (d, 1H), 1.52 (d, 2H), 1.41 (s, 4.5H), 1.39 (s, 4.5H). Step-2: To an ice-cooled solution of tert-butyl (S)-(2-(6,7-dichloro-8-methoxy-1-methyl-4-oxo- 1,3,4,5-tetrahydro-2H-pyrrolo[3,4-c]quinolin-2-yl)-2-oxoethyl)carbamate (617 mg, 1.35 mmol) in anhydrous DCM (13.5 mL) was added dropwise anhydrous pyridine (0.33 mL, 4.06 mmol) followed by trifluoromethanesulfonic anhydride (0.27 mL, 1.62 mmol) under argon atmosphere. The resulting reaction mixture was stirred for 1 h allowing the temperature to reach RT. Subsequently, the mixture was concentrated in vacuo and co-evaporated with anhydrous toluene (3 x 10.0 ml) to give crude (S)-2-((tert-butoxycarbonyl)glycyl)-6,7-dichloro-8-methoxy- 1-methyl-2,3-dihydro-1H-pyrrolo[3,4-c]quinolin-4-yl trifluoromethanesulfonate (650 mg, 82%) as a dark brown solid which was used as such in the next step. LC-MS (Method P): Rt = 4.18 min; m / z 588.4 [M+H]+; 1H NMR (400 MHz, CDCl3): δ 8.66 (br. s, 1H), 7.01 (s, 0.67H), 6.94 (s, 0.33H), 5.91 (q, 0.67H), 5.73 (q, 0.33H), 5.25 (d, 0.33H), 4.98 (s, 1.34H), 4.83 (dd, 0.33H), 4.15-4.04 (m, 2H), 4.09 (s, 1H), 4.07 (s, 2H), 1.72 (d, 3H), 1.50 (s, 4.5H), 1.49 (s, 4.5H). Synthesis of Intermediate 08 Step-1: To an ice-cooled solution of (S)-6,7-dichloro-8-methoxy-1-methyl-2,3-dihydro-1H- pyrrolo[3,4-c]quinoline hydrochloride (310 mg, 1.10 mmol) in H2SO4(5.0 mL) was added NBS (214 mg, 1.20 mmol) and the mixture was stirred for 30 min. The mixture was poured on ice and saturated solution of Na2S2O3 (1 mL) was added. The reaction mixture was treated with 5M NaOH solution till pH = 14 and extracted with DCM (2 x 25 mL). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated in vacuo to give (S)-9-bromo-6,7-dichloro-8-methoxy-1-methyl-2,3-dihydro-1H-pyrrolo[3,4-c]quinoline (395 mg, 99%) as a pale brown solid. LC-MS (Method P): Rt = 2.51 min; m / z 362.9 [M+H]+. The intermediate listed in the table below was prepared following a similar procedure to the one above using commercially available or described starting materials (use of appropriate reagents and purification methods known to the skilled in the art). Synthesis of Intermediate 09 Step-1: To a solution of 4-bromo-2-methoxy-benzonitrile (2.0 g, 9.24 mmol) in sulfuric acid (10 mL) at 0°C, was added potassium nitrate (1.0 g, 9.79 mmol) portion wise and the mixture stirred for 1h.The reaction mixture was poured onto a mixture of ice and water (150 mL) and the solid was filtered. The filtrate was extracted with ethyl acetate and the solid was added to this solution. The organic solution was washed with brine, dried over MgSO4 and concentrated in vacuo. The residue was purified by flash chromatography (80 g silica column, 0-30% EtOAc / PE) to give 4-bromo-2-methoxy-5-nitrobenzonitrile (2.02 g, 85 %) as a pale yellow solid. LC-MS (Method S): Rt = 1.3 min; m / z 241 [M+H]+. Step-2: To a cooled solution of 4-bromo-2-methoxy-5-nitro-benzonitrile (2.02 g, 7.70 mmol) in THF (40.0 mL) and acetic acid (2.6 mL, 46.21 mmol) was added Zinc flake, -325 mesh (5.0 g, 77 mmol). The reaction mixture was stirred for 2h, then diluted with ethyl acetate and filtered over celite. The filtrate was concentrated in vacuo and the residue was dissolved in ethyl acetate (200 mL) and a saturated solution NaHCO3. The mixture was filtered over celite and both phases were separated. The organic phase was washed with brine, dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by flash chromatography (80 g silica column, 0-100% EtOAc / Heptane) to give 5-amino-4-bromo-2-methoxybenzonitrile (1.35 g, 77 %) as a pale yellow solid. LC-MS (Method S): Rt = 1.14 min; m / z 227 [M+H]+.1H-NMR (400 MHz, DMSO-d6) d ppm 7.33 (s, 1 H) 7.06 (s, 1 H) 5.25 (s, 2 H) 3.81 (s, 3 H). Step-3: To a degassed of 1-(tert-butyl) 3-methyl (S)-5-methyl-4-(((trifluoromethyl)sulfonyl)oxy)- 2,5-dihydro-1H-pyrrole-1,3-dicarboxylate Int-01 (250 mg, 0.62 mmol), Bis(pinacolato)diboron (188 mg, 0.74 mmol) and dry potassium acetate (183 mg, 1.85 mmol) in 1,4-dioxane (2.5 mL) was added 1,1'-Bis(diphenylphosphino)ferrocene-palladium(ii)dichloride dichloromethane (51 mg, 61.6 µmol) and the mixture was stirred at 110°C overnight. The mixture was cooled to room temperature, filtered over celite and the residue was purified by flash chromatography (12g silica column, 0-30% EtOAc / PE) to give 1-(tert-butyl) 3-methyl (S)-5-methyl-4-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-2,5-dihydro-1H-pyrrole-1,3-dicarboxylate (230 mg, 100 %) as a yellow-green oi...

Claims

CLAIMS 1. A compound of formula (I), a stereo-isomeric form, a tautomer, a salt (in particular a pharmaceutically acceptable salt), solvate, hydrate, polymorph and / or prodrug thereof,wherein: - each dotted line (---) represents an optional double bond and whereby two adjacent dotted lines cannot form a double bond at the same time; - R1 is selected from the group comprising hydrogen, halogen, =O, alkyl, alkenyl, alkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, haloalkyl, haloalkenyl, haloalkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; wherein each of said alkyl, alkenyl, alkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, haloalkyl, haloalkenyl, haloalkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising halogen, -OH, =O, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, -C(O)OH, -NH2, -NHalkyl, and -N(alkyl)2; - R2 is selected from the group comprising hydrogen, halogen, =O, hydroxyl, alkyl, alkenyl, alkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, alkyloxyalkyl, mono- or di-alkylaminoalkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, haloalkyl, haloalkenyl, haloalkynyl, alkoxy, haloalkoxy, -CONR2aR2band - CO2R2c; wherein each of said alkyl, alkenyl, alkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, alkyloxyalkyl, mono- or di-alkylamino- alkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, haloalkyl, haloalkenyl, haloalkynyl, alkoxy and haloalkoxy is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising halogen, -OH, =O, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, -N3, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, -C(O)OH, -C(O)OR2c, -NH2, -NHalkyl, and -N(alkyl)2; - COR2d, -NR2aR2b, -NR2aCOR2d, -CONR2aR2b, and -OR2c;- R2a is selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; - R2b is selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; - R2c is selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; - R2d is selected from the group comprising hydroxyalkyl, alkyloxyalkyl, hydroxy, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; - or R1 and R2 together with the carbon atoms to which they are attached can form a heterocyclyl (e.g. pyrrolidinyl), wherein said heterocyclyl is unsubstituted or substituted with one or more substituents each independently selected from the group comprising halogen, -OH, =O, -SH, =S, - CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, -C(O)OH, -NH2, -NHalkyl, and -N(alkyl)2; - or R2 and X together with the atoms to which they are attached can form a heterocyclyl wherein said heterocyclyl is unsubstituted or substituted with one or more substituents each independently selected from the group comprising halogen, -OH, =O, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, -C(O)OH, -NH2, -NHalkyl, and -N(alkyl)2; - R3 is selected from the group comprising hydrogen, halogen, nitro, -CN, -NR3aR3b, - (CR3fR3g)q-NR3aR3b, -NR3a-(CR3fR3g)q-C(O)NR3aR3b, -NR3a-(CR3fR3g)q-CO2R3c, -NR3a- (CR3fR3g)q-OR3c, -NR3a-(CR3fR3g)q-PO(OR3i)2, -NR3a-(CR3fR3g)q-NR3aC(O)R3d, -SR3c, - S(O)R3d, -S(O)2R3c, -S(O)2-NR3aR3b, -OR3c, -(CR3fR3g)q-OR3c,,, oxo, -NR3aS(O)2R3d, -(CR3fR3g)q-NR3aS(O)2R3d, -NR3aC(O)R3d, - (CR3fR3g)q-NR3aC(O)R3d, -(CR3fR3g)q-CO2R3c, -(CR3fR3g)q-C(O)R3c, -(CR3fR3g)q-C(O)NR3aR3b, hydroxyl, sulfhydryl, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, dialkylamino, alkylaminoalkyl, di-alkyl-amino-alkyl, thioalkyl, alkoxyalkyl, alkyl-thio-alkyl, alkoxyalkylamino, cycloalkyl, cycloalkenyl, cycloalkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, heteroaryl, heterocyclyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl and heterocyclylalkynyl, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, alkylamino, dialkylamino, alkylaminoalkyl, di-alkyl-amino-alkyl, thioalkyl, alkoxyalkyl, alkyl-thio-alkyl,alkoxyalkylamino, cycloalkyl, cycloalkenyl, cycloalkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, heteroaryl, heterocyclyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl and heterocyclylalkynyl, is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising halogen, -OH, =O, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, -C(O)OH, -C(O)R3i, -C(O)-O-CH2-O-CO-R3i, - PO-(OR3i)2, -SO2F, -NH2, -NHalkyl, and -N(alkyl)2; - cycle A is selected from the group comprising aryl (such as phenyl), cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl and heteroaryl; - Y is NR3hor O; - each R6 is independently selected from the group comprising hydrogen, halogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, alkoxy, (mono- or di-)alkylamino, alkylthio, alkylthioalkyl, alkyloxyalkyl, (mono- or di-)alkyl-amino-alkyl, -(CR3fR3g)q-O- (CR3fR3g)v-CO2R3c, hydroxyalkyl, -(CR3fR3g)q-NR3aSO2R3d, -CO2R3c, -(CR3fR3g)q-O- (CR3fR3g)v-aryl, -(CR3fR3g)q-O-(CR3fR3g)v-heteroaryl, -CONR3aS(O)2R3d, -S(O)2R3d, - (CR3fR3g)q-O-(CR3fR3g)v-CN, -C(O)R3d, aryl, heteroaryl, heterocyclyl, -C(O)NR3aR3b, oxo, - S(O)2NR3aR3b, -OR3cand -(CR3fR3g)q-O-(CR3fR3g)v-O-aryl, wherein each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, alkoxy, (mono- or di-)alkylamino, alkylthio, alkylthioalkyl, alkyloxyalkyl, (mono- or di-)alkyl- amino-alkyl, aryl, heteroaryl and heterocyclyl is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising halogen, -OH, =O, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, -C(O)OH, -NH2, -NHalkyl, and -N(alkyl)2; or two R6 together with the carbon atom(s) to which they are attached can form a cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl or heteroaryl; wherein each of said cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl and heteroaryl is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising -OH, halogen, -NR3aR3b, aryl, =O, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, - SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, cycloalkenyl and cycloalkynyl; - R3a is selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, alkoxy, (mono- or di-)alkyl-amino, alkyloxyalkyl, alkylthioalkyl, (mono- or di-)alkyl-amino-alkyl, haloalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, -SO2-alkyl, aryl, heteroaryl and heterocyclyl;- R3b is selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; - R3c is selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, alkyloxyalkyl, alkylthioalkyl, (mono- or di-)alkyl-amino-alkyl, haloalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, hydroxycarbonyl-alkyl, aminoalkyl, aminoalkenyl, aminoalkynyl, aryl, heteroaryl and heterocyclyl; - R3d is selected from the group comprising alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, alkyloxyalkyl, alkoxy, (mono- or di-)alkyl-amino, (mono- or di-)alkyl-amino- alkyl, alkylthio, alkylthioalkyl, haloalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, aryl, heteroaryl and heterocyclyl; - each R3f and R3g are each independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, haloalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, -NH2, aminoalkyl, aminoalkenyl, aminoalkynyl, aryl, heteroaryl and heterocyclyl; - R3h is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; - R3i is selected from hydrogen, alkyl, cycloalkyl and aryl wherein each alkyl, cycloalkyl, and aryl is optionally further substituted with one or more halogen; - m is an integer selected from 0, 1, 2, 3, 4 or 5 - p is an integer selected from 0, 1, 2, 3, 4 or 5; - q is an integer selected from 0, 1, 2, 3, 4 or 5; - v is an integer selected from 0, 1, 2, 3, 4 or 5; - W is selected from -CO-, -SO2-, -SO(=NH)- (sulfoximinyl); - L is selected from -CRLgRLh-, -NRLb-, or a single bond; - RLg is selected from the group comprising hydrogen, halogen, alkyl, alkenyl, alkynyl, hydroxyalkyl, hydroxylalkenyl, hydroxyalkynyl, -NRLaRLb, aminoalkyl, aminoalkenyl, aminoalkynyl, haloalkyl, -C(O)NRLaRLb, alkoxy, alkylamino, dialkylamino, alkylaminoalkyl, di-alkyl-amino-alkyl, thioalkyl, alkoxyalkyl, alkyl-thio-alkyl, deuterium, cycloalkyl, cycloalkenyl and cycloalkynyl; - RLh is selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, deuterium, cycloalkyl, cycloalkenyl and cycloalkynyl; - RLa is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; - RLb is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; - or RLg and RLh together with the carbon atoms to which they are attached can form a cycloalkyl, cycloalkenyl, cycloalkynyl and heterocyclyl;- X is selected from the group comprising -ORXc, -NRXaRXb, aryl, heteroaryl, heterocyclyl, aminoalkyl, aminoalkenyl, aminoalkynyl, -S(O)2RXd, -NRXbS(O)2RXd, -NRXbC(O)ORXc, - OC(O)RXd, -C(O)NRXaRXb, -C(O)ORXc, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, alkyl, alkenyl, alkynyl, (mono- or di-)alkyl-amino-alkyl, thioalkyl, alkoxyalkyl, alkyl-thio-alkyl cycloalkyl, cycloalkenyl, cycloalkynyl and -N3, wherein each of said heteroaryl, heterocyclyl, aryl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, hydroxyalkyl, hydroxyalkenyl and hydroxyalkynyl is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising hydroxyalkyl, - C(O)NRXaRXb, heteroaryl, heterocyclyl, heterocyclyl substituted by alkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, -OH, =O, halogen, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, -C(O)OH, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, hydroxyalkoxy, aminoalkoxy, (mono- or di-)alkyl-aminoalkoxy, -NH2, - NHalkyl, and -N(alkyl)2; - RXa is selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkyloxyalkyl, aminoalkyl, aminoalkenyl, aminoalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heteroaryl, heterocyclyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl and heterocyclylalkynyl, wherein each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, alkyloxyalkyl, aminoalkyl, aminoalkenyl, aminoalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, heteroaryl, heterocyclyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl and heterocyclylalkynyl is unsubstituted or is substituted with one or more substituents each independently selected from -CONRXeRXf, hydroxyalkyl, heteroaryl, heterocyclyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, -OH, =O, halogen, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, -C(O)OH, O-alkyl, haloalkyl, alkoxy, haloalkoxy, -NH2, -NHalkyl, and -N(alkyl)2; - RXb is selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aminoalkyl, aminoalkenyl, aminoalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl, wherein each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, hydroxyalkyl, hydroxyalkenyl and hydroxyalkynyl is unsubstituted or is substituted with one or more substituents each independently selected from -CONRXeRXf, hydroxyalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, -OH, =O, halogen, -SH, =S, -CF3, -CHF2, - OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, C(O)OH, O-alkyl, haloalkyl, alkoxy,haloalkoxy, -NH2, -NHalkyl, and -N(alkyl)2; - each RXc is selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkyloxyalkyl, aminoalkyl, aminoalkenyl, aminoalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heteroaryl, heterocyclyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl and heterocyclylalkynyl, wherein each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, alkyloxyalkyl, aminoalkyl, aminoalkenyl, aminoalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, heteroaryl, heterocyclyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl and heterocyclylalkynyl is unsubstituted or is substituted with one or more substituents each independently selected from -CONRXaRXb, hydroxyalkyl, heteroaryl, heterocyclyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, -OH, =O, halogen, -SH, =S, - CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, -C(O)OH, haloalkyl, alkoxy, haloalkoxy, -NH2, -NHalkyl, and -N(alkyl)2; - RXd is selected from the group comprising alkyl, alkenyl, alkynyl, haloalkyl, aminoalkyl, aminoalkenyl, aminoalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heteroaryl, heterocyclyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl and heterocyclylalkynyl, wherein each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, heteroaryl, heterocyclyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl and heterocyclylalkynyl is unsubstituted or is substituted with one or more substituents each independently selected from - CONRXaRXb, hydroxyalkyl, heteroaryl, heterocycle, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, sulfhydryl, -SCF3, -SF5, cyano, nitro, oxo, amino, -C(O)OH, halogen, hydroxyl, haloalkyl, alkoxy and haloalkoxy; - each RXe and RXf are independently selected from alkyl, alkenyl, alkynyl, haloalkyl, aminoalkyl, aminoalkenyl, aminoalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heteroaryl, heterocyclyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl and heterocyclylalkynyl, wherein each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, heteroaryl, heterocyclyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl and heterocyclylalkynyl is unsubstituted or is substituted with one or more substituents each independently selected fromhydroxyalkyl, heteroaryl, heterocycle, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, sulfhydryl, -SCF3, -SF5, cyano, nitro, oxo, amino, -C(O)OH, halogen, hydroxyl, haloalkyl, alkoxy and haloalkoxy; - n is an integer selected from 1, 2, 3, or 4; - each R4 is independently selected from the group comprising halogen, -SCF3, -SF5, -CF3, -OCF3, -CHF2, -OCHF2, -B(OH)2, -O-SO2-F, -SO2-F, cyano, nitro, -OR4c, -NR4aR4b, - NR4aS(O)2R4d, -NR4aSO2NR4aR4b, -NR4aC(O)R4c, -NR4aC(O)OR4c, -NR4aC(O)NR4aR4b, SR4c, -S(O)R4d, -S(O)2R4c, -S(O)2NR4aR4b, -S(O)(NR4a)R4c, -S(NR4a)(NR4a) R4c, -C(O)OR4c, -C(O)R4c, -C(O)NR3aR3b, -P(O)R4aR4b, alkyl, alkenyl, alkynyl, haloalkyl haloalkoxy, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl and cycloalkynyl, wherein each of said alkyl, alkenyl, alkynyl, haloalkyl haloalkoxy, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, alkoxy, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl and cycloalkynyl is unsubstituted or is substituted with one or more substituents each independently selected from -OH, =O, halogen, -SH, =S, -CF3, - CHF2, -OCF3, -OCHF2, -SCF3, -SF5, -B(OH)2, cyano, nitro, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, hydroxyalkyl, haloalkyl, alkoxy, haloalkoxy, - C(O)OH, -C(O)Oalkyl, -C(O)NH2, -C(O)NHalkyl, -C(O)N(alkyl)2, -NH2, -NHalkyl, and - N(alkyl)2; - or two R4 together with the carbon atom(s) to which they are attached can form a cycloalkyl, cycloalkenyl, cycloalkynyl or heterocyclyl, wherein each of said cycloalkyl, cycloalkenyl, cycloalkynyl and heterocyclyl is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising -OH, =O, halogen, -SH, =S, -CF3, -CHF2, -OCF3, - OCHF2, -SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, cycloalkenyl, cycloalkynyl, hydroxyalkyl, haloalkyl, alkoxy, haloalkoxy, alkoxyalkyl, haloalkoxyalkyl, hydroxyalkoxyalkyl, -C(O)OH, -C(O)Oalkyl, -C(O)NH2, -C(O)NHalkyl, -C(O)N(alkyl)2, - NH2, -NHalkyl, and -N(alkyl)2; - R4a is selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, haloalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aminoalkyl, aminoalkenyl and aminoalkynyl; - R4b is selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; - R4c is selected from the group comprising hydrogen, alkyl, alkyl substituted with deuterium, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, alkoxyalkyl and (mono- or di-)alkyl-aminoalkyl;- R4d is selected from the group comprising alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl; - R5 is selected from the group comprising hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkyloxyalkyl, mono- or di-alkyl-amino-alkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl; wherein each of said alkyl, alkenyl, alkynyl, haloalkyl, alkyloxyalkyl, mono- or di-alkyl- amino-alkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aminoalkyl, aminoalkenyl, aminoalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, heterocyclylalkyl, heterocyclylalkenyl, and heterocyclylalkynyl, is unsubstituted or is substituted with one or more substituents each independently selected from the group comprising -OH, =O, halogen, -SH, =S, -CF3, - CHF2, - OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, hydroxyalkyl, haloalkyl, alkoxy, haloalkoxy, -C(O)OH, C(O)Oalkyl, -C(O)NH2, -C(O)NHalkyl, -C(O)N(alkyl)2, -NH2, - NHalkyl, and - N(alkyl)2; - or R3 and R5 together with the atoms to which they are attached form a heteroaryl or heterocyclyl wherein said heteroaryl or heterocyclyl is optionally substituted with one or more substituents independently selected from -OH, =O, halogen, -SH, =S, -CF3, -CHF2, - OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, phenyl, hydroxyalkyl, haloalkyl, alkoxy, haloalkoxy, -NH2, -NHalkyl, and -N(alkyl)2; - wherein when the moiety -W-L-X is -C(O)O-tert-butyl, then R3is not oxo or hydrogen; with the proviso that said compound is not: 1,3-dihydro-6,8-dimethoxy-4-methyl-N-(1-methylethyl)-2H-pyrrolo[3,4-c]quinoline-2- carboxamide, N-butyl-1,3-dihydro-6,8-dimethoxy-4-methyl-2H-pyrrolo[3,4-c]quinoline-2-carboxamide, 1,3-dihydro-6,8-dimethoxy-4-methyl-N-phenyl-2H-pyrrolo[3,4-c]quinoline-2-carboxamide, 1-(1,3-dihydro-6,8-dimethoxy-4-methyl-2H-pyrrolo[3,4-c]quinolin-2-yl)ethenone, N-(2-ethoxyphenyl)-1,3-dihydro-6,8-dimethoxy-4-methyl-2H-pyrrolo[3,4-c]quinoline-2- carboxamide, N-(3,4-dichlorophenyl)-1,3-dihydro-6,8-dimethoxy-4-methyl-2H-pyrrolo[3,4-c]quinoline-2- carboxamide, tert-butyl 6-(1-((tert-butoxycarbonyl)amino)propan-2-yl)-1-oxo-1,3-dihydro-2H-pyrrolo[3,4- c]quinoline-2-carboxylate, 1,3-dihydro-6,8-dimethoxy-4-methyl-N-[3-(trifluoromethyl)phenyl]-2H-pyrrolo[3,4-c]quinoline- 2-carboxamide,2-(2-chloroacetyl)-4-methyl-8-[(2-nitro-1-pyrrolidinyl)sulfonyl]-1H-pyrrolo[3,4-c]quinoline- 1,3(2H)-dione, 1,3-dihydro-4-methyl-8-[(2-nitro-1-pyrrolidinyl)sulfonyl]-α,1,3-trioxo-2H-pyrrolo[3,4- c]quinoline-2-acetyl chloride, 2,3-dihydro-8-methyl-2-[(4-methylphenyl)sulfonyl]-4-phenyl-1H-pyrrolo[3,4-c]quinolin-1-one, 7-chloro-2,3-dihydro-2-[(4-methylphenyl)sulfonyl]-4-phenyl-1H-pyrrolo[3,4-c]quinolin-1-one, 8-bromo-2,3-dihydro-2-[(4-methylphenyl)sulfonyl]-4-phenyl-1H-pyrrolo[3,4-c]quinolin-1-one, 8-chloro-2,3-dihydro-2-[(4-methylphenyl)sulfonyl]-4-phenyl-1H-pyrrolo[3,4-c]quinolin-1-one, 8-fluoro-2,3-dihydro-2-[(4-methylphenyl)sulfonyl]-4-phenyl-1H-pyrrolo[3,4-c]quinolin-1-one, 2,3-dihydro-8-methoxy-4-(6-methyl-1H-indol-3-yl)-2-[(4-methylphenyl)sulfonyl]-1H- pyrrolo[3,4-c]quinoline, 8-(1,1-dimethylethyl)-2,3-dihydro-4-(1H-indol-3-yl)-2-[(4-methylphenyl)sulfonyl]-1H- pyrrolo[3,4-c]quinoline, 2,3-dihydro-2-[(4-methylphenyl)sulfonyl]-8-(4-morpholinylsulfonyl)-4-phenyl-1H-pyrrolo[3,4- c]quinolin-1-one, (3aS,9bS)-2-(benzo[d][1,3]dioxol-5-ylsulfonyl)-8-hydroxy-5-methyl-1,2,3,3a,5,9b-hexahydro- 4H-pyrrolo[3,4-c]quinolin-4-one, (3aS,9bS)-2-(benzo[d][1,3]dioxol-5-ylsulfonyl)-5-methyl-4-oxo-2,3,3a,4,5,9b-hexahydro-1H- pyrrolo[3,4-c]quinoline-8-carbonitrile, (3aS,9bS)-2-(benzo[d][1,3]dioxol-5-ylsulfonyl)-8-fluoro-5-methyl-1,2,3,3a,5,9b-hexahydro-4H- pyrrolo[3,4-c]quinolin-4-one, tert-butyl (3aR,9bR)-1,3,3a,4,5,9b-hexahydro-2H-pyrrolo[3,4-c]quinoline-2-carboxylate, tert-butyl (3aS,9bR)-8-(2-(trifluoromethyl)phenyl)-1,3,3a,4,5,9b-hexahydro-2H-pyrrolo[3,4- c]quinoline-2-carboxylate,, , , .

2. The compound according to claim 1, wherein R1is selected from alkyl or hydroxyalkyl, such as methyl, hydroxymethyl and (n- or i-)propyl.

3. The compound according to any one of claims 1 and 2, wherein - R2is selected from the group comprising hydrogen, -CONR2aR2b, aminoalkyl, alkyl and hydroxyalkyl; - R2ais selected from hydrogen or alkyl; and- R2bis selected from hydrogen or alkyl.

4. The compound according to any one of claims 1 to 3 having structural formula (VI) or (VII)wherein each of R1, R3, R4, n, RXa, RXb, RXc, and RLghave the same meaning as that defined in claims 1 to 3.

5. The compound according to any one of claims 1 to 3 wherein - W is -C(O)-; - the moiety L-X is according to; - Z is N or O; - cycle B is a heterocyclyl or heteroaryl; - u is 0, 1, 2 or 3; and, - each R7is independently selected from hydroxyalkyl, -C(O)NRXaRXb, heteroaryl, heterocyclyl, heterocyclyl substituted by one or more alkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, -OH, =O, halogen, -SH, =S, -CF3, -CHF2, -OCF3, - OCHF2, -SCF3, -SF5, cyano, nitro, -C(O)OH, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, hydroxyalkoxy, aminoalkoxy, (mono- or di-)alkyl-aminoalkoxy, -NH2, -NHalkyl, and - N(alkyl)2.

6. The compound according to any one of claims 1 to 5 wherein R3is selected from hydrogen, alkyl, -NR3xR3yand -OR3z, wherein: - alkyl is optionally substituted by one, two or three substituents independently selected from halogen, -OH, =O, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, alkoxy, alkylthio, cycloalkyl, cycloalkenyl, cycloalkynyl, -C(O)OH, -C(O)R3i, -C(O)-O-CH2-O-CO-R3i, -PO-(OR3i)2, -NH2, -NHalkyl, and -N(alkyl)2; - each R3x, R3yand R3zare independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl and heterocyclyl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl and heterocyclyl are optionally further substituted by one, two or three substituents independently selectedfrom halogen, -OH, =O, -SH, =S, -CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, alkylthio, cycloalkyl, cycloalkenyl, cycloalkynyl, -C(O)OH, -C(O)R3i, -C(O)-O-CH2-O-CO-R3i, -PO-(OR3i)2, -NH2, -NHalkyl, and -N(alkyl)2; - or, R3xand R3ytogether form a heterocycle optionally substituted with one, two or three substituents independently selected from comprising halogen, -OH, =O, -SH, =S, -CF3, - CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, -C(O)OH, -NH2, -NHalkyl, and -N(alkyl)2.

7. The compound according to any one of claims 1 to 6, wherein - each R4is independently selected from the group comprising halogen, -CF3, -OCF3, -CHF2, -B(OH)2, -O-SO2-F, -SO2-F, -OCHF2, alkyl, -OR4c, haloalkyl, -CN, haloalkoxy, hydroxyalkyl, haloalkoxy, hydroxyalkyl, alkyloxyC1-6alkyl and cycloalkyl; or two R4together with the carbon atom(s) to which they are attached can form a cycloalkyl, a cycloalkenyl or heterocyclyl; - R4cis selected from the group comprising alkyl, alkyl substituted with deuterium, alkoxyalkyl, hydroxyalkyl and haloalkyl; and - n is an integer selected from 1, 2, 3, or 4.

8. The compound according to any one of claims 1 to 5, wherein R5is selected from the group comprising hydrogen, alkyl, haloalkyl, alkoxyalkyl, (mono- or di-)amino-alkyl, hydroxyalkyl, aminoalkyl, cycloalkylalkyl, and heterocyclylalkyl.

9. The compound according to any one of claims 1-3 having a structure according to formula (IVc) or (IVd),, wherein - R4.1, R4.2and R4.3have the same meaning as R4; - s is 0, 1 or 2; - t is 0 or 1; - each of R1, R2, R3, R4, L and X have the same meaning as that defined in any one of the claims 1 to 7.

10. The compound according to claim 9 wherein - R1is selected from C1-6alkyl or hydroxyC1-6alkyl, such as methyl, hydroxymethyl and (n- or i-)propyl. - R2is hydrogen; - -L-X is selected from –CH(RLg)-O-RXc, –CD(RLg)-O-RXc, –CH(RLg)-N(RXa)(RXb) or; - u is 0, 1, 2 or 3; - cycle B is a heterocyclyl or heteroaryl; - each R7is independently selected from hydroxyC1-6alkyl, -C(O)NRXaRXb, heteroaryl, heterocyclyl, heterocyclyl substituted by one or more C1-6alkyl, C1-6alkyl, C2-6alkenyl, C2- 6alkynyl, C3-10cycloalkyl, C5-10cycloalkenyl, C5-10cycloalkynyl, -OH, =O, halogen, -SH, =S, - CF3, -CHF2, -OCF3, -OCHF2, -SCF3, -SF5, cyano, nitro, -C(O)OH, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, hydroxyC1-6alkyl, hydroxyC1-6alkoxy, aminoC1-6alkoxy, mono-C1-6alkyl- aminoC1-6alkoxy, di-C1-6alkyl-aminoC1-6alkoxy, -NH2, -NHC1-6alkyl, and -N(C1-6alkyl)2; - R4.1and R4.3are independently selected from halogen , -CF3, -OCF3, -CHF2, -OCHF2, alkyl, -OR4c, haloC1-6alkyl, -CN, haloC1-6alkoxy, hydroxyC1-6alkyl and C3-10cycloalkyl; - R4.2is selected from hydrogen, halogen, -CF3, -OCF3, -CHF2, -OCHF2, C1-6alkyl, -OR4c, haloC1-6alkyl, -CN, haloC1-6alkoxy, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl and C3- 10cycloalkyl; - s and t are 0; - wherein Z, R7, R4c, RLg, RXa, RXb, and RXchave the same meaning as defined for any one of claims 1 to 7.

11. A pharmaceutical composition comprising a compound according to any one of claims 1 to 10 and a pharmaceutically acceptable carrier, solvent, adjuvant or diluent.

12. A compound according to any one of claims 1 to 10, or a pharmaceutical composition according to claim 11 for use as a medicament.

13. A compound or a pharmaceutical composition for use as a medicament according to claim 12, for use in treating or preventing a cGAS mediated disease, more in particular a disease with inappropriate activation of a type I interferon (IFN) response.

14. A compound or a pharmaceutical composition for use as a medicament according to claim 13, wherein said cGAS mediated disease is selected from systemic lupus erythematosus(SLE), cutaneous lupus erythematosus (CLE), lupus nephritis (LN), interferonopathies, psoriasis, insulin-dependent diabetes mellitus (IDDM), vasculitis, scleroderma, Aicardi Goutieres syndrome, dermatomyositis, sepsis, inflammatory bowel diseases, multiple sclerosis, rheumatoid arthritis, Sjogren's syndrome (SS), age related macular degeneration (AMD), Amyotrophic Lateral sclerosis (ALS), Fronto-temporal dementia (FTD), Alzheimer’s disease, Huntington’s disease and Parkinson’s disease.

15. A method for treating or preventing a cGAS mediated disease in a subject in need thereof, the method comprising administering to a subject in need of such treatment an effective amount of one or more compounds according to any one of claims 1 to 10 or a pharmaceutical composition according to claim 11, wherein in particular said cGAS mediated disease is an inflammation condition, yet more in particular is selected from systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), lupus nephritis (LN), interferonopathies, psoriasis, insulin-dependent diabetes mellitus (IDDM), vasculitis, scleroderma, Aicardi Goutieres syndrome, dermatomyositis, sepsis, inflammatory bowel diseases, multiple sclerosis, rheumatoid arthritis, Sjogren's syndrome (SS), age related macular degeneration (AMD), Amyotrophic Lateral sclerosis (ALS), Fronto-temporal dementia (FTD), Alzheimer’s disease, Huntington’s disease and Parkinson’s disease.

16. A method for the preparation of the compounds according to any one of claims 1-10, comprising the steps of: - coupling a pyrrolidine-containing compound of formula (A1) with an electrophile of formula LG-W-L-X-PG and further removing PG (if different than Me) thereby obtaining compound of formula (A2), wherein R1, R2, R3, R4, W, L, X and n have the meaning according to any one of claims 1-10, wherein PG is a protecting group and LG is a leaving group; or- reacting a compound of formula (A3) with a nucleophile of formula HR3and further removing PG (if different than Me) thereby obtaining compound of formula (A2), wherein R1, R2, R3, R4, W, L, X and n have the meaning according to any one of claims 1-10, wherein PG is a protecting group and LG is a leaving group; or(A3)(A2)- coupling a pyridone-containing compound of formula (A4) with an electrophile of formula R5-LG, and further removing PG (if different than Me) thereby obtaining compound of formula (A5) or (A6), wherein R1, R2, R5, W, L, X and n have the meaning according to any one of claims 1-10, wherein PG is a protecting group and LG is a leaving group and wherein group -OR5corresponds to group -OR3cas defined in any one of claims 1 to 10; or- reacting a compound of formula (A7) with a nucleophile of formula HX-PG and further removing PG thereby obtaining compound of formula (A2), wherein R1, R2, R3, R4, W, L, X and n have the meaning according to any one of claims 1-10, wherein PG is a protecting group and LG is a leaving group; or- reacting a halogen-containing compound of formula (A8) with a suitable R4.4 reagent (e.g. boronic acid or ester, organozinc, stannanes) by procedures known to the skilled in the art (Suzuki coupling, Negishi coupling, Stille coupling and the like) and further removing PG thereby obtaining compound of formula (A2a), wherein R1, R2, R3, R4, R4.4, W, L, X and n have the meaning according to any one of claims 1-10, wherein PG is a protecting group, X1 is a halogen;

Images